
<html lang="en"     class="pb-page"  data-request-id="1f360a20-308c-47a0-a340-0f7e3d9718a1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm900899g;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2010.53.issue-2"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy" /></meta><meta name="dc.Creator" content="Sherly  Quiles" /></meta><meta name="dc.Creator" content="Kevin P.  Raisch" /></meta><meta name="dc.Creator" content="Leisa L.  Sanford" /></meta><meta name="dc.Creator" content="James A.  Bonner" /></meta><meta name="dc.Creator" content="Ahmad  Safavy" /></meta><meta name="dc.Description" content="The goal of this study was to design paclitaxel (PTX)-monoclonal antibody (mAb) prodrug conjugates (PTXMAbs) with the ability to deliver therapeutically significant doses of the drug to the tumor w..." /></meta><meta name="Description" content="The goal of this study was to design paclitaxel (PTX)-monoclonal antibody (mAb) prodrug conjugates (PTXMAbs) with the ability to deliver therapeutically significant doses of the drug to the tumor w..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 3, 2009" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm900899g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm900899g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm900899g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm900899g" /></link>
        
    
    

<title>Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm900899g" /></meta><meta property="og:title" content="Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0008.jpeg" /></meta><meta property="og:description" content="The goal of this study was to design paclitaxel (PTX)-monoclonal antibody (mAb) prodrug conjugates (PTXMAbs) with the ability to deliver therapeutically significant doses of the drug to the tumor while avoiding the previously observed solubility limitations of conjugates with PTX:mAb molar ratios of &gt;3. New PTX conjugates were synthesized using the discrete poly(ethylene glycol) (dPEG) as linkers. These compounds, PTX-L-Lys[(dPEG12)3-dPEG4]-dPEG6-NHS (9a and 9b, for L = GL or SX, respectively), were then conjugated to the antiepidermal growth factor receptor mAb, C225 at increasing PTX:C225 ratios, producing completely soluble conjugates. Unlike the earlier PTXMAbs, buffered solutions of these conjugates remained homogeneous for extended periods of time. Fluorescence-activated cell sorting (FACS) analysis indicated preserved immunogenicity of the conjugates at all four substitution ratios, while cytotoxicity studies in MDA-MB-468 breast cancer cells indicated preservation of drug cytotoxicity. These conjugates may have potential in the development of high-drug-load tumor-targeting taxanes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm900899g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm900899g">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm900899g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm900899g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm900899g&amp;href=/doi/10.1021/jm900899g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 586-594</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm900838g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901052r" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sherly++Quiles">Sherly Quiles</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+P.++Raisch">Kevin P. Raisch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leisa+L.++Sanford">Leisa L. Sanford</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+A.++Bonner">James A. Bonner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ahmad++Safavy">Ahmad Safavy</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Radiation Oncology, School of Medicine</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">the Comprehensive Cancer Center</span></div><div class="aff-info" id="aff3"><span class="aff-text">University of Alabama at Birmingham, Birmingham, Alabama 35294</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: (205) 934-3681. Fax: (205) 975-7060. E-mail: <a href="/cdn-cgi/l/email-protection#3a695b5c5b4c437a4f5b58145f5e4f"><span class="__cf_email__" data-cfemail="4516242324333c053024276b202130">[email protected]</span></a>. Address: The Comprehensive Cancer Center, University of Alabama at Birmingham, 1825 University Blvd., SHEL 701, Birmingham, AL 35294-2182.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm900899g&amp;href=/doi/10.1021%2Fjm900899g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 586–594</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 3, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 June 2009</li><li><span class="item_label"><b>Published</b> online</span>3 December 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm900899g" title="DOI URL">https://doi.org/10.1021/jm900899g</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D586%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSherly%2BQuiles%252C%2BKevin%2BP.%2BRaisch%252C%2BLeisa%2BL.%2BSanford%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D2%26contentID%3Djm900899g%26title%3DSynthesis%2Band%2BPreliminary%2BBiological%2BEvaluation%2Bof%2BHigh-Drug-Load%2BPaclitaxel-Antibody%2BConjugates%2Bfor%2BTumor-Targeted%2BChemotherapy%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D594%26publicationDate%3DJanuary%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm900899g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2517</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">51</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm900899g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sherly&quot;,&quot;last_name&quot;:&quot;Quiles&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;P. Raisch&quot;},{&quot;first_name&quot;:&quot;Leisa&quot;,&quot;last_name&quot;:&quot;L. Sanford&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;A. Bonner&quot;},{&quot;first_name&quot;:&quot;Ahmad&quot;,&quot;last_name&quot;:&quot;Safavy&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;586-594&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm900899g&quot;},&quot;abstract&quot;:&quot;The goal of this study was to design paclitaxel (PTX)-monoclonal antibody (mAb) prodrug conjugates (PTXMAbs) with the ability to deliver therapeutically significant doses of the drug to the tumor while avoiding the previously observed solubility limitations of conjugates with PTX:mAb molar ratios of &gt;3. New PTX conjugates were synthesized using the discrete poly(ethylene glycol) (dPEG) as linkers. These compounds, PTX-L-Lys[(dPEG12)3-dPEG4]-dPEG6-NHS (9a and 9b, for L = GL or SX, respectively), were then conjugated to the antiepidermal growth factor receptor mAb, C225 at increasing PTX:C225 ratios, producing completely soluble conjugates. Unlike the earlier PTXMAbs, buffered solutions of these conjugates remained homogeneous for extended periods of time. Fluorescence-activated cell sorting (FACS) analysis indicated preserved immunogenicity of the conjugates at all four substitution ratios, while cytotoxicity studies in MDA-MB-468 breast cancer cells indicated preservation of drug cytotoxicity. These conjugate&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900899g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900899g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900899g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900899g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm900899g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900899g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm900899g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm900899g&amp;href=/doi/10.1021/jm900899g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm900899g" /></input><a href="/doi/pdf/10.1021/jm900899g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1007 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm900899g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm900899g%26sid%3Dliteratum%253Aachs%26pmid%3D19958000%26genre%3Darticle%26aulast%3DQuiles%26date%3D2010%26atitle%3DSynthesis%2Band%2BPreliminary%2BBiological%2BEvaluation%2Bof%2BHigh-Drug-Load%2BPaclitaxel-Antibody%2BConjugates%2Bfor%2BTumor-Targeted%2BChemotherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D2%26spage%3D586%26epage%3D594%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290644" title="Molecular properties">Molecular properties</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The goal of this study was to design paclitaxel (PTX)-monoclonal antibody (mAb) <i>prodrug</i> conjugates (PTXMAbs) with the ability to deliver therapeutically significant doses of the drug to the tumor while avoiding the previously observed solubility limitations of conjugates with PTX:mAb molar ratios of >3. New PTX conjugates were synthesized using the discrete poly(ethylene glycol) (dPEG) as linkers. These compounds, PTX-<b>L</b>-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-NHS (<b>9a</b> and <b>9b</b>, for <b>L</b> = GL or SX, respectively), were then conjugated to the antiepidermal growth factor receptor mAb, C225 at increasing PTX:C225 ratios, producing completely soluble conjugates. Unlike the earlier PTXMAbs, buffered solutions of these conjugates remained homogeneous for extended periods of time. Fluorescence-activated cell sorting (FACS) analysis indicated preserved immunogenicity of the conjugates at all four substitution ratios, while cytotoxicity studies in MDA-MB-468 breast cancer cells indicated preservation of drug cytotoxicity. These conjugates may have potential in the development of high-drug-load tumor-targeting taxanes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Research on targeted therapy of malignancies has attracted a great deal of interest during the past several years based on its well-justified rationale, the efficient and specific delivery of cytotoxic agents to the tumor tissue. The immediate benefit of this tumor-specific delivery is 2-fold: increasing the effective dose of the antitumor agent and decreasing the extent of its related side effects and toxicity. Receptor-based targeted treatment of cancer through the application of tumor-recognizing molecules (TRMs) has advanced considerably during the past several years with the development of monoclonal antibodies<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> and, later, small molecule peptides capable of binding to tumor cell surface receptors.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> A number of drug-,<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7-10)</a> toxin-,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> and radioisotope<a onclick="showRef(event, 'ref4 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref4 ref13 ref14">(4, 13, 14)</a> conjugates of TRMs have been developed with some currently in clinical use. A rationally designed conjugate capable of recognizing and localizing on its target, and delivering the cytotoxic payload in an efficient and timely fashion, will be an invaluable armament against cancer.</div><div class="NLM_p">Since its discovery, paclitaxel (PTX,<a class="ref internalNav" href="#fn1" aria-label="a">a</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: ACN, acetonitrile; CAN, acetonitrile; CHL, chloroform; DCC, <i>N</i>,<i>N</i>-dicyclohexyl carbodiimide; DCM, dichloromethane; DIEA, <i>N</i>,<i>N</i>-diisopropyl ethylamine; dPEG, discrete PEG; EGFR, epidermal growth factor receptor; FACS, fluorescent-activated cell sorting; FITC, fluorescein isothiocyanate; GL, glutarate or glutaric acid; mAb, monoclonal antibody; MTL, methanol; NHS, <i>N</i>-hydroxy succinimide; PTX, paclitaxel; RP, reversed-phase; SE-HPLC, size-exclusion HPLC; SX, succinate or succinic acid; TIPS, triisopropylsilane; WTR, water.</p></div> taxol, <b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) has been the focus of much research toward the design and synthesis of analogues with improved physical, chemical, and pharmacological properties.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> The first clinical trial of PTX for metastatic breast cancer was reported by Holmes et al. in 1991 and involved 25 patients treated with 250 mg/m<sup>2</sup> over 24 h. Three complete and 11 partial responses for an overall response rate of 57% were observed;<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> ever since, the drug has generated impressive responses from patients with metastatic disease such as the anthracycline-resistant breast cancer patients.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Reichman et al. reported an overall response rate of 62% for 26 patients, with metastatic breast cancer and with prior adjuvant therapy, including 3 complete responses.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Seidman et al. reported a 32.8% overall response in patients, 66% of whom had failed two or more prior treatments for metastatic disease.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In a study by Chang et al., a 62% overall response was reported in patients treated with taxol.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of paclitaxel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite these positive therapeutic features, taxanes suffer from such drawbacks as dose-limiting toxicities at the clinically administered quantities and lack of aqueous solubility. The negligible solubility of PTX (0.25 μg/mL in water) has led to the currently used formulations of this drug, which have been reported to cause medium to severe hypersensitivity reactions.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> A peripheral neuropathy is induced by PTX, which becomes more severe by cumulative dosing, and an arthralgia−myalgia syndrome results 2−5 days after administration of taxol.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Other systemic toxicities include cardiac arrhythmias, alopecia, mucositis, and fatigue.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Accordingly, design and development of water-soluble tumor-targeting taxane derivatives for excipient-free formulations, and with no or ameliorated human toxicity, is of great interest.</div><div class="NLM_p">To this end, our laboratory previously reported the syntheses of bombesin receptor-directed PTX-peptide<a onclick="showRef(event, 'ref7 ref26'); return false;" href="javascript:void(0);" class="ref ref7 ref26">(7, 26)</a> and epidermal growth factor receptor-directed PTXMAb conjugates.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> All conjugates showed an enhancement in the drug cytotoxicity, presumably due to receptor-specific delivery, with small but significant antitumor activity as compared to the unconjugated drug.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, although the peptide conjugates, in which the drug and peptide moieties were connected by a PEG linker, showed high aqueous solubility, the solubility of the antibody conjugates were limited to a PTX:mAb molar ratio of 3.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Conjugates with drug-to-mAb ratios (D:mAb) higher than 3 precipitated from the solution and were lost. At the same time, antitumor activity studies in animals showed that conjugates with higher drug loads were required for a significant therapeutic activity. This could be expected because, with a large molecular weight (>155000 Da), the antibody conjugate could deliver only a small dose of the drug (MW 853.9 Da) at a D:mAb of 3. Furthermore, the fractional tumor uptake of MAbs would be an added hurdle to the delivery of therapeutically significant doses of mAb-conjugated drugs.</div><div class="NLM_p last">In an attempt to overcome these shortcomings, we hypothesized that conjugation of a highly water-soluble PTX, designed with the appropriate functionality for mAb attachment, might yield high-drug-load (HDL) conjugates which would retain the native aqueous solubility of the antibody moiety. Furthermore, in contrast to the previously prepared low-drug-load compounds,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the HDL conjugates would be expected to have enhanced antitumor efficacy as well. This article reports the design and synthesis of new and highly water-soluble PTX derivatives and their corresponding HDL antibody conjugates with sustained solubility, immunoreactivity, and cytotoxic activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Two basic requirements for a successful tumor-targeted drug delivery are the preservation of the targeting element integrity and the delivery of a therapeutically significant dose of the drug to the intended site. In our earlier work, we reported the synthesis and evaluation of paclitaxel conjugates to the <i>chimeric anti</i>-epidermal growth factor receptor (EGFR) antibody C225<a onclick="showRef(event, 'ref3 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref3 ref29 ref30 ref31 ref32">(3, 29-32)</a> for the targeted chemotherapy of EGFR-positive tumors.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> In that work, PTX was linked to the antibody by the short and lipophilic linkers, succinic (SX) or glutaric (GL) acids. EGF is a transmembrane protein of the tyrosine kinase growth factor family, and its receptor<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> is overexpressed in a number of human malignancies including breast, colorectal, ovarian, lung, and head and neck cancers.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38 ref39">(35-39)</a></div><div class="NLM_p">Despite the development of a successful and reproducible conjugation chemistry, the results indicated a solubility barrier which was consistently encountered beyond a PTX:mAb of 3. To circumvent this problem, the present approach employed a branched and highly water-soluble derivative of PTX containing an amine-directed conjugation site for mAb attachment.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Synthesis</h3><div class="NLM_p">The syntheses of the soluble preconjugation PTX (compounds <b>9a</b> and <b>9b</b>) are shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. As the central branching point, <i>N</i><sup>α</sup>-Boc-protected lysine was used to provide three orthogonal coupling functionalities. The free ε-amine group of Boc-Lys was attached to the branched dPEG by an amide bond through the NHS-activated polymer <b>2</b>. This reaction did not require any C-terminal protection of the amino acid, which simplified the overall process. To further increase the water solubility of the conjugate, the free carboxylic acid of the intermediate compound <b>5</b> was then ligated to the dPEG hexamer <b>3</b>, leading to compound <b>6</b>. The MALDI mass spectra of compounds <b>5</b> and <b>6</b> showed MWs with 100 mass units less than calculated, indicating the cleavage of the Boc group (MW 101 Da), and regeneration of the corresponding amine, during the course of the spectroscopy. This was presumably due to the limited stability of this protecting group under high-energy conditions such as heating and laser irradiation.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Water-Soluble PTX−dPEG Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) DCM/MT, RT; (ii) NHS, DCC, DCM, <b>3</b>; (iii) TIPS/TFA; (iv) PTX-<b>L</b>-NHS, DIEA, DCM; (v) NHS, DCC, DCM.</p></p></figure><div class="NLM_p">Acid deprotection of <b>6</b>, followed by the coupling of compound <b>7</b> to PTXGLNHS or PTXSXNHS yielded products <b>8a</b> or <b>8b</b>, respectively. Activation of the carboxyl functions of <b>8a</b> and <b>8b</b> afforded the conjugation-ready activated esters <b>9a</b> and <b>9b</b>, respectively. The overall yields of these syntheses were 27% for <b>9a</b> and 30% for <b>9b</b>. The calculated and measured molecular weights of compounds <b>5</b>−<b>9</b>, as well as the corresponding deviations, are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Attempts to produce well-resolved and informative NMR spectra for these compounds were not successful due to high signal interference, large peak size differences, and crowded patterns of the corresponding spectra (see sample <sup>1</sup>H NMR of PTX, and dPEGs 2 and 3 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). However, mass spectrometry and analytical HPLC clearly established the compounds identities and degrees of purity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Calculated and Measured Molecular Weights (MWs) of the dPEG Linkers and PTX−dPEG Conjugates</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="left">compd</th><th align="center" char=".">MW<sub>c</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th align="center" char=".">MW<sub>e</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th align="center" char=".">%ΔMW<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>5</b></td><td align="char" char=".">2552</td><td align="char" char=".">2551</td><td align="char" char=".">0.04</td></tr><tr valign="top"><td align="left"><b>6</b></td><td align="char" char=".">2887</td><td align="char" char=".">2886</td><td align="char" char=".">0.03</td></tr><tr valign="top"><td align="left"><b>7</b></td><td align="char" char=".">2787</td><td align="char" char=".">2788</td><td align="char" char=".">0.04</td></tr><tr valign="top"><td align="left"><b>8a</b></td><td align="char" char=".">3737</td><td align="char" char=".">3740</td><td align="char" char=".">0.08</td></tr><tr valign="top"><td align="left"><b>8b</b></td><td align="char" char=".">3723</td><td align="char" char=".">3759</td><td align="char" char=".">0.97</td></tr><tr valign="top"><td align="left"><b>9a</b></td><td align="char" char=".">3834</td><td align="char" char=".">3830</td><td align="char" char=".">0.1</td></tr><tr valign="top"><td align="left"><b>9b</b></td><td align="char" char=".">3820</td><td align="char" char=".">3857</td><td align="char" char=".">0.97</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Calculated molecular weight (MW).</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Experimental MW by MALDI-TOF MS.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Absolute value calculated from MW<sub>c</sub> − MW<sub>e</sub>/MW<sub>c</sub> × 100.</p></div></div></div><div class="NLM_p">Although the large size of the dPEG linkers used in this study necessitated the use of MALDI TOF MS, we found that some molecular fragmentation of the dPEGs could occur under the experimental conditions of this analytical modality. This fragmentation resulted in the formation of multipeak spectral patterns of the intermediate and final products of Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and was true even of the commercially supplied branched dPEG. This compound (<b>2</b> of Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, MW 2420) did not show the exact MW when analyzed by MALDI. When analyzed by positive-mode electrospray (ES) MS, however, the doubly charged MW was readily observed (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). This fragmentation, and not presence of impurities, explains the multipeak patterns in MALDI spectra, although the observed MWs were in complete agreement with the calculated ones (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). It should be emphasized that the ES MS could not be used for MWs larger than 1800 Da due to the inherent limitations of the instrument.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of the single-MW dPEG branched (<b>2</b>) and linear (<b>3</b>) linkers used in the synthesis of the soluble PTX, <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) 50 mM PBS, pH 8.1.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Antibody Conjugation</h3><div class="NLM_p">Targeting the lysine ε-amine groups of the antibody (<b>10</b>, Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), the activated esters <b>9a</b> and <b>9b</b> were readily conjugated to C225 at observed (MALDI) molar ratios which corresponded to the stoichiometrically calculated ratios (PTX:C225)<sub>c</sub>. The product conjugates were purified by dialysis, and the batch purity was evaluated by analytical SE-HPLC, which indicated very high purities. This high degree of purity was due to the exhaustive dialysis in a large (50000 Da) MW cutoff membrane, which was expected to exclude any and all small-molecule starting material and reagents and retain only the large protein molecules. The purified products were then analyzed by MALDI-TOF mass spectrometry, which clearly showed the formation of the target conjugates in real time. Using the MALDI MWs of the whole conjugate, the unconjugated C225, and the substituting drug-linker conjugate, the PTX:C225 molar ratios were calculated through eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>.<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/jm-2009-00899g_m001.gif" alt="" /></img><span class="labelSpan">(1)</span></span>where MW<sub>mconj</sub>, MW<sub>C225</sub>, and MW<sub>dconj</sub> are the MWs of the final mAb conjugate, C225, and drug conjugates (compounds <b>9a</b> or <b>9b</b>), respectively, and 115 is the MW of the departing NHS after mAb coupling.</div><div class="NLM_p">The results of conjugation reactions are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. As shown in this table, the measured PTX:C225 ratios, (PTX:C225)<sub>m</sub>, increased from 2 to 12 (<b>11a</b>−<b>11d</b>), and from 2 to 10 (<b>11e</b>−<b>11h</b>) when the (PTX:C225)<sub>c</sub> was raised from 5 to 50. The increase in the number of substituted drugs is also reflected in the SEC-HPLC retention times (<i>t</i><sub>R</sub>) as indicated by an inverse correlation, shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for the representative conjugates <b>11a</b>−<b>11d</b>. A <i>t</i><sub>R</sub> shortening of about 0.35 min was noticed for the conjugates with the highest PTX:C225 (compounds <b>11d</b> and <b>11h</b>, Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) as compared to the unconjugated antibody and due to a MW increase of about 37000−47000 Da. At the same time, conjugation efficiency (%CE, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) was decreased, presumably due to the decrease in the availability of the lysine ε-amine binding sites of the antibody.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Size-exclusion chromatograms (SE-HPLC) and MALDI-TOF mass spectra of C225 (A) and conjugates <b>11a</b>−<b>11d</b> (B−E) illustrating the degrees of purity and MWs for these compounds, respectively. SEC retention times decrease while the MALDI peaks broaden as the MW increases. The smaller left peaks in the mass spectra are the doubly charged half-MW peaks. All MALDI analyses were made with external calibration against bovine serum albumin at 66430.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Physicochemical Properties of the <b>9a</b>/<b>9b</b>-C225 Conjugation Reactions and Their Corresponding Conjugate Products<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center">conjugate</th><th align="center">MW<sub>e</sub><a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></th><th align="center" char=".">(PTX:C225)<sub>c</sub><a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></th><th align="center">(PTX:C225)<sub>m</sub><a class="ref internalNav" href="#t2fn3" aria-label="d">d</a></th><th align="center">% yield<sub>p</sub><a class="ref internalNav" href="#t2fn4" aria-label="e">e</a></th><th align="center">% CE<a class="ref internalNav" href="#t2fn5" aria-label="f">f</a></th><th align="center"><i>t</i><sub>R</sub> (min)<a class="ref internalNav" href="#t2fn6" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>225</b></td><td align="left">151800</td><td align="char" char=".">0</td><td align="left">0</td><td align="left">NA<a class="ref internalNav" href="#t2fn7" aria-label="h">h</a></td><td align="left">NA</td><td align="left">8.1</td></tr><tr valign="top"><td align="left"><b>11a</b> (<b>11e</b>)</td><td align="left">158298 (158050)</td><td align="char" char=".">5</td><td align="left">2 (2)</td><td align="left">77 (72)</td><td align="left">40 (60)</td><td align="left">8.08 (8.02)</td></tr><tr valign="top"><td align="left"><b>11b</b> (<b>11f</b>)</td><td align="left">162625 (169414)</td><td align="char" char=".">10</td><td align="left">3 (5)</td><td align="left">90 (86)</td><td align="left">30 (50)</td><td align="left">8.00 (8.00)</td></tr><tr valign="top"><td align="left"><b>11c</b> (<b>11g</b>)</td><td align="left">171763 (173674)</td><td align="char" char=".">20</td><td align="left">5 (6)</td><td align="left">88 (86)</td><td align="left">25 (35)</td><td align="left">7.91 (7.94)</td></tr><tr valign="top"><td align="left"><b>11d</b> (<b>11h</b>)</td><td align="left">198575 (188800)</td><td align="char" char=".">50</td><td align="left">12 (10)</td><td align="left">96 (92)</td><td align="left">24 (20)</td><td align="left">7.75 (7.77)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Values for the <b>9b</b>−C225 conjugates are shown in parentheses.</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">Measured by MALDI-TOF MS.</p></div><div class="footnote" id="t2fn2"><sup>c</sup><p class="last">Calculated stoichiometric ratios.</p></div><div class="footnote" id="t2fn3"><sup>d</sup><p class="last">Measured ratios from MALDI-TOF MWs and eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>.</p></div><div class="footnote" id="t2fn4"><sup>e</sup><p class="last">% Yield of protein recovery.</p></div><div class="footnote" id="t2fn5"><sup>f</sup><p class="last">Conjugation efficiency, calculated from (PTX:C225)<sub>m</sub>/(PTX:C225)<sub>c</sub> × 100.</p></div><div class="footnote" id="t2fn6"><sup>g</sup><p class="last">SEC-HPLC retention times at 280 nm.</p></div><div class="footnote" id="t2fn7"><sup>h</sup><p class="last">NA: not applicable.</p></div></div></div><div class="NLM_p">Furthermore, it should be noted that MALDI MS always yields broadened signals for MAbs. The reason is the existence of a combination of antibodies with different MWs but with the same antigen-binding activity. In fact, the term “<i>monoclonal</i>” refers to this latter property of MAbs and not to a MW homogeneity. This variation in molecular size, in turn, results in a variation in the response of individual molecules to conjugation reactions, thus leading to further peak broadening in the spectra of the product conjugates. This broadening usually increases with the conjugation number as is evident here in the spectra shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.</div><div class="NLM_p last">Whereas the conjugates with PTX:C225 of >3 invariably precipitated and were lost in the previously reported conjugations,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> no precipitation and loss of antibody was observed in this work; the yields of protein recovery ranged from 77% to 96%, and interestingly, with the latter yield belonging to the conjugates with the highest PTX:C225.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Aqueous Solubility</h3><div class="NLM_p last">During the course of this work, a number of potential water-soluble linkers were tested (Safavy, unpublished results). Among these, were the dendrimer polyamine PAMAM and linear amino PEG-carboxylic acids with different molecular sizes and all suitably heterofunctionalized for mAb conjugation. Although the search for the right linker was not exhaustive, it was observed that even with these inherently hydrophilic linkers, the PTX loading of >3−5 would result in the precipitation of the resulting conjugates. In general, when the linker was placed in a “middle” position, that is, flanked by PTX on one side and another relatively large molecule such as PAMAM or a mAb on the other, the overall solubility was lost beyond the 3-PTX substitution number. The other alternative, the use of a solubilizing linker as a pendant group with only one end attached to the rest of the molecule and possessing a branched structure was, therefore, considered. An expected advantage of a branched design was to provide a larger “hydrophilic sphere” in contrast to a long straight-chain solubilizer of the same molecular weight. These considerations led to the use of the branched and single-MW (discrete) PEG (dPEG) <b>2</b>, shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. The rationale for using a dPEG, as opposed to the conventional polydispersed PEGs, was the possibility of exact stoichiometric calculations. A single-MW preconjugation PTX would make possible the execution of controlled conjugation reactions with known D:mAb molar ratios. As it turned out, this design of the PTX derivatives <b>9a</b> and <b>9b</b> did indeed produce completely water-soluble, high-drug-load antibody conjugates. Refrigerated buffered solutions of the conjugates (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, compounds <b>11a</b>−<b>11h</b>) remained indefinitely clear and homogeneous.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Cell Binding Activity</h3><div class="NLM_p">An important consideration in the practice of mAb conjugation is the preservation of the immunoreactivity (IR) of the antibody as a direct factor in target recognition. An impaired IR would lead to reduced tumor-delivered doses of the drug, and therefore, to reduced therapeutic efficacies. As the preservation of the IR is expected to be inversely proportional to the conjugation degree, the cell binding activity of these high-load conjugates were of primary interest. FACS analysis was performed on each conjugate to compare their binding ability to MDA-MB-468 human breast carcinoma cells as compared to the unconjugated antibody C225. This experiment was carried out with the conjugates of the glutarate derivative <b>9a</b> as the main candidate for in vivo studies (see <a class="ref internalNav" href="#sec2_5" aria-label="Cytotoxicity">Cytotoxicity</a> section, below). As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, in all compounds, conjugation of compound <b>9a</b> at different D:mAb ratios, had no detectable effect on the IR of the antibody. All conjugates did bind to the cell surface EGFRs to the same extent as did the parent antibody. Any reduction in the antigen binding ability of the conjugate would have led to a shift in the location of the corresponding fluorescence peak with respect to that of the unconjugated C225 peak (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. FACS analyses of the unconjugated C225 (B) and PTX conjugates <b>11a</b>−<b>11d</b> (C−F, respectively) against MDA-MB-468 human breast carcinoma cells. All conjugates showed a significant shift in the light intensity compared to a no-mAb run (A), indicating the preserved immunoreactivity of the antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Cytotoxicity</h3><div class="NLM_p">Glutaric acid (GL) and succinic acid (SX) are the most frequently used linkers for the attachment of PTX to antibodies, peptides, and polymers. We have shown previously that under physiologic conditions, the GL linkage was about 17 times more stable against hydrolysis, and thus PTX release, than was the SX linkage.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In addition to the direct kinetics experiments, this difference in stability was shown by the negligible in vitro cell killing activity of the PTXGLC225 when the drug exposure time was 24 h (Safavy, unpublished results). On the other hand, the in vivo activity observed for PTXGLC225 was absent in the case of PTXSXC225, presumably due to a rapid release and excretion of the drug which occurred prior to its peak tumor uptake.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Accordingly, we proposed the use of GL linkers for PTX conjugates intended for systemic (in vivo) applications while SX was suggested for in vitro studies.</div><div class="NLM_p">The linker effect was confirmed also in the present study when only negligible cytotoxicity was observed for the GL-linked conjugates <b>11a</b>−<b>11d</b> (data not shown), although the FACS studies had demonstrated the preservation of the immunoreactivity of the C225 moiety. To extend the validity of the previous findings on linker−cytotoxicity relationships to the conjugates of the present study, we also synthesized the SX-linked versions of PTXdPEGC225 conjugates solely for cytotoxicity evaluation. The synthesis was carried out through the same method as for the GL conjugates and as shown in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, leading to the preparation of conjugates <b>11e</b>−<b>11h</b>. As expected, all SX conjugates showed cytotoxic activity against MDA-MB-468 human breast carcinoma cell line in a cell proliferation assay. In this assay, the cells were treated with either the blank medium, free PTX, or each of the <b>11e</b>−<b>11h</b> conjugates for 24 h, followed by removal of the treatments and continuation of the incubation for an additional 72 h. An equimolar dose of PTX was used in all treated groups. Viable cells were then counted, and the cell numbers in each group was normalized against the untreated controls. The conjugates showed the same cytotoxic activity as the unconjugated drug, indicating complete preservation of PTX activity. These results are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cell proliferation inhibition in MDA-MB-468 human breast carcinoma cell line treated with either free PTX or each of the <b>11e</b>−<b>11h</b> conjugates at 10 nM drug equivalent concentration and with a 24 h exposure time. Surviving cell numbers were normalized against the untreated controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In an effort to produce high-drug-load, yet water-soluble, paclitaxel conjugates for tumor-targeted chemotherapy of cancer, novel derivatives of the antitumor drug paclitaxel (PTX, taxol) were synthesized and were conjugated to the chimeric anti-EGFR mAb, C225. The conjugation number increased in direct proportion to the increasing drug stoichiometry, reaching a D:mAb ratio of 12 and 10 for the two highest load compounds. Unlike the previously reported low-drug-load conjugates with limited aqueous solubility at D:mAb of >3, these conjugates were highly soluble in physiologic buffers at ambient and refrigerated temperatures and thus may be suitable for excipient-free clinical formulations. As evidenced by FACS analysis, conjugation of these compounds did not alter the immunoreactivity of the parent antibody at up to a PTX:mAb molar ratios of 12. The retention of the drug cytotoxicity was also demonstrated through cell proliferation assays against a human breast cancer cell line. To our knowledge, no other PTXMAb conjugates with these high D:mAb ratios have been previously reported. With the ability to carry, target, and deliver a therapeutically significant load of the drug, these compounds may have potential in the development of tumor-targeting PTX conjugates for clinical applications.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> General Information</h3><div class="NLM_p last">Paclitaxel <i>hemi</i>-glutarate and <i>hemi</i>-succinate and their corresponding <i>N</i>-hydroxysuccinimide esters (PTXGLNHS and PTXSXNHS) were prepared by the methods of Deutsch et al.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and Luo and Prestwich,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> respectively. C225 (Erbitux) was generously provided by ImClone Systems (New York, NY). Discrete PEG (dPEG) linkers (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, compounds <b>2</b> and <b>3</b>) were purchased from Quanta BioDesign, Ltd. (Powell, OH). Buffers and aqueous solvents were prepared with metal-free purified water (18.2 MΩ) obtained from a Milli-QF system (Millipore, Bedford, MA). Dry solvents were of Sigma-Aldrich (Milwaukee, WI) anhydrous grade, which were kept over 4 Å molecular sieves before use. All compounds used in this work were of ≥95% purity. Measures of purities were provided by the manufacturers for the commercially supplied compounds. The purities of the intermediate and final product organic compounds were determined by thin-layer chromatography (TLC) (for non-UV-active compounds) or by reversed-phase (RP) HPLC and TLC (for UV-active compounds). The purities of the drug−antibody conjugates were determined by size-exclusion (SE) HPLC. TLC analyses were performed on aluminum backed silica gel 60 F<sub>254</sub> plates (Merck, Darmstadt, Germany), eluted with 15:1:84, v/v, methanol:HOAc:chloroform. TLC results are reported for each compound in the form of the corresponding <i>R</i><sub>f</sub> values with the corresponding purities shown in parentheses. Products <b>5</b>, <b>6</b>, and <b>7</b> were visualized by iodine (I<sub>2</sub>) and ninhydrine staining, respectively. Products <b>8a</b>, <b>8b</b>, <b>9a</b>, and <b>9b</b> were detected by both UV light and I<sub>2</sub> staining. RP-HPLC was performed with a Beckman System Gold instrument operated by Beckman 32 Karat Version 5.0 software and equipped with a System Gold 166 UV/VIS detector (Beckman Coulter, Fullerton, CA) at 254 nm. Analytical and preparative RP-HPLC was performed in 4.6 mm × 250 mm, C18, and 22 mm × 250 mm, C8 columns with 5 μm particle size (GraceVydac, Deerfield, IL), respectively. Elution solvents were 0.1% TFA:H<sub>2</sub>O (solvent A) and 0.1:60:40, TFA:CH<sub>3</sub>CN:H<sub>2</sub>O, v/v, (solvent B). A solvent B gradient of 10−90% was used in each run and within 20 min (analytical runs) or 90 min (preparative runs). SEC-HPLC was performed with a BioRad model 5000 Titanium System (BioRad, Richmond, CA) equipped with a model 1806 UV/VIS detector at 280 nm. For analytical SEC-HPLC, a Biosil 7.8 mm × 300 mm column (BioRad) equipped with a Biosil 7.8 mm × 80 mm guard column was used. A 10 mM phosphate buffer containing 300 mM NaCl, 10 mM Na<sub>2</sub>SO<sub>4</sub>, and 10% (v/v) DMSO was used as solvent. Protein concentrations were determined using a BCA protein assay kit (Thermo Scientific, Rockford, IL) according to the manufacturer protocol. FACS analyses were performed on a Becton Dickinson FACScan (BD Biosciences, San Jose, CA) using CellQuest v.3.1 software. Fluorescein-labeled mouse antihuman secondary antibody (Invitrogen, Frederick, MD) was used as the secondary antibody and was excited by 488 nm blue laser followed by detection in FL1 channel on a log scale of mean fluorescence intensity.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> MALDI-TOF Mass Spectrometry</h3><div class="NLM_p">For compounds <b>5</b>−<b>9</b> the MALDI MS analyses were performed with a Voyager Elite mass spectrometer in positive mode and with delayed extraction technology (PerSeptive Biosystems, Framingham, MA). Sinapinic acid was used as matrix, and samples were prepared in a 50:50 (v/v) mixture of 0.1% TFA/acetonitrile. One μL of the prepared sample was then spotted onto MALDI stainless steel target and air-dried before analysis. A 1 pmol/L solution of bovine serum albumin was used as internal standard.</div><div class="NLM_p last">For C225 and all antibody conjugates MALDI MS was performed with a Bruker Reflex III MALDI-TOF with a linear detector and in positive mode. The protein solution was mixed with sinapinic acid matrix solution (6 mg/mL, 50:50 CAN:H<sub>2</sub>O, v/v, containing 0.1% TFA) at proper ratios depending on the sample concentration. One μL of the prepared sample was then spotted onto MALDI stainless steel target and air-dried before analysis. External calibration was performed with bovine serum albumin with [M + H] average mass (<i>m</i>/<i>z</i>) of 66430.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Boc-Lys[(dPEG12)<sub>3</sub>-dPEG4]-OH, <b>5</b></h3><div class="NLM_p last">To the solution of dPEG <b>2</b> (450 mg, 186 μmol) in DCM was added a solution of Boc-lysine (<b>4</b>, 54.5 mg, 221.3 μmol) in three parts of 43.5, 5, and 6 mg, within 24 h, under argon and with stirring. The complete disappearance of the starting material <b>2</b>, as monitored by TLC, was observed after an additional 48 h. The solvents were distilled in vacuum, and the residual oil was redissolved in 10 mL of purified water. The turbid mixture was transferred into a dialysis membrane and was dialyzed first against 2 L of 150 mM chloride buffer for 2 h and then in water (3 × 2 L) for 5 h, both at 4 °C. Lyophilization of the clear solution afforded the product <b>5</b> as a light-yellow oil. Yield: 366 mg, 74%. <i>R</i><sub>f</sub>: 0.62 (I<sub>2</sub>, one spot). MALDI MS: (M + H)<sup>+</sup>-Boc, 2551−100 = 2451 (calcd 2552).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Boc-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-OH, <b>6</b></h3><div class="NLM_p">Conjugate <b>5</b> (351 mg, 132.5 μmol) was dissolved in DCM and a solution of NHS (61 mg, 530 μmol) in THF was added under argon. After cooling the mixture in ice, a solution of DCC (34.25 mg, 166 μmol) in DCM was added in several portions. The ice bath was removed, and the reaction mixture was stirred at ambient temperature for 48 h. The solid precipitate was filtered off, and the solvents were distilled in vacuum to a viscous clear oil.</div><div class="NLM_p last">The oily activated ester was redissolved in dry DMF (1 mL), and a solution of the dPEG6 (<b>3</b>, 51.5 mg, 145.7 μmol) in MTL (800 μL), containing 38.2 μL (219 μmol) DIEA was slowly added. A second portion of <b>3</b> (5.5 mg, 15.6 μmol) in 500 μL of MTL was added after 18 h. After another 3 h, the solvents were removed in vacuum and the residual oil was redissolved in 2 mL of 50 mM, acetate buffer at pH 4.1. The solution was dialyzed against 3 × 2 L of water at 4 °C and for 20 h. The slight quantity of particulate mass was removed by centrifugation, and the clear solution was lyophilized to afford <b>6</b> as a highly viscous clear oil. Yield: 244 mg (61%). <i>R</i><sub>f</sub>: 0.6 (I<sub>2</sub>, product + one minor spot). MALDI MS: (M + H)<sup>+</sup>-Boc, 2886−100 = 2786 (calcd 2887).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> H-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-OH·TFA, <b>7</b></h3><div class="NLM_p last">To an argon-purged ice-cold round-bottomed flask containing conjugate <b>6</b> (230 mg, 77 μmol) was added 5 mL of a mixture of TIPS and TFA (5:95, v/v) and the solution was incubated at ambient temperature for 30 min. The solvents were removed in vacuum, followed by addition and distillation of 10 mL of CHL. The oily product <b>7</b> was kept under high vacuum for 12 h. Yield: 224 mg (100%). <i>R</i><sub>f</sub>: 0.3 (ninhydrin, product + one minor spot). MS: (M + H)<sup>+</sup> 2788 (calcd 2787).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> PTXGL-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-OH, <b>8a</b></h3><div class="NLM_p last">The amine salt <b>7</b> (223.4 mg, 77 μmol) was dissolved in DCM (5 mL) and solution of PTXGLNHS or PTXSXNHS (93.2 mg, 87.5 μmol) in 2 mL dry DCM was added under argon. DIEA (200 μmol) was added in 30 μL portions to raise the pH of the reaction to ∼pH 8, as tested on a wet pH paper. The clear solution was stirred at ambient temperature for 12 h. Solvent was removed in vacuum and the crude product was purified by column chromatography in a 2.3 cm × 12 cm column eluted with 0.1% HOAc in chloroform and a 0−7% MTL gradient. The isolated product was redissolved in ACN:water (70:30, v/v), followed by lyophilization, to remove traces of HOAc and to afford a semisolid product. Yield: 297 mg (62%). <i>R</i><sub>f</sub>: 0.79 (UV and I<sub>2</sub>, one spot). <i>t</i><sub>R</sub> (RP-HPLC) 23.5 min (>98%). MALDI MS: (M + H)<sup>+</sup> 3740 (calcd 3737).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> PTXSX-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-OH, <b>8b</b></h3><div class="NLM_p last">The same procedure as for <b>8a</b> was used except for the use of PTXSXNHS (92 mg, 87.5 μmol). Yield: 215 mg (73%). <i>R</i><sub>f</sub>: 0.71 (UV and I<sub>2</sub>, one spot); <i>t</i><sub>R</sub> (RP-HPLC) 23.4 min (98.7%). MALDI MS: (M + H)<sup>+</sup> 3759 (calcd 3723).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> PTXGL-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-NHS, <b>9a</b></h3><div class="NLM_p last">A solution of NHS (19.94 mg, 173.3 μmol) in 500 μL of THF was added to that of <b>8a</b> (297 mg, 75.2 μmol) in 5 mL of DCM under argon, followed by the addition of DCC (24.5 mg, 118.4 μmol) in DCM (1 mL). The solution was stirred at room temperature overnight, producing a white solid precipitate. A second portion of DCC (10 mg, 48.5 μmol) in 300 μL of DCM was added and the reaction was stirred at ambient temperature for an additional 48 h. The solvents were distilled in vacuum, the semisolid residue was treated with a mixture of ACN:WTR (60:40, v/v), and the solid precipitate was removed by centrifugation. The product <b>9a</b> was purified by preparative RP-HPLC. Yield: 140 mg (47%). <i>R</i><sub>f</sub>: 0.65 (UV and I<sub>2</sub>, one spot); <i>t</i><sub>R</sub> (RP-HPLC) 24.16 min (>98%). MALDI MS: (M + H)<sup>+</sup> 3830 (calcd 3834).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> PTXSX-Lys[(dPEG12)<sub>3</sub>-dPEG4]-dPEG6-NHS, <b>9b</b></h3><div class="NLM_p last">The same procedure as for <b>9a</b> was used except for the use of <b>8b</b> (287.5 mg, 75.2 μmol). Yield: 268.3 mg (91%). <i>R</i><sub>f</sub>: 0.54 (UV and I<sub>2</sub>, one spot); <i>t</i><sub>R</sub> (RP-HPLC) 23.18 min (96.4%). MALDI MS: (M + H)<sup>+</sup> 3857 (calcd 3820).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure for Antibody Conjugation</h3><div class="NLM_p last">The antibody solution was buffer-exchanged by filtration in Centricon-50 centrifuge funnels (Millipore, Bedford, MA) at 4000 rpm into an 8.1 mM PBS at pH 8.1, and the protein concentration was measured. For each conjugation, 600 μL of the antibody solution containing 2 mg (1.3 × 10<sup>−5</sup> mmol) was chilled in an ice bath and a measured amount of <b>9a</b> or <b>9b</b> in the same buffer was added with gentle stirring at 0 °C. The calculated <b>9a</b>/<b>9b</b>:C225 molar ratios were 5, 10, 20, and 50. After 1 h, the solution was dialyzed in a 50-K MWCO membrane against 4 × 2 L of DPBS for 12 h at 4 °C. The product was analyzed for purity by SEC-HPLC. Formation of the product conjugates and the number of substituted drugs per C225 were determined by MALDI-TOF MS and using eq <a class="ref internalNav" href="#eq1" aria-label="1">1</a>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Cell Proliferation Assays</h3><div class="NLM_p last">MDA-MB-468 human breast carcinoma cells (American Type Culture Collection, Manassas, VA) were maintained as monolayers in 75 cm tissue culture flasks using their respective cell culture medium containing 10% fetal bovine serum and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. Incubation was at 37 °C under a humidified 5% CO<sub>2</sub>:air atmosphere (standard conditions) for five days. The cells were harvested when in midlog growth and their concentration was determined using a particle counter (Beckman Coulter, Inc., Fullerton, CA). An aliquot of the cell suspension was diluted in culture medium for delivery to a 24-well tissue culture plate at a range of 10000−30000 per mL per well. After 24 h, quadruplicate wells were inoculated with either the medium as untreated controls or a test compound at a 10 nM drug equivalent concentration. After 24 h of incubation, the wells were aspirated, washed once with 1 mL of PBS, and were refilled with 1 mL treatment-free medium. Following a 96-h post-treatment incubation under standard conditions, the viable cells were counted and the numbers were normalized to the number of untreated controls. The extent of cytotoxicity in treated wells as compared to the controls was calculated using Microsoft Excel software program (Microsoft Corp., Redmond, WA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25"><a href="/doi/suppl/10.1021/jm900899g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Comparative <sup>1</sup>H NMR for paclitaxel, polymers <b>2</b> and <b>3</b>, and product <b>9a</b>, mass spectra, and HPLC charts. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm900899g/suppl_file/jm900899g_si_001.pdf">jm900899g_si_001.pdf (3.79 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm900899g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmad Safavy</span> - <span class="hlFld-Affiliation affiliation">the Comprehensive Cancer Center</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7a291b1c1b0c033a0f1b18541f1e0f"><span class="__cf_email__" data-cfemail="dd8ebcbbbcaba49da8bcbff3b8b9a8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sherly Quiles</span> - <span class="hlFld-Affiliation affiliation">Department of Radiation Oncology, School of Medicine</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin P. Raisch</span> - <span class="hlFld-Affiliation affiliation">the Comprehensive Cancer Center</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leisa L. Sanford</span> - <span class="hlFld-Affiliation affiliation">Department of Radiation Oncology, School of Medicine</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James A. Bonner</span> - <span class="hlFld-Affiliation affiliation">the Comprehensive Cancer Center</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported in part through grants from the Susan G. Komen for the Cure (A.S., award no. BCTR0707430), Department of Defense (DOD) Breast Cancer Research Program (A.S., award no. DAMD17-02-1-0268), and DOD Prostate Cancer Research Program (A.S., award no. DAMD17-02-1-0004). The UAB Flow Cytometry Core Facility was funded by NIH P30 grant no. AR48311. We acknowledge the assistance of D. Ray Moore and Landon Wilson (UAB Mass Spectroscopy Shared Facility) in the molecular weight determinations, and of Enid Keyser (FACS Core Facility) in the antibody binding activity analyses. Contribution of Dr. Qiaoli Liang (University of Alabama, Chemistry Mass Spectrometry Facility) in the determination of antibody conjugates molecular weights and formatting of the related data is greatly acknowledged. Sally Lagan and David Fisher are thanked for preparing the manuscript and preparation of figures, respectively.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kohler, G. M., C.</span><span> </span><span class="NLM_article-title">Continuous cultures of fused cells secreting antibody of predefined specificity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">497</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1038%2F256495a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=1172191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1975&pages=495-497&author=G.+M.%2C+C.+Kohler&title=Continuous+cultures+of+fused+cells+secreting+antibody+of+predefined+specificity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultures of fused cells secreting antibody of predefined specificity</span></div><div class="casAuthors">Kohler G; Milstein C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5517</span>),
    <span class="NLM_cas:pages">495-7</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLHx9X4gieguxsqfvU0ziafW6udTcc2eZrMcQCPq6EVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D&md5=b5003f0bd9ce2870718bc392c40b89eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F256495a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F256495a0%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DG.%2BM.%252C%2BC.%26atitle%3DContinuous%2520cultures%2520of%2520fused%2520cells%2520secreting%2520antibody%2520of%2520predefined%2520specificity%26jtitle%3DNature%26date%3D1975%26volume%3D256%26spage%3D495%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Goodwin, D. A.</span><span> </span><span class="NLM_article-title">Stategies for antibody targeting</span> <span class="citation_source-journal">Antib. Immunoconjugate Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK38Xks1GmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=427-434&author=D.+A.+Goodwin&title=Stategies+for+antibody+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for antibody targeting</span></div><div class="casAuthors">Goodwin, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Antibody, Immunoconjugates, and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-34</span>CODEN:
                <span class="NLM_cas:coden">AIRAEB</span>;
        ISSN:<span class="NLM_cas:issn">0892-7049</span>.
    </div><div class="casAbstract">A review with 51 refs.  Hybridoma technol. has made large amts. of monoclonal antibody available in the form of highly homogeneous specific reagents for clin. use.  Pretargeted radioimmunodetection (PRAID), is a method of tumor imaging in which the antibody and the radiolabel are administered sep.  Nonradioactive antibody is given 1st (pretargeted), and allowed adequate time to reach max. tumor concn.  Depending on the antibody, this may take several days.  At the time of max. tumor concn. of nonradioactive antibody, the blood is quickly cleared of excess circulating nonradioactive antibody using a special i.v. "chase".  The radiolabel then is given and imaging done in 1-3 h.  The use of short-lived tracers (hours) to image antibodies that localize slowly (days) in vivo is an important advance made possible by this new technol.  An improvement in this system is the development of bispecific antibodies that could bind both in chelate and a tumor antigen.  Either hybrid antibodies or antibody conjugates could be used for this application.  It is clear that research into methods of controlling antibody background has produced many promising leads.  Methods of background redn. will be as important to the eventual successful clin. application of antibodies, as are improvements in antibody affinity, specificity and decreased antigenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9-QvQT4onIbVg90H21EOLACvtfcHk0likiWfVa3yK4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks1GmtLk%253D&md5=9b80120ab210e67eb57cd847703230ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DD.%2BA.%26atitle%3DStategies%2520for%2520antibody%2520targeting%26jtitle%3DAntib.%2520Immunoconjugate%2520Radiopharm.%26date%3D1991%26volume%3D4%26spage%3D427%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mamot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallab, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotin, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11631</span><span class="NLM_x">–</span> <span class="NLM_lpage">11638</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11631-11638&author=C.+Mamotauthor=D.+C.+Drummondauthor=C.+O.+Nobleauthor=V.+Kallabauthor=Z.+Guoauthor=K.+Hongauthor=D.+B.+Kirpotinauthor=J.+W.+Park&title=Epidermal+growth+factor+receptor-targeted+immunoliposomes+significantly+enhance+the+efficacy+of+multiple+anticancer+drugs+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DNoble%26aufirst%3DC.%2BO.%26aulast%3DKallab%26aufirst%3DV.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor-targeted%2520immunoliposomes%2520significantly%2520enhance%2520the%2520efficacy%2520of%2520multiple%2520anticancer%2520drugs%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11631%26epage%3D11638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Richman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denardo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Donnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuscano, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukis, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meares, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamborn, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNardo, G. L.</span><span> </span><span class="NLM_article-title">High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5920</span><span class="NLM_x">–</span> <span class="NLM_lpage">5927</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1158%2F1078-0432.CCR-05-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16115934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5920-5927&author=C.+M.+Richmanauthor=S.+J.+Denardoauthor=R.+T.+O%27Donnellauthor=A.+Yuanauthor=S.+Shenauthor=D.+S.+Goldsteinauthor=J.+M.+Tuscanoauthor=T.+Wunauthor=H.+K.+Chewauthor=P.+N.+Laraauthor=D.+L.+Kukisauthor=A.+Natarajanauthor=C.+F.+Mearesauthor=K.+R.+Lambornauthor=G.+L.+DeNardo&title=High-dose+radioimmunotherapy+combined+with+fixed%2C+low-dose+paclitaxel+in+metastatic+prostate+and+breast+cancer+by+using+a+MUC-1+monoclonal+antibody%2C+m170%2C+linked+to+indium-111%2Fyttrium-90+via+a+cathepsin+cleavable+linker+with+cyclosporine+to+prevent+human+anti-mouse+antibody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody</span></div><div class="casAuthors">Richman, Carol M.; DeNardo, Sally J.; O'Donnell, Robert T.; Yuan, Aina; Shen, Sui; Goldstein, Desiree S.; Tuscano, Joseph M.; Wun, Ted; Chew, Helen K.; Lara, Primo N.; Kukis, David L.; Natarajan, Arutselvan; Meares, Claude F.; Lamborn, Kathleen R.; DeNardo, Gerald L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5920-5927</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach.  In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer.  Exptl. Design: Patients were imaged with indium-111 (111In)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-peptide-m170.  One week later, yttrium-90 (90Y)-m170 was infused (12 mCi/m2 for prostate cancer and 22 mCi/m2 for breast cancer).  Initial cohorts received radioimmunotherapy alone.  Subsequent cohorts received radioimmunotherapy followed 48 h later by paclitaxel (75 mg/m2).  Cyclosporine was given to prevent development of human anti-mouse antibody.  Results: Bone and soft tissue metastases were targeted by 111In-m170 in 15 of the 16 patients imaged.  Three prostate cancer patients treated with radioimmunotherapy alone had no grade 3 or 4 toxicity.  With radioimmunotherapy and paclitaxel, two of three prostate cancer patients developed transient grade 4 neutropenia.  Four breast cancer patients treated with radioimmunotherapy alone had grade 3 or 4 myelosuppression.  With radioimmunotherapy and paclitaxel, both breast cancer patients developed grade 4 neutropenia.  Three breast cancer patients required infusion of previously harvested peripheral blood stem cells because of neutropenic fever or bleeding.  One patient in this trial developed human anti-mouse antibody in contrast to 12 of 17 patients in a prior trial using m170-radioimmunotherapy without cyclosporine.  Conclusions: 111In/90Y-m170 targets prostate and breast cancer and can be combined with paclitaxel with toxicity limited to marrow suppression at the dose levels above.  The max. tolerated dose of radioimmunotherapy and fixed-dose paclitaxel with peripheral blood stem cell support has not been reached.  Cyclosporine is effective in preventing human anti-mouse antibody, suggesting the feasibility of multidose, "fractionated" therapy that could enhance clin. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpab64hSW9k67Vg90H21EOLACvtfcHk0likiWfVa3yK4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Cju7k%253D&md5=7be8a557a016b53ab4b5e7afd7ddbd34</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0211%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DC.%2BM.%26aulast%3DDenardo%26aufirst%3DS.%2BJ.%26aulast%3DO%2527Donnell%26aufirst%3DR.%2BT.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DGoldstein%26aufirst%3DD.%2BS.%26aulast%3DTuscano%26aufirst%3DJ.%2BM.%26aulast%3DWun%26aufirst%3DT.%26aulast%3DChew%26aufirst%3DH.%2BK.%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DKukis%26aufirst%3DD.%2BL.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DMeares%26aufirst%3DC.%2BF.%26aulast%3DLamborn%26aufirst%3DK.%2BR.%26aulast%3DDeNardo%26aufirst%3DG.%2BL.%26atitle%3DHigh-dose%2520radioimmunotherapy%2520combined%2520with%2520fixed%252C%2520low-dose%2520paclitaxel%2520in%2520metastatic%2520prostate%2520and%2520breast%2520cancer%2520by%2520using%2520a%2520MUC-1%2520monoclonal%2520antibody%252C%2520m170%252C%2520linked%2520to%2520indium-111%252Fyttrium-90%2520via%2520a%2520cathepsin%2520cleavable%2520linker%2520with%2520cyclosporine%2520to%2520prevent%2520human%2520anti-mouse%2520antibody%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5920%26epage%3D5927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Arap, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1126%2Fscience.279.5349.377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9430587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1cXmtl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=377-380&author=W.+Arapauthor=R.+Pasqualiniauthor=E.+Ruoslahti&title=Cancer+treatment+by+targeted+drug+delivery+to+tumor+vasculature+in+a+mouse+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model</span></div><div class="casAuthors">Arap, Wadih; Pasqualini, Renata; Ruoslllahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5349</span>),
    <span class="NLM_cas:pages">377-380</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels.  When coupled to the anticancer drug doxorubicin, two of these peptides - one contg. an αv integrin-binding Arg-Gly-Asp motif and the other an Asn-Gly-Arg motif - enhanced the efficacy of the drug against human breast cancer xenografts in nude mice and also reduced its toxicity.  These results indicate that it may be possible to develop targeted chemotherapy strategies that are based on selective expression of receptors in tumor vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV-EmRwSP4s7Vg90H21EOLACvtfcHk0lg7F-SYZbF3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtl2juw%253D%253D&md5=3e0b95b3309a5cdc1353bf7e6de36ff8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5349.377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5349.377%26sid%3Dliteratum%253Aachs%26aulast%3DArap%26aufirst%3DW.%26aulast%3DPasqualini%26aufirst%3DR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCancer%2520treatment%2520by%2520targeted%2520drug%2520delivery%2520to%2520tumor%2520vasculature%2520in%2520a%2520mouse%2520model%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D377%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Novel agents on the horizon for cancer therapy</span> <span class="citation_source-journal">CA: Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=111-137&author=W.+W.+Maauthor=A.+A.+Adjei&title=Novel+agents+on+the+horizon+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520agents%2520on%2520the%2520horizon%2520for%2520cancer%2520therapy%26jtitle%3DCA%253A%2520Cancer%2520J.%2520Clin.%26date%3D2009%26volume%3D59%26spage%3D111%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span> </span><span class="NLM_article-title">Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4919</span><span class="NLM_x">–</span> <span class="NLM_lpage">4924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990355x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4919-4924&author=A.+Safavyauthor=K.+P.+Raischauthor=M.+B.+Khazaeliauthor=D.+J.+Buchsbaumauthor=J.+A.+Bonner&title=Paclitaxel+derivatives+for+targeted+therapy+of+cancer%3A+toward+the+development+of+smart+taxanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm990355x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990355x%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26atitle%3DPaclitaxel%2520derivatives%2520for%2520targeted%2520therapy%2520of%2520cancer%253A%2520toward%2520the%2520development%2520of%2520smart%2520taxanes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4919%26epage%3D4924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onetto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slichenmyer, W.</span><span> </span><span class="NLM_article-title">Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=10080588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Wmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=478-484&author=A.+W.+Tolcherauthor=S.+Sugarmanauthor=K.+A.+Gelmonauthor=R.+Cohenauthor=M.+Salehauthor=C.+Isaacsauthor=L.+Youngauthor=D.+Healeyauthor=N.+Onettoauthor=W.+Slichenmyer&title=Randomized+phase+II+study+of+BR96-doxorubicin+conjugate+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer</span></div><div class="casAuthors">Tolcher, Anthony W.; Sugarman, Steven; Gelmon, Karen A.; Cohen, Roger; Saleh, Mansoor; Isaacs, Claudine; Young, Leslie; Healey, Diane; Onetto, Nicole; Slichenmyer, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">478-484</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approx. eight doxorubicin mols.  The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues.  Preclin. xenograft models demonstrated significant antitumor activity, including cures.  A randomized phase II design was chosen to est. the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin.  Patients with measurable metastatic breast cancer and immunohistochem. evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 h or doxorubicin 60 mg/m2 every 3 wk.  Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution.  Cross-over to the apposite treatment arm was allowed with progressive or persistently stable disease.  Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable.  There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin.  No patient experienced a clin. significant hypersensitivity reaction.  The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematol. toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent.  The BR96-doxorubicin immunoconjugate has limited clin. antitumor activity in metastatic breast cancer.  The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFxjI_yzFwbVg90H21EOLACvtfcHk0lg7F-SYZbF3wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Wmur8%253D&md5=2596451b74b51e8e807c0cad537869d2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DHealey%26aufirst%3DD.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DSlichenmyer%26aufirst%3DW.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520BR96-doxorubicin%2520conjugate%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D478%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Guided molecular missiles for tumor-targeting chemotherapy—case studies using the second-generation taxoids as warheads</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=108-119&author=I.+Ojima&title=Guided+molecular+missiles+for+tumor-targeting+chemotherapy%E2%80%94case+studies+using+the+second-generation+taxoids+as+warheads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Far700093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700093f%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DGuided%2520molecular%2520missiles%2520for%2520tumor-targeting%2520chemotherapy%25E2%2580%2594case%2520studies%2520using%2520the%2520second-generation%2520taxoids%2520as%2520warheads%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D108%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Singh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinko, P. J.</span><span> </span><span class="NLM_article-title">Recent trends in targeted anticancer prodrug and conjugate design</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1802</span><span class="NLM_x">–</span> <span class="NLM_lpage">1826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.2174%2F092986708785132997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=18691040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1802-1826&author=Y.+Singhauthor=M.+Palomboauthor=P.+J.+Sinko&title=Recent+trends+in+targeted+anticancer+prodrug+and+conjugate+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recent trends in targeted anticancer prodrug and conjugate design</span></div><div class="casAuthors">Singh, Yashveer; Palombo, Matthew; Sinko, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1802-1826</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs are often nonselective antiproliferative agents (cytotoxins) that preferentially kill dividing cells by attacking their DNA at some level.  The lack of selectivity results in significant toxicity to non-cancerous proliferating cells.  These toxicities along with drug resistance exhibited by the solid tumors are major therapy limiting factors that result into poor prognosis for patients.  Prodrug and conjugate design involves the synthesis of inactive drug derivs. that are converted to an active form inside the body and preferably at the site of action.  Classical prodrug and conjugate design have focused on the development of prodrugs that can overcome physicochem. (e.g., soly., chem. instability) or biopharmaceutical problems (e.g., bioavailability, toxicity) assocd. with common anticancer drugs.  The recent targeted prodrug and conjugate design, hinge on the selective delivery of anticancer agents to tumor tissues thereby avoiding their cytotoxic effects on non-cancerous cells.  Targeting strategies have attempted to take advantage of low extracellular pH, elevated enzymes in tumor tissues, the hypoxic environment inside the tumor core, and tumor-specific antigenes expressed on tumor cell surfaces.  The present review highlights recent trends in prodrug and conjugate rationale and design for cancer treatment.  The various approaches that are currently being explored are critically analyzed and a comparative account of the advantages and disadvantages assocd. with each approach is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraaVRH_vxxs7Vg90H21EOLACvtfcHk0lgUQ4kElDOJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbo%253D&md5=dcb67c51e04c97d8a838188e2b29b000</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F092986708785132997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785132997%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DPalombo%26aufirst%3DM.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DRecent%2520trends%2520in%2520targeted%2520anticancer%2520prodrug%2520and%2520conjugate%2520design%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1802%26epage%3D1826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Akamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreitman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junghans, R. P.</span><span> </span><span class="NLM_article-title">A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9829749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Ogu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=2825-2832&author=Y.+Akamatsuauthor=J.+C.+Murphyauthor=K.+F.+Nolanauthor=P.+Thomasauthor=R.+J.+Kreitmanauthor=S.+O.+Leungauthor=R.+P.+Junghans&title=A+single-chain+immunotoxin+against+carcinoembryonic+antigen+that+suppresses+growth+of+colorectal+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells</span></div><div class="casAuthors">Akamatsu, Y.; Murphy, J. C.; Nolan, K. F.; Thomas, P.; Kreitman, R. J.; Leung, S-O.; Junghans, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2825-2832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have engineered an anti-carcinoembryonic antigen (CEA) single-chain immunotoxin derived from humanized anti-CEA antibody (hMN14) and a truncated Pseudomonas exotoxin (PE), PE40.  The purified anti-CEA immunotoxin (hMN14(Fv)-PE40) was first measured for binding affinity against a CEA-pos. colorectal carcinoma cell line and compared with its parental IgG and the monovalent Fab fragment.  The Ka of sFv-PE40, Fab, and IgG were 5×107, 6×107, and 3×108 M-1, resp.  There was no affinity loss by conversion of Fab to the single-chain Fv, but these monovalent forms were 5-6-fold reduced in affinity compared with the parental IgG.  In cytotoxicity assays, the hMN14(Fv)-PE40 showed specific growth suppression of CEA-expressing colon cancer cell lines MIP-CEA (high CEA) and LS174T (moderate CEA) with IC50s of 12 ng/mL (0.2 nM) and 69 ng/mL (1.1 nM).  These IC50s correlated inversely with the surface expression of CEA, such that 50% killing was equiv. for each cell type when expressed in toxin mols. bound/cell (3000-5000).  The presence of sol. CEA up to 1000 ng/mL did not affect the cytotoxicity against CEA-expressing cells, with 50% suppression only at 4000 ng/mL that correlated with the binding Kd of the single-chain Fv.  The stability of the hMN14(Fv)-PE40 mol. at 37° was confirmed by bioassay and by lack of aggregation.  The authors' hMN14(Fv)-PE40 may be clin. useful for tumors with high CEA expression without affecting normal tissues with low or absent CEA, even in patients with high sol. antigen levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh9Ql_BJv4LVg90H21EOLACvtfcHk0lgUQ4kElDOJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Ogu78%253D&md5=64ef9865b5db5b4be8eff0562dd13ea6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAkamatsu%26aufirst%3DY.%26aulast%3DMurphy%26aufirst%3DJ.%2BC.%26aulast%3DNolan%26aufirst%3DK.%2BF.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DKreitman%26aufirst%3DR.%2BJ.%26aulast%3DLeung%26aufirst%3DS.%2BO.%26aulast%3DJunghans%26aufirst%3DR.%2BP.%26atitle%3DA%2520single-chain%2520immunotoxin%2520against%2520carcinoembryonic%2520antigen%2520that%2520suppresses%2520growth%2520of%2520colorectal%2520carcinoma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26spage%3D2825%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kreitman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastan, I.</span><span> </span><span class="NLM_article-title">Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2F%28SICI%291097-0215%2819990331%2981%3A1%3C148%3A%3AAID-IJC24%3E3.0.CO%3B2-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=10077166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVKrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1999&pages=148-155&author=R.+J.+Kreitmanauthor=Q.+C.+Wangauthor=D.+J.+FitzGeraldauthor=I.+Pastan&title=Complete+regression+of+human+B-cell+lymphoma+xenografts+in+mice+treated+with+recombinant+anti-CD22+immunotoxin+RFB4%28dsFv%29-PE38+at+doses+tolerated+by+cynomolgus+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys</span></div><div class="casAuthors">Kreitman, Robert J.; Wang, Qing-Cheng; FitzGerald, David J. P.; Pastan, Ira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-155</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">RFB4(dsFv)-PE38 is a recombinant immunotoxin in which the variable light domain (VL) is disulfide bonded via cysteine residues to the variable heavy domain (VH), which in turn is fused to PE38, a mutant form of Pseudomonas exotoxin A.  RFB4 binds to CD22, which is a differentiation antigen expressed on the majority of B-cell leukemias and lymphomas.  To examine the potential efficacy of RFB4(dsFv)-PE38 when administered at a dose schedule appropriate for phase I testing, mice bearing CA46 human CD22+ Burkitt's lymphoma xenografts were treated on alternate days i.v. for 3 doses (QOD ×3).  Complete regressions were obsd. in 80% and 100% of mice treated with 200 and 275 μg/kg QOD ×3, resp.  The higher dose was 27% of the LD50 and 34% of the LD10 in mice.  Because RFB4(dsFv)-PE38 is stable at 37°, it could also be given by continuous infusion using pumps placed in the peritoneal cavity; complete regressions also resulted from this mode of administration.  To study toxicol., a pilot toxicol. study of RFB4(dsFv)-PE38 was undertaken in cynomolgus monkeys, which like humans but unlike mice have CD22, which binds RFB4.  Doses of 100 and 500 μg/kg i.v. QOD ×3 were well tolerated, indicating that a dose that cured tumors in mice was tolerated by primates.  Based on these preclin. results, RFB4(dsFv)-PE38 is being developed for the treatment of patients with CD22-pos. leukemias and lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKJFEyUhlGbVg90H21EOLACvtfcHk0lgUQ4kElDOJvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVKrs70%253D&md5=06f42e084559abd2da1a47d498119302</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819990331%2981%3A1%3C148%3A%3AAID-IJC24%3E3.0.CO%3B2-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819990331%252981%253A1%253C148%253A%253AAID-IJC24%253E3.0.CO%253B2-L%26sid%3Dliteratum%253Aachs%26aulast%3DKreitman%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%2BC.%26aulast%3DFitzGerald%26aufirst%3DD.%2BJ.%26aulast%3DPastan%26aufirst%3DI.%26atitle%3DComplete%2520regression%2520of%2520human%2520B-cell%2520lymphoma%2520xenografts%2520in%2520mice%2520treated%2520with%2520recombinant%2520anti-CD22%2520immunotoxin%2520RFB4%2528dsFv%2529-PE38%2520at%2520doses%2520tolerated%2520by%2520cynomolgus%2520monkeys%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D81%26spage%3D148%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazooband, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span> </span><span class="NLM_article-title">De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0100861" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1elt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=317-326&author=A.+Safavyauthor=D.+C.+Smithauthor=A.+Bazoobandauthor=D.+J.+Buchsbaum&title=De+novo+synthesis+of+a+new+diethylenetriaminepentaacetic+acid+%28DTPA%29+bifunctional+chelating+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Synthesis of a New Diethylenetriaminepentaacetic Acid (DTPA) Bifunctional Chelating Agent</span></div><div class="casAuthors">Safavy, Ahmad; Smith, Dale C., Jr.; Bazooband, Alireza; Buchsbaum, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diethylene triamine pentaacetic acid (DTPA) has been in extensive use as a metal chelator in the development of radiopharmaceuticals and contrast agents.  The former application uses DTPA mostly as a bifunctional chelating agent (BCA) conjugated to tumor-targeting vehicles (TTVs) such as monoclonal antibodies (MAbs) and receptor-directed peptides.  A new bifunctional DTPA deriv. was synthesized by a fully org. scheme.  This compd., N4,Nα,Nα,Nε,Nε-[pentakis(carboxymethyl)]-N4-(carboxymethyl)-2,6-diamino-4-azahexanoic hydrazide was prepd. by a convergent synthesis strategy using Nα-benzyloxycarbonyl-2,3-diaminopropionic acid as the starting compd.  This com. available material was used to build a functionalized triamine which served as the mol. core template for assembling the target mol.  To evaluate the conjugation and radiolabeling capabilities of this new mol., it was covalently attached to the anti-TAG-72 MAb, ΔCH2HuCC49, and the conjugate was radiolabeled in near-quant. yields with yttrium-90 (90Y) and lutetium-177 (177Lu).  Biodistribution of the 177Lu-labeled DTPA-ΔCH2HuCC49 in tumor-bearing nude mice demonstrated preservation of the immunoreactivity of the MAb as indicated by high tumor uptake.  In addn. to the introduction of a new bifunctional DTPA, this work reports on a novel synthetic approach for prepn. of this useful metal chelator and introduces a new conjugation protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUCv_CrUQglLVg90H21EOLACvtfcHk0lhFV3dg96Zp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1elt7s%253D&md5=76c4c4a03e891027edeb9db81d5966a3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbc0100861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0100861%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DBazooband%26aufirst%3DA.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26atitle%3DDe%2520novo%2520synthesis%2520of%2520a%2520new%2520diethylenetriaminepentaacetic%2520acid%2520%2528DTPA%2529%2520bifunctional%2520chelating%2520agent%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Targeted therapy of cancer: new prospects for antibodies and immunoconjugates</span> <span class="citation_source-journal">CA: Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2006&pages=226-243&author=R.+M.+Sharkeyauthor=D.+M.+Goldenberg&title=Targeted+therapy+of+cancer%3A+new+prospects+for+antibodies+and+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DTargeted%2520therapy%2520of%2520cancer%253A%2520new%2520prospects%2520for%2520antibodies%2520and%2520immunoconjugates%26jtitle%3DCA%253A%2520Cancer%2520J.%2520Clin.%26date%3D2006%26volume%3D56%26spage%3D226%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Recent advances in the new generation taxane anticancer agents</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16787308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=125-139&author=R.+Geneyauthor=J.+Chenauthor=I.+Ojima&title=Recent+advances+in+the+new+generation+taxane+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the new generation taxane anticancer agents</span></div><div class="casAuthors">Geney, R.; Chen, J.; Ojima, I.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-139</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in the design and preclin. evaluations of promising new generation taxane anticancer agents were reviewed in this article.  Paclitaxel and docetaxel are two of the most important anticancer drugs today.  However, recent reports have shown that treatment with these drugs often encounters undesirable side effects as well as drug resistance.  Therefore, it is important to develop new taxane anticancer agents with fewer side effects, superior pharmacol. properties, and improved activity against drug-resistant human cancers.  Structure-activity relationship (SAR) studies led to the discovery of a series of highly active second-generation taxanes.  One of them, "Ortataxel" (SB-T-101131, IDN5109, BAY59-8862), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines, as well as human tumor xenografts in mice.  It is orally active and is currently in phase II clin. trials.  Photoaffinity labeling of microtubules and P-glycoprotein using photoreactive radiolabeled taxoids has disclosed the drug-binding domain of tubulin as well as Pgp.  Together with information on microtubule-bound fluorine-labeled taxoids obtained by solid-state NMR studies, the bioactive conformation of paclitaxel and taxoids appears to emerge.  Novel taxane-monoclonal antibody (mAb) immunoconjugates, have shown highly promising results for the tumor-specific delivery and release of an extremely cytotoxic, second-generation taxane.  Also, another novel series of second generation taxanes conjugated with n-3 polyunsatd. fatty acids, e.g. decosahexaenoic acid (DHA), has exhibited impressive antitumor activity with min. general toxicity against the highly drug-resistant DLD-1 human colon cancer xenografts in SCID mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZJJWUM_nE7Vg90H21EOLACvtfcHk0lhFV3dg96Zp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSqtbg%253D&md5=69be8a1b7f9742652898a5de8bbef505</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520the%2520new%2520generation%2520taxane%2520anticancer%2520agents%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D125%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirikae, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirikae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respicio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slayden, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050920y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=463-466&author=Q.+Huangauthor=F.+Kirikaeauthor=T.+Kirikaeauthor=A.+Pepeauthor=A.+Aminauthor=L.+Respicioauthor=R.+A.+Slaydenauthor=P.+J.+Tongeauthor=I.+Ojima&title=Targeting+FtsZ+for+antituberculosis+drug+discovery%3A+noncytotoxic+taxanes+as+novel+antituberculosis+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FtsZ for Antituberculosis Drug Discovery: Noncytotoxic Taxanes as Novel Antituberculosis Agents</span></div><div class="casAuthors">Huang, Qing; Kirikae, Fumiko; Kirikae, Teruo; Pepe, Antonella; Amin, Amol; Respicio, Laurel; Slayden, Richard A.; Tonge, Peter J.; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of 120 taxanes identified a no. of compds. that exhibited significant antituberculosis activity.  Rational optimization of selected compds. led to the discovery that the C-seco-taxane-multidrug-resistance (MDR) reversal agents (C-seco-TRAs) are noncytotoxic at the upper limit of soly. and detection (>80 μM), while maintaining MIC99 values of 1.25-2.5 μM against drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis (MTB).  Treatment of MTB cells with TRA 3aa and 10a at the MIC caused filamentation and prolongation of the cells, a phenotypic response to FtsZ inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFdPVd5P1UtbVg90H21EOLACvtfcHk0lhFV3dg96Zp0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7O&md5=40a2673981184262ba3d1dc2d6e0019f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm050920y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050920y%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKirikae%26aufirst%3DF.%26aulast%3DKirikae%26aufirst%3DT.%26aulast%3DPepe%26aufirst%3DA.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DRespicio%26aufirst%3DL.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DTargeting%2520FtsZ%2520for%2520antituberculosis%2520drug%2520discovery%253A%2520noncytotoxic%2520taxanes%2520as%2520novel%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Holmes, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theriault, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raber, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1797</span><span class="NLM_x">–</span> <span class="NLM_lpage">1805</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1093%2Fjnci%2F83.24.1797-a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=1683908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK38%252FnvFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1991&pages=1797-1805&author=F.+A.+Holmesauthor=R.+S.+Waltersauthor=R.+L.+Theriaultauthor=A.+D.+Formanauthor=L.+K.+Newtonauthor=M.+N.+Raberauthor=A.+U.+Buzdarauthor=D.+K.+Fryeauthor=G.+N.+Hortobagyi&title=Phase+II+trial+of+taxol%2C+an+active+drug+in+the+treatment+of+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer</span></div><div class="casAuthors">Holmes F A; Walters R S; Theriault R L; Forman A D; Newton L K; Raber M N; Buzdar A U; Frye D K; Hortobagyi G N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1797-805</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation of many phase I clinical trials.  Consequently, investigators and the National Cancer Institute recommended that phase I and II studies of this agent use 24-hour infusions and antiallergic medications.  Using a premedication regimen effective in preventing hypersensitivity reactions, we have performed a phase II trial of taxol in patients with metastatic breast cancer.  Taxol was administered to 25 patients at a dose of 250 mg/m2 by 24-hour infusion every 21 days.  These patients had received only one prior chemotherapy regimen, either adjuvant to surgery or for metastatic disease; all but two had received doxorubicin.  In 60% of the patients, the dominant site of disease was the viscera.  All patients were assessable.  In April 1991, at a median time on study of 9 months (range, 5-13+ months), the objective response rate was 56% (12% complete and 44% partial; 95% confidence interval, 35%-76%).  Disease progressed in only 8% of the patients.  The median number of courses of therapy was 11.  Granulocytopenia was the dose-limiting toxic effect, but neutropenia with fever occurred in only 5% of 232 courses.  A chronic glove-and-stocking neuropathy developed in most patients, but no allergic reactions occurred.  We conclude that taxol is an active agent in the treatment of metastatic breast cancer and that it warrants continued study.  Currently, we are conducting a phase I trial of taxol plus doxorubicin.  Future trials should address the optimal effective dose, the optimal sequencing of combinations, mechanisms of drug resistance in tumors, and dose-limiting toxic effects (particularly cardiac toxic effects of taxol given as a single agent or in drug combinations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPnJK3qzA2H0loaUqgkFHkfW6udTcc2eYpCTp8xZ4Zjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FnvFaqtw%253D%253D&md5=0ad79290315081933dabf72ce788ba8e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F83.24.1797-a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F83.24.1797-a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DF.%2BA.%26aulast%3DWalters%26aufirst%3DR.%2BS.%26aulast%3DTheriault%26aufirst%3DR.%2BL.%26aulast%3DForman%26aufirst%3DA.%2BD.%26aulast%3DNewton%26aufirst%3DL.%2BK.%26aulast%3DRaber%26aufirst%3DM.%2BN.%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26aulast%3DFrye%26aufirst%3DD.%2BK.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DPhase%2520II%2520trial%2520of%2520taxol%252C%2520an%2520active%2520drug%2520in%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1991%26volume%3D83%26spage%3D1797%26epage%3D1805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Robert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asmar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilegbodu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobleigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCullough, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2786</span><span class="NLM_x">–</span> <span class="NLM_lpage">2792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1200%2FJCO.2005.04.1764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16782917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28XntV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2786-2792&author=N.+Robertauthor=B.+Leyland-Jonesauthor=L.+Asmarauthor=R.+Beltauthor=D.+Ilegboduauthor=D.+Loeschauthor=R.+Rajuauthor=E.+Valentineauthor=R.+Sayreauthor=M.+Cobleighauthor=K.+Albainauthor=C.+McCulloughauthor=L.+Fuchsauthor=D.+Slamon&title=Randomized+phase+III+study+of+trastuzumab%2C+paclitaxel%2C+and+carboplatin+compared+with+trastuzumab+and+paclitaxel+in+women+with+HER-2-overexpressing+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer</span></div><div class="casAuthors">Robert, Nicholas; Leyland-Jones, Brian; Asmar, Lina; Belt, Robert; Ilegbodu, Des; Loesch, David; Raju, Robert; Valentine, Elizabeth; Sayre, Robert; Cobleigh, Melody; Albain, Kathy; McCullough, Cecelia; Fuchs, Lea; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2786-2792</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2-overexpressing metastatic breast cancer (MBC).  Patients and Methods: HER-2 overexpression was defined as immunohistochem. staining scores of 2+ or 3+.  Between Nov. 1998 and May 2002, 196 women with HER-2-overexpressing MBC were randomly assigned to six cycles of either trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 every 3 wk (TP), or trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 and carboplatin area under the time-concn. curve = 6 every 3 wk (TPC) followed by weekly trastuzumab alone.  Results: Baseline characteristics of the 196 patients were well balanced between study arms.  Objective: response rate (ORR) was 52% (95% CI, 42% to 62%) for TPC vs. 36% (95% CI, 26% to 46%) for TP (P = .04).  Median progression-free survival (PFS) was 10.7 mo for TPC and 7.1 mo for TP (hazard ratio [HR], 0.66; 95% CI, 0.59 to 0.73; P = .03).  Improved clin. outcomes with TPC were most evident in HER-2 3+ patients, with an ORR of 57% (95% CI, 45% to 70%) v 36% (95% CI, 25% to 48%; P = .03) and median PFS of 13.8 v 7.6 mo (P = .005) for TPC and TP, resp. (HR, 0.55; 95% CI, 0.46 to 0.64).  Both regimens were well tolerated, and febrile neutropenia and neurotoxicity occurred infrequently; grade 4 neutropenia occurred more frequently with TPC (P < .01).  Conclusion: The addn. of carboplatin to paclitaxel and trastuzumab improved ORR and PFS in women with HER-2-overexpressing MBC.  This well-tolerated regimen represents a new therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXh2vAA2AjbVg90H21EOLACvtfcHk0lj7nfPFsb8jPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntV2hu7g%253D&md5=67b8f4e8e0d04bd141197cb71499b8e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.1764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.1764%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DN.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DAsmar%26aufirst%3DL.%26aulast%3DBelt%26aufirst%3DR.%26aulast%3DIlegbodu%26aufirst%3DD.%26aulast%3DLoesch%26aufirst%3DD.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DValentine%26aufirst%3DE.%26aulast%3DSayre%26aufirst%3DR.%26aulast%3DCobleigh%26aufirst%3DM.%26aulast%3DAlbain%26aufirst%3DK.%26aulast%3DMcCullough%26aufirst%3DC.%26aulast%3DFuchs%26aufirst%3DL.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DRandomized%2520phase%2520III%2520study%2520of%2520trastuzumab%252C%2520paclitaxel%252C%2520and%2520carboplatin%2520compared%2520with%2520trastuzumab%2520and%2520paclitaxel%2520in%2520women%2520with%2520HER-2-overexpressing%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2786%26epage%3D2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Reichman, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakes, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surbone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span> </span><span class="NLM_article-title">Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1943</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7691998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2c%252FhsFaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=1943-1951&author=B.+S.+Reichmanauthor=A.+D.+Seidmanauthor=J.+P.+Crownauthor=R.+Heelanauthor=T.+B.+Hakesauthor=D.+E.+Lebwohlauthor=T.+A.+Gilewskiauthor=A.+Surboneauthor=V.+Currieauthor=C.+A.+Hudis&title=Paclitaxel+and+recombinant+human+granulocyte+colony-stimulating+factor+as+initial+chemotherapy+for+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer</span></div><div class="casAuthors">Reichman B S; Seidman A D; Crown J P; Heelan R; Hakes T B; Lebwohl D E; Gilewski T A; Surbone A; Currie V; Hudis C A; et al</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1943-51</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  A phase II study of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) as initial chemotherapy for metastatic breast cancer was conducted.  Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was used to ameliorate myelosuppression, the anticipated dose-limiting toxicity.  PATIENTS AND METHODS:  Twenty-eight patients with bidimensionally measurable breast cancer who had not received prior chemotherapy for metastatic disease were treated.  Taxol was administered at 250 mg/m2 as a continuous 24-hour intravenous (i.v.) infusion every 21 days. rhG-CSF was administered at 5 micrograms/kg/d subcutaneously on days 3 through 10.  RESULTS:  Objective responses were observed in 16 of 26 assessable patients (62%; 95% confidence interval, 41% to 80%).  There were three (12%) complete responses (CRs) and 13 (50%) partial responses (PRs).  Ten of 16 patients (63%) who had received prior adjuvant chemotherapy responded, which included one CR and four PRs among eight patients who had received prior doxorubicin-containing therapy.  Responses were observed in all sites of metastatic disease.  The median time to first objective response was 5 weeks (range, 1 to 14).  Administration of rhG-CSF was associated with a short duration of neutropenia (median, 2 days with absolute neutrophil count < 500 cells/microL).  Eight of 26 patients (31%) who received more than one course received subsequent therapy without dose reduction.  One hundred seventy-eight cycles of treatment were administered, with a median of six cycles per patient (range, one to 19).  Eight courses (4.5%) were associated with admissions for neutropenic fever.  Twenty-two patients (79%) did not require admission for neutropenic fever.  Treatment was well tolerated.  Adverse effects included generalized alopecia in all patients.  Myalgias, arthralgias, and peripheral neuropathy were mild.  No hypersensitivity reactions and no cardiac toxicity were observed.  CONCLUSION:  Taxol is highly active as initial chemotherapy for metastatic breast cancer.  Administration of rhG-CSF reduced the incidence, depth, and duration of neutropenia, compared with published prior experience.  Further studies of Taxol in breast cancer, including combinations with other active agents, are clearly warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlCSSJJnBNcZggzHGM8X5CfW6udTcc2eZCVo-H3kIk47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FhsFaitg%253D%253D&md5=4d98a5b727efd94964f8d936d3d39792</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReichman%26aufirst%3DB.%2BS.%26aulast%3DSeidman%26aufirst%3DA.%2BD.%26aulast%3DCrown%26aufirst%3DJ.%2BP.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DHakes%26aufirst%3DT.%2BB.%26aulast%3DLebwohl%26aufirst%3DD.%2BE.%26aulast%3DGilewski%26aufirst%3DT.%2BA.%26aulast%3DSurbone%26aufirst%3DA.%26aulast%3DCurrie%26aufirst%3DV.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26atitle%3DPaclitaxel%2520and%2520recombinant%2520human%2520granulocyte%2520colony-stimulating%2520factor%2520as%2520initial%2520chemotherapy%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1993%26volume%3D11%26spage%3D1943%26epage%3D1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Seidman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichman, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakes, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsythe, P.</span><span> </span><span class="NLM_article-title">Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7537798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2M3ls12gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1995&pages=1152-1159&author=A.+D.+Seidmanauthor=B.+S.+Reichmanauthor=J.+P.+Crownauthor=T.+J.+Yaoauthor=V.+Currieauthor=T.+B.+Hakesauthor=C.+A.+Hudisauthor=T.+A.+Gilewskiauthor=J.+Baselgaauthor=P.+Forsythe&title=Paclitaxel+as+second+and+subsequent+therapy+for+metastatic+breast+cancer%3A+activity+independent+of+prior+anthracycline+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response</span></div><div class="casAuthors">Seidman A D; Reichman B S; Crown J P; Yao T J; Currie V; Hakes T B; Hudis C A; Gilewski T A; Baselga J; Forsythe P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1152-9</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  Two phase II clinical trials were performed to determine efficacy and tolerability of paclitaxel (Taxol; Bristol-Myers Squibb Co, Wallingford, CT) and granulocyte colony-stimulating factor ([G-CSF] Neupogen; Amgen, Inc, Thousand Oaks, CA) as second or subsequent therapy for metastatic breast cancer.  PATIENTS AND METHODS:  Paclitaxel plus G-CSF was administered as a second stage IV regimen to 25 patients with metastatic breast cancer at a dose of 250 mg/m2 intravenously over 24 hours.  Fifty-two patients received paclitoxel plus G-CSF at 200 mg/m2 as a third or subsequent regimen (no restriction on number of prior regimens or on prior high-dose chemotherapy).  All patients had received prior anthracycline treatment, and ultimately had progressive bidimensionally measurable disease.  RESULTS:  Twenty-five of 76 patients (32.8%) had a major objective response (95% confidence interval [CI], 14% to 37%).  The median duration of response was 7 months (range, 1 to 20+).  Responses were as likely in patients with disease demonstrated to be unresponsive to anthracycline, ie, de novo resistance (11 of 37, or 30%) as in those with disease that once exhibited anthracycline sensitivity, ie, acquired resistance, (10 of 31, or 32%).  G-CSF administration was associated with febrile neutropenic episodes in 36 of 402 cycles (9%) in 16 of 76 patients (21%).  CONCLUSION:  Paclitaxel's clinically significant activity against metastatic breast cancer extends to patients with many prior chemotherapy regimens.  The lack of impact of prior doxorubicin therapy on the likelihood of subsequent response to paclitaxel suggests an important role for this agent in the treatment of refractory metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT91Me59PbBsJ0d-O_J5C0AfW6udTcc2eZCVo-H3kIk47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3ls12gtA%253D%253D&md5=acefa73c8d652b510aa8e5506a964aa5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeidman%26aufirst%3DA.%2BD.%26aulast%3DReichman%26aufirst%3DB.%2BS.%26aulast%3DCrown%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DT.%2BJ.%26aulast%3DCurrie%26aufirst%3DV.%26aulast%3DHakes%26aufirst%3DT.%2BB.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGilewski%26aufirst%3DT.%2BA.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DForsythe%26aufirst%3DP.%26atitle%3DPaclitaxel%2520as%2520second%2520and%2520subsequent%2520therapy%2520for%2520metastatic%2520breast%2520cancer%253A%2520activity%2520independent%2520of%2520prior%2520anthracycline%2520response%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1995%26volume%3D13%26spage%3D1152%26epage%3D1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Chang, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boros, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asbury, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubins, J.</span><span> </span><span class="NLM_article-title">Dose-escalation study of weekly 1 h paclitaxel administration in patients with refractory cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">S17-69</span><span class="NLM_x">–</span> <span class="NLM_lpage">S17-71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=S17-69-S17-71&author=A.+Y.+Changauthor=L.+Borosauthor=R.+Asburyauthor=L.+Huiauthor=J.+Rubins&title=Dose-escalation+study+of+weekly+1+h+paclitaxel+administration+in+patients+with+refractory+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DBoros%26aufirst%3DL.%26aulast%3DAsbury%26aufirst%3DR.%26aulast%3DHui%26aufirst%3DL.%26aulast%3DRubins%26aufirst%3DJ.%26atitle%3DDose-escalation%2520study%2520of%2520weekly%25201%2520h%2520paclitaxel%2520administration%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D1997%26volume%3D24%26spage%3DS17-69%26epage%3DS17-71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Dorr, R. T.</span><span> </span><span class="NLM_article-title">Pharmacology and toxicology of Cremophor EL diluent</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">S11</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1994&pages=S11-S14&author=R.+T.+Dorr&title=Pharmacology+and+toxicology+of+Cremophor+EL+diluent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DR.%2BT.%26atitle%3DPharmacology%2520and%2520toxicology%2520of%2520Cremophor%2520EL%2520diluent%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1994%26volume%3D28%26spage%3DS11%26epage%3DS14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhew, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolcsak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanaugh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernacki, R. J.</span><span> </span><span class="NLM_article-title">Activity of paclitaxel liposome formulations against human ovarian tumor xenografts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2F%28SICI%291097-0215%2819970328%2971%3A1%3C103%3A%3AAID-IJC17%3E3.0.CO%3B2-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9096672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Kisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=103-107&author=A.+Sharmaauthor=E.+Mayhewauthor=L.+Bolcsakauthor=C.+Cavanaughauthor=P.+Harmonauthor=A.+Janoffauthor=R.+J.+Bernacki&title=Activity+of+paclitaxel+liposome+formulations+against+human+ovarian+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of paclitaxel liposome formulations against human ovarian tumor xenografts</span></div><div class="casAuthors">Sharma, Amarnath; Mayhew, Eric; Bolcsak, Lois; Cavanaugh, C.; Harmon, P.; Janoff, Andrew; Bernacki, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Although the current clin. formulation of paclitaxel (Taxol) is an important new anti-cancer agent, it has significant side effects, some of which are related to its formulation in Cremophor/ethanol.  Paclitaxel is difficult to formulate for i.v. administration because of its poor aq. soly.  Here, the authors report the therapeutic effects of 2 liposome formulations of paclitaxel against human ovarian A121 tumor growing as an s.c. xenograft in athymic nude mice.  The liposome formulations used were ETL and TTL, which have 1 or 3 lipid components, resp.  TTL was used as a reconstituted lyophilizate or as a stable aq. suspension.  ETL was used as a reconstituted lyophilizate only.  Both paclitaxel-liposome formulations were much better tolerated than Taxol after i.v. or i.p. administration.  The acute reactions seen after Taxol administration did not occur when paclitaxel-liposome formulations were administered.  All ETL and TTL prepns. significantly delayed A121 tumor growth similarly to Taxol at equiv. doses and schedules.  Based on pharmacokinetic data, it is possible that paclitaxel rapidly dissocs. from ETL or TTL after i.v. administration and distributes in a manner similarly to Taxol.  ETL and TTL formulations may be useful clin. not only for eliminating toxic effects of the Cremophor/ethanol vehicle but also for allowing alterations in route and schedule of drug administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLcDMGT9gNgrVg90H21EOLACvtfcHk0liMsMY6AADy8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Kisrw%253D&md5=b59185fa89dffd0868a6364b56756b93</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819970328%2971%3A1%3C103%3A%3AAID-IJC17%3E3.0.CO%3B2-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819970328%252971%253A1%253C103%253A%253AAID-IJC17%253E3.0.CO%253B2-J%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMayhew%26aufirst%3DE.%26aulast%3DBolcsak%26aufirst%3DL.%26aulast%3DCavanaugh%26aufirst%3DC.%26aulast%3DHarmon%26aufirst%3DP.%26aulast%3DJanoff%26aufirst%3DA.%26aulast%3DBernacki%26aufirst%3DR.%2BJ.%26atitle%3DActivity%2520of%2520paclitaxel%2520liposome%2520formulations%2520against%2520human%2520ovarian%2520tumor%2520xenografts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1997%26volume%3D71%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Payne, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhingra, K.</span><span> </span><span class="NLM_article-title">Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia</span> <span class="citation_source-journal">South. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1097%2F00007611-199605000-00022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=8638189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK283htFSntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1996&pages=542-545&author=J.+Y.+Payneauthor=F.+Holmesauthor=P.+R.+Cohenauthor=R.+Gagelauthor=A.+Buzdarauthor=K.+Dhingra&title=Paclitaxel%3A+severe+mucocutaneous+toxicity+in+a+patient+with+hyperbilirubinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia</span></div><div class="casAuthors">Payne J Y; Holmes F; Cohen P R; Gagel R; Buzdar A; Dhingra K</div><div class="citationInfo"><span class="NLM_cas:title">Southern medical journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">542-5</span>
        ISSN:<span class="NLM_cas:issn">0038-4348</span>.
    </div><div class="casAbstract">Paclitaxel is a novel anticancer drug that is being increasingly used to treat cancer of the breast and other organs.  We describe a patient with metastatic breast cancer and liver dysfunction who had severe mucocutaneous toxicity after administration of a standard dose of paclitaxel.  Another interesting finding in this patient was that the administration of paclitaxel led to a prompt resolution of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia, which had previously proven to be refractory to multiple conventional antihypercalcemic agents as well as anthracycline-containing chemotherapy combination.  The need for definitive guidelines for paclitaxel administration in the setting of hepatic dysfunction and the potentially unique sensitivity of PTHrP--producing cells to paclitaxel are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM3w-66-99mDslzEEsg76ufW6udTcc2eaE3oma-V6gw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283htFSntg%253D%253D&md5=0a1a937b4d78a6ec9c7baafc75e4aedf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00007611-199605000-00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007611-199605000-00022%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DJ.%2BY.%26aulast%3DHolmes%26aufirst%3DF.%26aulast%3DCohen%26aufirst%3DP.%2BR.%26aulast%3DGagel%26aufirst%3DR.%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DDhingra%26aufirst%3DK.%26atitle%3DPaclitaxel%253A%2520severe%2520mucocutaneous%2520toxicity%2520in%2520a%2520patient%2520with%2520hyperbilirubinemia%26jtitle%3DSouth.%2520Med.%2520J.%26date%3D1996%26volume%3D89%26spage%3D542%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">Paclitaxel (taxol)</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1056%2FNEJM199504133321507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7885406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1995&pages=1004-1014&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=Paclitaxel+%28taxol%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel (taxol)</span></div><div class="casAuthors">Rowinsky E K; Donehower R C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1004-14</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDsoUwRBKuB62q3xNe7a7QfW6udTcc2eaE3oma-V6gw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D&md5=918362934f39ee3362db9d2bed1c71cb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJM199504133321507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199504133321507%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DPaclitaxel%2520%2528taxol%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D332%26spage%3D1004%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matusiak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatnagar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helson, L.</span><span> </span><span class="NLM_article-title">Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide “scorpion” molecule</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc050224c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=565-570&author=A.+Safavyauthor=K.+P.+Raischauthor=D.+Matusiakauthor=S.+Bhatnagarauthor=L.+Helson&title=Single-drug+multiligand+conjugates%3A+synthesis+and+preliminary+cytotoxicity+evaluation+of+a+paclitaxel-dipeptide+%E2%80%9Cscorpion%E2%80%9D+molecule"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Drug Multiligand Conjugates: Synthesis and Preliminary Cytotoxicity Evaluation of a Paclitaxel-Dipeptide "Scorpion" Molecule</span></div><div class="casAuthors">Safavy, Ahmad; Raisch, Kevin P.; Matusiak, Damien; Bhatnagar, Saloni; Helson, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the targeting properties of receptor-directed drug-peptide conjugates, a multiligand approach was proposed and a model "scorpion" conjugate consisting of two peptide "claws" and a paclitaxel (PTX) "tail", was synthesized.  The cell surface receptor-directed peptide used in this single-drug multiligand (SDML) model was a segment of the amphibian peptide bombesin (BBN) which had the Y6Q7W8A9V10G11H12L13M14-NH2 sequence, designated here as BBN[6-14].  Due to the lipophilic nature of both PTX and BBN[6-14], "scorpion" conjugate had a low water soly.  To enhance the soly., PEG derivs. of this conjugate were prepd. with the polymer inserted either in the claws or in the tail regions.  In a preliminary random screening, "scorpion" conjugate showed superior cytotoxic activity in several GRPR-pos. human cancer cell lines as compared to free PTX and two single-drug single-ligand (SDSL) conjugates.  In a receptor blocking expt., addn. of excess unconjugated BBN[6-14] ligand reduced the cytotoxicity of "scorpion" conjugate , indicating the receptor-mediated mechanism of drug delivery.  The PEG-derived conjugates showed activities which were intermediate between SDSL and the SDML congeners.  Also, an increase in the no. of the PEG segments lowered cytotoxicity, possibly due to steric hindrance against ligand-receptor binding.  Taken together, these results demonstrate the potential of the multiligand approach in the design of receptor-targeting conjugates for tumor-specific drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcE2tKB3qP6LVg90H21EOLACvtfcHk0lgC6XO7X77W6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFKiu7k%253D&md5=6831d78ca852d106412788c1bc7d6404</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbc050224c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc050224c%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DMatusiak%26aufirst%3DD.%26aulast%3DBhatnagar%26aufirst%3DS.%26aulast%3DHelson%26aufirst%3DL.%26atitle%3DSingle-drug%2520multiligand%2520conjugates%253A%2520synthesis%2520and%2520preliminary%2520cytotoxicity%2520evaluation%2520of%2520a%2520paclitaxel-dipeptide%2520%25E2%2580%259Cscorpion%25E2%2580%259D%2520molecule%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D565%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waksal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arani, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc020033z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=302-310&author=A.+Safavyauthor=J.+A.+Bonnerauthor=H.+Waksalauthor=D.+J.+Buchsbaumauthor=G.+Y.+Gillespieauthor=M.+B.+Khazaeliauthor=R.+B.+Araniauthor=D.+T.+Chenauthor=M.+Carpenterauthor=K.+P.+Raisch&title=Synthesis+and+biological+evaluation+of+paclitaxel-C225+conjugate+as+a+model+for+targeted+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Paclitaxel-C225 Conjugate as a Model for Targeted Drug Delivery</span></div><div class="casAuthors">Safavy, Ahmad; Bonner, James A.; Waksal, Harlan W.; Buchsbaum, Donald J.; Gillespie, G. Yancey; Khazaeli, M. B.; Arani, Ramin; Chen, Dung-Tsa; Carpenter, Mark; Raisch, Kevin P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-310</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumor-targeted drug delivery is an attractive strategy in cancer treatment.  We have previously reported a paclitaxel model conjugate using a bombesin receptor-recognizing peptide in which the drug cytotoxicity against H1299 human nonsmall cell lung cancer was enhanced compared to unconjugated taxol.  In an effort to expand the development of tumor-recognizing taxanes, paclitaxel (PTX, taxol) was conjugated to the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb) Erbitux (C225) to serve as a model MAb-mediated drug delivery compd.  Thus, paclitaxel was derivatized at its 2'-hydroxy function by introduction of a succinate linker, and the carboxyl group of the latter was covalently attached to C225 through amide bond formation.  The final product conjugate (PTXC225) was analyzed mass spectrometrically for assessment of the drug-to-antibody ratios.  Cytotoxicity screening of the drug-antibody conjugate against A431, UM-SCC-1, and UM-SCC-6 cells indicated an enhancement in cytotoxic effect of paclitaxel as compared to those of the free drug, the intact antibody, and a phys. mixt. of the 2 (the controls).  In A431 cells, the conjugate showed 25% of apoptosis induction as compared to little or no apoptosis caused by the controls.  Biodistribution anal. of the PTXC225 in tumor-implanted nude mice and a tyrosine-kinase assay showed that conjugation of the drug did not interfere with the immunoreactivity of the antibody.  The 24-h tumor uptake of C225 and PTXC225 were 11.7 and 7.1% of the injected dose/g of tissue (percent ID/g), resp., which were not significantly different.  Also, in A431-implanted nude mice, the conjugate and C225 showed tumor growth inhibition effects of 57.2 and 41.2%, resp., against a saline-treated control, which were not significantly different from each other.  This lack of difference in the in vivo antitumor activity of the MAb-delivered drug and free PTX may be due to either a relatively low dose of the antibody-delivered drug (346 μg/kg), or an untimely release of it, or both.  The tumor growth inhibition pattern of the conjugate, however, was identical to that of C225, indicating that the attachment of PTX did not affect the antigen-binding and growth inhibitory features of the MAb.  These preliminary results demonstrate the potential of tumor-targeted delivery of taxol as a promising strategy in cancer treatment and warrant further work to develop more suitable drug-MAb linkers as well as improved dosage and treatment protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXG8dWRogOALVg90H21EOLACvtfcHk0lgC6XO7X77W6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsQ%253D%253D&md5=a7f8436350e960ac5dc9a073d2a08953</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fbc020033z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc020033z%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DWaksal%26aufirst%3DH.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26aulast%3DGillespie%26aufirst%3DG.%2BY.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DArani%26aufirst%3DR.%2BB.%26aulast%3DChen%26aufirst%3DD.%2BT.%26aulast%3DCarpenter%26aufirst%3DM.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520paclitaxel-C225%2520conjugate%2520as%2520a%2520model%2520for%2520targeted%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D302%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safavy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span> </span><span class="NLM_article-title">Site-specifically traced drug release and biodistribution of a paclitaxel−antibody conjugate toward optimization of the linker structure</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049868v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Wnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1264-1274&author=A.+Safavyauthor=G.+I.+Georgauthor=D.+Vander+Veldeauthor=K.+P.+Raischauthor=K.+Safavyauthor=M.+Carpenterauthor=W.+Wangauthor=J.+A.+Bonnerauthor=M.+B.+Khazaeliauthor=D.+J.+Buchsbaum&title=Site-specifically+traced+drug+release+and+biodistribution+of+a+paclitaxel%E2%88%92antibody+conjugate+toward+optimization+of+the+linker+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure</span></div><div class="casAuthors">Safavy, Ahmad; Georg, Gunda I.; Vander Velde, David; Raisch, Kevin P.; Safavy, Kamellia; Carpenter, Mark; Wang, Wenquan; Bonner, James A.; Khazaeli, M. B.; Buchsbaum, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1274</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumor-directed drug delivery is a promising strategy in cancer treatment, and in this field, monoclonal antibodies constitute an important class of targeting vehicles.  A crit. issue in the design of targeting conjugates is the timing of the release of the cytotoxic payload, with the ideal situation being the release at the max. tumor uptake of the targeting mol.  A site-specific radiolabeling technique was used to elucidate the biodistribution and in vivo drug release pattern of an antibody conjugate of paclitaxel in which the drug and the antibody moieties were connected by a succinate (SX) linker.  In this new method, a metabolite of PTX, 3'-(4-hydroxyphenyl)paclitaxel (3'-OH-PTXSX) was used as a tyrosine mimic for the synthesis of the drug site-labeled conjugate.  This was achieved by iodogen 125I-labeling of 3'-OH-PTXSX and subsequent conjugation to C225.  The antibody site-labeled conjugate (ASL, PTXSX-[125I]-C225) was prepd. by direct radioiodination of PTXSXC225.  Biodistribution of these compds. was studied in Balb/c nude mice bearing DU-145 human prostate carcinoma xenografts.  While the 4 and 24 h tumor uptake (in percent injected dose per g of tissue, %ID/g) for [125I]-3'-OH-PTXSXC225 were 3.3 ± 1.5 and 1.7 ± 0.6%ID/g, the PTXSX-[125I]-C225 showed tumor uptake values of 3.8 ± 4.2 and 14.8 ± 4.2%ID/g at these time points.  This difference in the tumor uptake over time indicated an early cleavage of the drug with respect to the antibody tumor localization.  This was further confirmed by an in vitro drug release kinetics study leading to a half-life of about 2 h for PTXSXC225 under physiol. conditions.  To increase the stability of the PTX-MAb bond, a new conjugate (PTXGLC225) with glutaric acid (GL) as the linker was synthesized.  Under the same conditions, the PTXGLC225 showed a 16-fold increase in the half-life (t1/2) of the drug release.  The effect of the increased t1/2 of this compd. on the antitumor activity of the conjugate was tested in a DU-145 human prostate tumor-implanted mouse model.  In comparison to a previous similar expt. with PTXSXC225, better antitumor activity was obsd. for the PTXGLC225 conjugate as compared to controls.  These results demonstrated the first time use of radioiodinated 3'-OH-PTX for in vivo tracing of a paclitaxel conjugate and application of the resulting information to the design of a therapeutically more useful PTX-MAb linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgUYAfOcd_LVg90H21EOLACvtfcHk0ljN_wyACgT5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Wnsrs%253D&md5=81008be7a100d819caef0269c36adeb4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbc049868v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049868v%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DVander%2BVelde%26aufirst%3DD.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DSafavy%26aufirst%3DK.%26aulast%3DCarpenter%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26atitle%3DSite-specifically%2520traced%2520drug%2520release%2520and%2520biodistribution%2520of%2520a%2520paclitaxel%25E2%2588%2592antibody%2520conjugate%2520toward%2520optimization%2520of%2520the%2520linker%2520structure%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D1264%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Naramura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisfeld, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, B. M.</span><span> </span><span class="NLM_article-title">Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma</span> <span class="citation_source-journal">Cancer Immunol. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1007%2FBF01518458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=8402738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1Wis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=343-349&author=M.+Naramuraauthor=S.+D.+Gilliesauthor=J.+Mendelsohnauthor=R.+A.+Reisfeldauthor=B.+M.+Mueller&title=Therapeutic+potential+of+chimeric+and+murine+anti-%28epidermal+growth+factor+receptor%29+antibodies+in+a+metastasis+model+for+human+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma</span></div><div class="casAuthors">Naramura, Mayumi; Gillies, Stephen D.; Mendelsohn, John; Reisfeld, Ralph A.; Mueller, Barbara M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">343-9</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    </div><div class="casAbstract">On many tumors, high nos. of epidermal growth factor (EGF) receptors provide a target for antibody-mediated tumor therapy.  The authors evaluate here the therapeutic potential of a mouse/human chimeric anti-(EGF receptor) antibody and compare it to the parental murine antibody in a xenograft model for metastatic melanoma.  The authors' model is based on the human cell line M24met, which overexpresses the EGF receptor and metastasizes spontaneously in SCID mice.  Both the chimeric anti-(EGF receptor) antibody (ch225) and the mouse monoclonal antibody (m225) exhibited saturable, high-affinity binding to M24met cells and were equiv. in their ability to target M24met tumors in mice.  Neither anti-(EGF receptor) antibodies nor EGF modulated the growth of M24met cells in vitro.  Further anal. revealed that the EGF receptor on these cells is not phosphorylated upon EGF binding, indicating an anomalous receptor on these cells.  In antibody-dependent cellular cytotoxicity expts., ch225 and m225 were potent mediators of M24met cytolysis by effector cells.  Antibody-mediated cytotoxicity revealed a marked species preference, with ch225 activating human peripheral blood mononuclear cells and m225 activating mouse splenocytes and to a lesser degree mouse macrophages.  Neither antibody mediated cytolysis in the presence of human complement.  In SCID mice, m225 suppressed spontaneous metastasis considerably while ch225 had only a modest effect.  Thus, in the M24met melanoma tumor model, anti-(EGF receptor) antibodies suppress spontaneous metastasis solely by activating immune effector cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxMnBHqdxx7Vg90H21EOLACvtfcHk0ljN_wyACgT5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1Wis70%253D&md5=a26106f7ccdf2c4cf6a8363a6db8ca82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2FBF01518458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01518458%26sid%3Dliteratum%253Aachs%26aulast%3DNaramura%26aufirst%3DM.%26aulast%3DGillies%26aufirst%3DS.%2BD.%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DReisfeld%26aufirst%3DR.%2BA.%26aulast%3DMueller%26aufirst%3DB.%2BM.%26atitle%3DTherapeutic%2520potential%2520of%2520chimeric%2520and%2520murine%2520anti-%2528epidermal%2520growth%2520factor%2520receptor%2529%2520antibodies%2520in%2520a%2520metastasis%2520model%2520for%2520human%2520melanoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D1993%26volume%3D37%26spage%3D343%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Goldstein, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prewett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuklys, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span> </span><span class="NLM_article-title">Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9815926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK28XjvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=1311-1318&author=N.+I.+Goldsteinauthor=M.+Prewettauthor=K.+Zuklysauthor=P.+Rockwellauthor=J.+Mendelsohn&title=Biological+efficacy+of+a+chimeric+antibody+to+the+epidermal+growth+factor+receptor+in+a+human+tumor+xenograft+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model</span></div><div class="casAuthors">Goldstein, Neil I.; Prewett, Marie; Zuklys, Kazys; Rockwell, Patricia; Mendelsohn, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1311-18</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There seems to be an assocn. between up-regulation of the epidermal growth factor receptor (EGFR) and poor clin. prognosis for a no. of human cancers.  The 225 antibody is a highly specific murine monoclonal antibody that binds specifically to the human EGFR with an affinity equal to its ligand, competes with the ligand for binding, and blocks activation of the receptor tyrosine kinase.  In addn., 225 has been shown to inhibit the growth of human tumor xenografts in athymic nude mice.  The 225 antibody has recently been chimerized with human IgG1 in its const. region to increase its clin. utility by decreasing the potential for generation of human anti-mouse antibodies in recipients.  This report compares the biol. effects of 225 and its chimeric counterpart (designated C225) against established A431 tumor xenografts in nude mice.  C225 was more effective than 225 in inhibiting tumor growth in this model.  In addn., many of the animals treated with C225 were tumor free at the end of each treatment protocol.  The dissocn. const. of C225 was about 5-fold lower than 225.  This suggested that the increased capacity of C225 to compete with ligand for binding to the EGFR was responsible for its enhanced in vivo antitumor effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeedZsCNr2urVg90H21EOLACvtfcHk0ljN_wyACgT5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvF2gsA%253D%253D&md5=d2e6bb5aadb3999f91c785db383521d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DN.%2BI.%26aulast%3DPrewett%26aufirst%3DM.%26aulast%3DZuklys%26aufirst%3DK.%26aulast%3DRockwell%26aufirst%3DP.%26aulast%3DMendelsohn%26aufirst%3DJ.%26atitle%3DBiological%2520efficacy%2520of%2520a%2520chimeric%2520antibody%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520a%2520human%2520tumor%2520xenograft%2520model%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1995%26volume%3D1%26spage%3D1311%26epage%3D1318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Karashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaton, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettaway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinney, C. P.</span><span> </span><span class="NLM_article-title">Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1253</span><span class="NLM_x">–</span> <span class="NLM_lpage">1264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=12006546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1253-1264&author=T.+Karashimaauthor=P.+Sweeneyauthor=J.+W.+Slatonauthor=S.+J.+Kimauthor=D.+Kedarauthor=J.+I.+Izawaauthor=Z.+Fanauthor=C.+Pettawayauthor=D.+J.+Hicklinauthor=T.+Shuinauthor=C.+P.+Dinney&title=Inhibition+of+angiogenesis+by+the+antiepidermal+growth+factor+receptor+antibody+ImClone+C225+in+androgen-independent+prostate+cancer+growing+orthotopically+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone c225 in androgen-independent prostate cancer growing orthotopically in nude mice</span></div><div class="casAuthors">Karashima, Takashi; Sweeney, Paul; Slaton, Joel W.; Kim, Sun J.; Kedar, Daniel; Izawa, Jonathan I.; Fan, Zhen; Pettaway, Curtis; Hicklin, Daniel J.; Shuin, Taro; Dinney, Colin P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1253-1264</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In human androgen-independent prostate cancer (PCa), epidermal growth factor receptor (EGFR) regulates angiogenesis, tumor growth, and progression.  In this study, we evaluated whether the blockade of EGFR by the anti-EGFR antibody ImClone C225 (IMC-C225) inhibited tumor growth and metastasis by inhibiting angiogenesis, and whether paclitaxel enhanced the results of therapy in androgen-independent PCa.  PC-3M-LN4 PCa cells were implanted orthotopically in athymic nude mice and treated with i.p. IMC-C225 (1 mg twice a week) and/or paclitaxel (200 μg once a week).  In vitro treatment of PC-3M-LN4 with IMC-C225 inhibited EGFR autophosphorylation without any significant antiproliferative effect.  In contrast, in vivo therapy with IMC-C225 alone (P < 0.05) or in combination with paclitaxel (P < 0.005) significantly inhibited PCa growth and metastasis.  Serum levels of interleukin (IL) 8 were lower after therapy, and IL-8 mRNA expression was down-regulated within the tumors after therapy.  The down-regulation of IL-8 correlated with reduced microvessel d.  IMC-C225 reduced tumor cell proliferation, enhanced p27kip1 expression, and induced tumor and endothelial cell apoptosis.  These studies indicate that IMC-C225 has significant antitumor effect in this murine model, mediated in part by inhibition of cellular proliferation and angiogenesis, and by enhancement of apoptosis.  The simultaneous administration of paclitaxel enhanced this effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14K44uXs-lbVg90H21EOLACvtfcHk0ljjoUs_T_LYlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVWjs78%253D&md5=c4f4a7ef4a34df1602c867d29cfea4ee</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarashima%26aufirst%3DT.%26aulast%3DSweeney%26aufirst%3DP.%26aulast%3DSlaton%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DKedar%26aufirst%3DD.%26aulast%3DIzawa%26aufirst%3DJ.%2BI.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DPettaway%26aufirst%3DC.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DDinney%26aufirst%3DC.%2BP.%26atitle%3DInhibition%2520of%2520angiogenesis%2520by%2520the%2520antiepidermal%2520growth%2520factor%2520receptor%2520antibody%2520ImClone%2520C225%2520in%2520androgen-independent%2520prostate%2520cancer%2520growing%2520orthotopically%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1253%26epage%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Reusch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davol, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, L. G.</span><span> </span><span class="NLM_article-title">Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1158%2F1078-0432.CCR-05-1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16397041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=183-190&author=U.+Reuschauthor=M.+Sundaramauthor=P.+A.+Davolauthor=S.+D.+Olsonauthor=J.+B.+Davisauthor=K.+Demelauthor=J.+Nissimauthor=R.+Rathoreauthor=P.+Y.+Liuauthor=L.+G.+Lum&title=Anti-CD3+x+anti-epidermal+growth+factor+receptor+%28EGFR%29+bispecific+antibody+redirects+T-cell+cytolytic+activity+to+EGFR-positive+cancers+in+vitro+and+in+an+animal+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model</span></div><div class="casAuthors">Reusch, Ursula; Sundaram, Magesh; Davol, Pamela A.; Olson, Sarah D.; Davis, James B.; Demel, Kurt; Nissim, Julie; Rathore, Ritesh; Liu, Paul Y.; Lum, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Targeting epidermal growth factor receptor (EGFR) overexpressed by many epithelial-derived cancer cells with anti-EGFR monoclonal antibodies (mAb) inhibits their growth.  A limited no. of clin. responses in patients treated with the anti-EGFR mAb, (cetuximab), may reflect variability in EGFR type or signaling in neoplastic cells.  This study combines EGFR-targeting with the non-MHC-restricted cytotoxicity of anti-CD3 activated T cells (ATC) to enhance receptor-directed cytotoxicity.  Exptl. Design: ATC from normal and patient donors were expanded ex vivo.  Specific cytolytic activity of ATC armed with anti-CD3 x anti-EGFR (EGFRBi) against EGFR-expressing cancer cells derived from lung, pancreas, colon, prostate, brain, skin, or EGFR-neg. breast cancer cells was evaluated in 51Cr release assays.  In vivo studies comparing tumor growth delay induced by EGFRBi-armed ATCs or cetuximab were done in severe combined immunodeficient/Beige mice (SCID-Beige) bearing COLO 356/FG pancreatic and LS174T colorectal tumors.  Results: At effector/target ratios from 3.125 to 50, both EGFRBi-armed normal and patient ATC were significantly more cytotoxic, by 23% to 79%, against EGFR-pos. cells over ATC, cetuximab, anti-CD3 alone, or ATC armed with irrelevant BiAb directed at CD20.  EGFRBi-armed ATC also secreted significantly higher levels of some TH1/TH2 cytokines compared with ATC alone.  In mice, i.v. infusions of EGFRBi-armed ATC (0.001 mg equiv./infusion) were equally effective as cetuximab (1 mg/infusion) alone for significantly delaying growth of established COLO 356/FG but not LS174T tumors compared with mice that received ATC alone or vehicle (P < 0.001).  Conclusions: Combining EGFR antibody targeting with T cell-mediated cytotoxicity may overcome some limitations assocd. with EGFR-targeting when using cetuximab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi9hOZnWz2zbVg90H21EOLACvtfcHk0ljjoUs_T_LYlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gltw%253D%253D&md5=e61989eca1e15a817609cf95db16cfeb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1855%26sid%3Dliteratum%253Aachs%26aulast%3DReusch%26aufirst%3DU.%26aulast%3DSundaram%26aufirst%3DM.%26aulast%3DDavol%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BD.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDemel%26aufirst%3DK.%26aulast%3DNissim%26aufirst%3DJ.%26aulast%3DRathore%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%2BY.%26aulast%3DLum%26aufirst%3DL.%2BG.%26atitle%3DAnti-CD3%2520x%2520anti-epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bispecific%2520antibody%2520redirects%2520T-cell%2520cytolytic%2520activity%2520to%2520EGFR-positive%2520cancers%2520in%2520vitro%2520and%2520in%2520an%2520animal%2520model%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D183%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Thompson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. N.</span><span> </span><span class="NLM_article-title">The EGF receptor: structure, regulation and potential role in malignancy</span> <span class="citation_source-journal">Cancer Surv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=2824044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaL1c%252Flt1Krug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1985&pages=767-788&author=D.+M.+Thompsonauthor=G.+N.+Gill&title=The+EGF+receptor%3A+structure%2C+regulation+and+potential+role+in+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The EGF receptor: structure, regulation and potential role in malignancy</span></div><div class="casAuthors">Thompson D M; Gill G N</div><div class="citationInfo"><span class="NLM_cas:title">Cancer surveys</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">767-88</span>
        ISSN:<span class="NLM_cas:issn">0261-2429</span>.
    </div><div class="casAbstract">Retroviral onc genes are derived from cellular proto-oncogenes that may function in normal cellular growth control.  The epidermal growth factor (EGF) receptor is the proto-oncogene of erbB; both possess intrinsic protein tyrosine kinase activity, a property shared by several retroviral onc genes.  The EGF receptor is a transmembrane glycoprotein with an external EGF binding domain and a cytoplasmic region that is homologous with other tyrosine kinases. erbB lacks the EGF binding and carboxyl terminal regions, which are thought to be important in regulation.  The EGF receptor is regulated by several mechanisms: stimulation by ligand binding and self-phosphorylation, inhibition by heterologous phosphorylation and downregulation by ligand.  EGF binding stimulates several early events, including phosphatidylinositol (PI) turnover in A431 cells.  A PI kinase activity copurifies with the EGF receptor and some other tyrosine kinases, but this is a contaminant as it can be separated from the EGF receptor.  Although the role of proto-onc genes in human malignancy is incompletely defined, increased numbers of EGF receptors are present in several types of human tumours.  Overexpression of EGF receptors, as occurs in human epidermoid carcinoma A431 cells, can augment cell growth because of increased formation of active ligand:receptor complexes.  Gene amplification is the mechanism underlying overexpression of EGF receptors in A431 cells and in some glioblastoma multiforme tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl44d6i0TfOS86Js-BCLiifW6udTcc2eZE7MZZaq74Hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c%252Flt1Krug%253D%253D&md5=ad2ee6e58aded1a439c41e73b5785560</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DD.%2BM.%26aulast%3DGill%26aufirst%3DG.%2BN.%26atitle%3DThe%2520EGF%2520receptor%253A%2520structure%252C%2520regulation%2520and%2520potential%2520role%2520in%2520malignancy%26jtitle%3DCancer%2520Surv.%26date%3D1985%26volume%3D4%26spage%3D767%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">The epidermal growth factor receptor as a multi-functional allosteric protein</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3119</span><span class="NLM_x">–</span> <span class="NLM_lpage">3123</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00409a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=3119-3123&author=J.+Schlessinger&title=The+epidermal+growth+factor+receptor+as+a+multi-functional+allosteric+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbi00409a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00409a002%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520as%2520a%2520multi-functional%2520allosteric%2520protein%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D3119%26epage%3D3123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Carpenter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span> </span><span class="NLM_article-title">Epidermal growth factor</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1146%2Fannurev.bi.48.070179.001205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=382984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaE1MXltVers78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1979&pages=193-216&author=G.+Carpenterauthor=S.+Cohen&title=Epidermal+growth+factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor</span></div><div class="casAuthors">Carpenter, Graham; Cohen, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-216</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review with 206 refs. on the physiol., chem., and phys. properties of the title compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNYFT7lWszw7Vg90H21EOLACvtfcHk0liM9woqf3XH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltVers78%253D&md5=d883ab25e84f3d627980a46ce234a655</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.48.070179.001205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.48.070179.001205%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DG.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DEpidermal%2520growth%2520factor%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1979%26volume%3D48%26spage%3D193%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Pathak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matrisian, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magun, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, S. E.</span><span> </span><span class="NLM_article-title">Effect of epidermal growth factor on clonogenic growth of primary human tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2Fijc.2910300611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=6298120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaL3sXkslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1982&pages=745-750&author=M.+A.+Pathakauthor=L.+M.+Matrisianauthor=B.+E.+Magunauthor=S.+E.+Salmon&title=Effect+of+epidermal+growth+factor+on+clonogenic+growth+of+primary+human+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of epidermal growth factor on clonogenic growth of primary human tumor cells</span></div><div class="casAuthors">Pathak, Meera A.; Matrisian, Lynn M.; Magun, Bruce E.; Salmon, Sydney E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-50</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">The effect of epidermal growth factor (EGF)  [62229-50-9] on the soft agar colony-forming ability of fresh human tumor cells was assessed in 40 specimens obtained from various types of carcinoma, including those of the breast, endometrium, ovary, and other sites.  Cells from 4 established human tumor cell lines (3 breast and 1 endometrial) were also studied.  The addn. of EGF at 50 ng/mL resulted in a 50% higher cloning efficiency in soft agar in 40% of the samples of fresh human tumors.  When cells from tumor cell lines were plated in semi-solid medium contg. EGF, the no. of colonies formed was at least twice as high as controls.  Specific receptors for EGF were detected by using radioiodinated EGF in early-passage cell cultures from some of the tumors tested for clonogenicity.  The no. of receptors ranged from 0.3 to 3.27 × 105/cell.  Cells from 2 melanoma specimens possessed <0.3 × 103 EGF receptors/cell.  No correlation was found between the no. of EGF receptors on a cell surface and the mitogenic effect of EGF on the same tumor cells grown in semisolid medium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zWIham5RPrVg90H21EOLACvtfcHk0liM9woqf3XH5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXkslKluw%253D%253D&md5=fc8540da514879ee616ce713ed52087a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910300611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910300611%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DM.%2BA.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26aulast%3DMagun%26aufirst%3DB.%2BE.%26aulast%3DSalmon%26aufirst%3DS.%2BE.%26atitle%3DEffect%2520of%2520epidermal%2520growth%2520factor%2520on%2520clonogenic%2520growth%2520of%2520primary%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1982%26volume%3D30%26spage%3D745%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Singletary, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brock, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, A. M.</span><span> </span><span class="NLM_article-title">Biological effect of epidermal growth factor on the in vitro growth of human tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1987&pages=403-406&author=S.+E.+Singletaryauthor=F.+L.+Bakerauthor=G.+Spitzerauthor=S.+L.+Tuckerauthor=B.+Tomasovicauthor=W.+A.+Brockauthor=J.+A.+Ajaniauthor=A.+M.+Kelly&title=Biological+effect+of+epidermal+growth+factor+on+the+in+vitro+growth+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingletary%26aufirst%3DS.%2BE.%26aulast%3DBaker%26aufirst%3DF.%2BL.%26aulast%3DSpitzer%26aufirst%3DG.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DTomasovic%26aufirst%3DB.%26aulast%3DBrock%26aufirst%3DW.%2BA.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DA.%2BM.%26atitle%3DBiological%2520effect%2520of%2520epidermal%2520growth%2520factor%2520on%2520the%2520in%2520vitro%2520growth%2520of%2520human%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1987%26volume%3D47%26spage%3D403%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Real, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berciano, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Juan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Roman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafarga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Luna, J. L.</span><span> </span><span class="NLM_article-title">Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">8151</span><span class="NLM_x">–</span> <span class="NLM_lpage">8157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8151-8157&author=P.+J.+Realauthor=A.+Benitoauthor=J.+Cuevasauthor=M.+T.+Bercianoauthor=A.+de+Juanauthor=P.+Cofferauthor=J.+Gomez-Romanauthor=M.+Lafargaauthor=J.+M.+Lopez-Vegaauthor=J.+L.+Fernandez-Luna&title=Blockade+of+epidermal+growth+factor+receptors+chemosensitizes+breast+cancer+cells+through+up-regulation+of+Bnip3L"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReal%26aufirst%3DP.%2BJ.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DCuevas%26aufirst%3DJ.%26aulast%3DBerciano%26aufirst%3DM.%2BT.%26aulast%3Dde%2BJuan%26aufirst%3DA.%26aulast%3DCoffer%26aufirst%3DP.%26aulast%3DGomez-Roman%26aufirst%3DJ.%26aulast%3DLafarga%26aufirst%3DM.%26aulast%3DLopez-Vega%26aufirst%3DJ.%2BM.%26aulast%3DFernandez-Luna%26aufirst%3DJ.%2BL.%26atitle%3DBlockade%2520of%2520epidermal%2520growth%2520factor%2520receptors%2520chemosensitizes%2520breast%2520cancer%2520cells%2520through%2520up-regulation%2520of%2520Bnip3L%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8151%26epage%3D8157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Reilly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scollard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallis, K. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1031</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1023-1031&author=R.+M.+Reillyauthor=P.+Chenauthor=J.+Wangauthor=D.+Scollardauthor=R.+Cameronauthor=K.+A.+Vallis&title=Preclinical+pharmacokinetic%2C+biodistribution%2C+toxicology%2C+and+dosimetry+studies+of+111In-DTPA-human+epidermal+growth+factor%3A+an+auger+electron-emitting+radiotherapeutic+agent+for+epidermal+growth+factor+receptor-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DScollard%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DR.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26atitle%3DPreclinical%2520pharmacokinetic%252C%2520biodistribution%252C%2520toxicology%252C%2520and%2520dosimetry%2520studies%2520of%2520111In-DTPA-human%2520epidermal%2520growth%2520factor%253A%2520an%2520auger%2520electron-emitting%2520radiotherapeutic%2520agent%2520for%2520epidermal%2520growth%2520factor%2520receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1023%26epage%3D1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Deutsch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugwitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suffness, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalkow, L.</span><span> </span><span class="NLM_article-title">Synthesis of congeners and prodrugs: water soluble prodrugs of taxol with potent antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00124a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=788-792&author=H.+Deutschauthor=J.+Glinskiauthor=M.+Hernandezauthor=R.+Haugwitzauthor=V.+Narayananauthor=M.+Suffnessauthor=L.+Zalkow&title=Synthesis+of+congeners+and+prodrugs%3A+water+soluble+prodrugs+of+taxol+with+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00124a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00124a011%26sid%3Dliteratum%253Aachs%26aulast%3DDeutsch%26aufirst%3DH.%26aulast%3DGlinski%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DHaugwitz%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DV.%26aulast%3DSuffness%26aufirst%3DM.%26aulast%3DZalkow%26aufirst%3DL.%26atitle%3DSynthesis%2520of%2520congeners%2520and%2520prodrugs%253A%2520water%2520soluble%2520prodrugs%2520of%2520taxol%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D788%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prestwich, G. D.</span><span> </span><span class="NLM_article-title">Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9900338" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXksF2ltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=755-763&author=Y.+Luoauthor=G.+D.+Prestwich&title=Synthesis+and+selective+cytotoxicity+of+a+hyaluronic+acid-antitumor+bioconjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Selective Cytotoxicity of a Hyaluronic Acid-Antitumor Bioconjugate</span></div><div class="casAuthors">Luo, Yi; Prestwich, Glenn D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A cell-targeted prodrug was developed for the anti-cancer drug Taxol, using hyaluronic acid (HA) as the drug carrier.  HA-Taxol bioconjugates were synthesized by linking the Taxol 2'-OH via a succinate ester to adipic dihydrazide-modified HA (HA-ADH).  The coupling of Taxol-NHS ester and HA-ADH provided several HA bioconjugates with different levels of ADH modification and different Taxol loadings.  A fluorescent BODIPY-HA was also synthesized to illustrate cell targeting and uptake of chem. modified HA using confocal microscopy.  HA-Taxol conjugates showed selective toxicity toward the human cancer cell lines (breast, colon, and ovarian) that are known to overexpress HA receptors, while no toxicity was obsd. toward a mouse fibroblast cell line at the same concns. used with the cancer cells.  The drug carrier HA-ADH was completely nontoxic.  The selective cytotoxicity is consistent with the results from confocal microscopy, which demonstrated that BODIPY-HA only entered the cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ObajqdMOPbVg90H21EOLACvtfcHk0lhcrqFTfnug5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksF2ltLs%253D&md5=0d98607a32ee66e70381d4018457c831</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbc9900338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9900338%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPrestwich%26aufirst%3DG.%2BD.%26atitle%3DSynthesis%2520and%2520selective%2520cytotoxicity%2520of%2520a%2520hyaluronic%2520acid-antitumor%2520bioconjugate%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D755%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 51 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madduri  Srinivasarao</span> and <span class="hlFld-ContribAuthor ">Philip S.  Low</span>  . </span><span class="cited-content_cbyCitation_article-title">Ligand-Targeted Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2017,</strong> <em>117 </em>
                                    (19)
                                     , 12133-12164. <a href="https://doi.org/10.1021/acs.chemrev.7b00013" title="DOI URL">https://doi.org/10.1021/acs.chemrev.7b00013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.7b00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.7b00013%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DLigand-Targeted%252BDrug%252BDelivery%26aulast%3DSrinivasarao%26aufirst%3DMadduri%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07012017%26date%3D12092017%26date%3D11102017%26volume%3D117%26issue%3D19%26spage%3D12133%26epage%3D12164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiren  Xu</span>, <span class="hlFld-ContribAuthor ">Guifeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Cuong  Tran</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Li</span>, <span class="hlFld-ContribAuthor ">Tyler H.  Heibeck</span>, <span class="hlFld-ContribAuthor ">Mary Rose  Masikat</span>, <span class="hlFld-ContribAuthor ">Qi  Cai</span>, <span class="hlFld-ContribAuthor ">Alexander R.  Steiner</span>, <span class="hlFld-ContribAuthor ">Aaron K.  Sato</span>, <span class="hlFld-ContribAuthor ">Trevor J.  Hallam</span>, and <span class="hlFld-ContribAuthor ">Gang  Yin</span>  . </span><span class="cited-content_cbyCitation_article-title">RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (6)
                                     , 1034-1043. <a href="https://doi.org/10.1021/acs.oprd.6b00072" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00072%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRP-HPLC%252BDAR%252BCharacterization%252Bof%252BSite-Specific%252BAntibody%252BDrug%252BConjugates%252BProduced%252Bin%252Ba%252BCell-Free%252BExpression%252BSystem%26aulast%3DXu%26aufirst%3DYiren%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04032016%26date%3D08062016%26date%3D17062016%26date%3D31052016%26volume%3D20%26issue%3D6%26spage%3D1034%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Wenzhou    Li </span><span class="hlFld-ContribAuthor "> James L.    Kerwin    </span><span class="hlFld-ContribAuthor "> John    Schiel </span><span class="hlFld-ContribAuthor "> Trina    Formolo </span><span class="hlFld-ContribAuthor "> Darryl    Davis </span><span class="hlFld-ContribAuthor "> Andrew    Mahan </span><span class="hlFld-ContribAuthor "> Sabrina A.    Benchaar </span>. </span><span class="cited-content_cbyCitation_article-title">Structural Elucidation of Post-Translational Modifications in Monoclonal Antibodies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 119-183. <a href="https://doi.org/10.1021/bk-2015-1201.ch003" title="DOI URL">https://doi.org/10.1021/bk-2015-1201.ch003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2015-1201.ch003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2015-1201.ch003%26sid%3Dliteratum%253Aachs%26atitle%3DStructural%252BElucidation%252Bof%252BPost-Translational%252BModifications%252Bin%252BMonoclonal%252BAntibodies%26aulast%3DLi%26aufirst%3DWenzhou%26date%3D2015%26date%3D2015%26spage%3D119%26epage%3D183%26atitle%3DState-of-the-Art%252Band%252BEmerging%252BTechnologies%252Bfor%252BTherapeutic%252BMonoclonal%252BAntibody%252BCharacterization%252BVolume%252B2.%252BBiopharmaceutical%252BCharacterization%25253A%252BThe%252BNISTmAb%252BCase%252BStudy%26aulast%3DSchiel%26aufirst%3DJohn%2BE.%26date%3D2015%26date%3D2015%26volume%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing-Xiao  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao-Ding  Xu</span>, <span class="hlFld-ContribAuthor ">Wei-Hai  Chen</span>, and <span class="hlFld-ContribAuthor ">Xian-Zheng  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Multi-Functional Envelope-Type Nanoparticles Assembled from Amphiphilic Peptidic Prodrug with Improved Anti-Tumor Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2014,</strong> <em>6 </em>
                                    (1)
                                     , 593-598. <a href="https://doi.org/10.1021/am404680n" title="DOI URL">https://doi.org/10.1021/am404680n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/am404680n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fam404680n%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DMulti-Functional%252BEnvelope-Type%252BNanoparticles%252BAssembled%252Bfrom%252BAmphiphilic%252BPeptidic%252BProdrug%252Bwith%252BImproved%252BAnti-Tumor%252BActivity%26aulast%3DChen%26aufirst%3DJing-Xiao%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D22102013%26date%3D15122013%26date%3D20122013%26date%3D08012014%26date%3D15122013%26volume%3D6%26issue%3D1%26spage%3D593%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min Hee  Lee</span>, <span class="hlFld-ContribAuthor ">Jin Young  Kim</span>, <span class="hlFld-ContribAuthor ">Ji Hye  Han</span>, <span class="hlFld-ContribAuthor ">Sankarprasad  Bhuniya</span>, <span class="hlFld-ContribAuthor ">Jonathan L.  Sessler</span>, <span class="hlFld-ContribAuthor ">Chulhun  Kang</span>, and <span class="hlFld-ContribAuthor ">Jong Seung  Kim</span>  . </span><span class="cited-content_cbyCitation_article-title">Direct Fluorescence Monitoring of the Delivery and Cellular Uptake of a Cancer-Targeted RGD Peptide-Appended Naphthalimide Theragnostic Prodrug. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2012,</strong> <em>134 </em>
                                    (30)
                                     , 12668-12674. <a href="https://doi.org/10.1021/ja303998y" title="DOI URL">https://doi.org/10.1021/ja303998y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja303998y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja303998y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDirect%252BFluorescence%252BMonitoring%252Bof%252Bthe%252BDelivery%252Band%252BCellular%252BUptake%252Bof%252Ba%252BCancer-Targeted%252BRGD%252BPeptide-Appended%252BNaphthalimide%252BTheragnostic%252BProdrug%26aulast%3DLee%26aufirst%3DMin%2BHee%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D26042012%26date%3D06062012%26date%3D01082012%26date%3D29052012%26volume%3D134%26issue%3D30%26spage%3D12668%26epage%3D12674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Raisul  Abedin</span>, <span class="hlFld-ContribAuthor ">Kaitlyne  Powers</span>, <span class="hlFld-ContribAuthor ">Rachel  Aiardo</span>, <span class="hlFld-ContribAuthor ">Dibbya  Barua</span>, <span class="hlFld-ContribAuthor ">Sutapa  Barua</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-86762-6" title="DOI URL">https://doi.org/10.1038/s41598-021-86762-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-86762-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-86762-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DAntibody%2525E2%252580%252593drug%252Bnanoparticle%252Binduces%252Bsynergistic%252Btreatment%252Befficacies%252Bin%252BHER2%252Bpositive%252Bbreast%252Bcancer%252Bcells%26aulast%3DAbedin%26aufirst%3DMuhammad%2BRaisul%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhilash  Rana</span>, <span class="hlFld-ContribAuthor ">Seema  Bhatnagar</span>. </span><span class="cited-content_cbyCitation_article-title">Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104946. <a href="https://doi.org/10.1016/j.bioorg.2021.104946" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104946%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAdvancements%252Bin%252Bfolate%252Breceptor%252Btargeting%252Bfor%252Banti-cancer%252Btherapy%25253A%252BA%252Bsmall%252Bmolecule-drug%252Bconjugate%252Bapproach%26aulast%3DRana%26aufirst%3DAbhilash%26date%3D2021%26volume%3D112%26spage%3D104946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Ma</span>, <span class="hlFld-ContribAuthor ">Sifan  Yu</span>, <span class="hlFld-ContribAuthor ">Shuaijian  Ni</span>, <span class="hlFld-ContribAuthor ">Baoxian  Zhang</span>, <span class="hlFld-ContribAuthor ">Angela Chun Fai  Kung</span>, <span class="hlFld-ContribAuthor ">Jin  Gao</span>, <span class="hlFld-ContribAuthor ">Aiping  Lu</span>, <span class="hlFld-ContribAuthor ">Ge  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.626910" title="DOI URL">https://doi.org/10.3389/fcell.2021.626910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.626910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.626910%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DTargeting%252BStrategies%252Bfor%252BEnhancing%252BPaclitaxel%252BSpecificity%252Bin%252BChemotherapy%26aulast%3DMa%26aufirst%3DYuan%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Gymnopoulos</span>, <span class="hlFld-ContribAuthor ">Oscar  Betancourt</span>, <span class="hlFld-ContribAuthor ">Vincent  Blot</span>, <span class="hlFld-ContribAuthor ">Ryo  Fujita</span>, <span class="hlFld-ContribAuthor ">Diana  Galvan</span>, <span class="hlFld-ContribAuthor ">Vincent  Lieuw</span>, <span class="hlFld-ContribAuthor ">Sophie  Nguyen</span>, <span class="hlFld-ContribAuthor ">Jeanette  Snedden</span>, <span class="hlFld-ContribAuthor ">Christine  Stewart</span>, <span class="hlFld-ContribAuthor ">Jose  Villicana</span>, <span class="hlFld-ContribAuthor ">Jon  Wojciak</span>, <span class="hlFld-ContribAuthor ">Eley  Wong</span>, <span class="hlFld-ContribAuthor ">Raul  Pardo</span>, <span class="hlFld-ContribAuthor ">Neki  Patel</span>, <span class="hlFld-ContribAuthor ">Francois  D’Hooge</span>, <span class="hlFld-ContribAuthor ">Balakumar  Vijayakrishnan</span>, <span class="hlFld-ContribAuthor ">Conor  Barry</span>, <span class="hlFld-ContribAuthor ">John A.  Hartley</span>, <span class="hlFld-ContribAuthor ">Philip W.  Howard</span>, <span class="hlFld-ContribAuthor ">Roland  Newman</span>, <span class="hlFld-ContribAuthor ">Julia  Coronella</span>. </span><span class="cited-content_cbyCitation_article-title">TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2020,</strong> <em>14 </em>
                                    (1)
                                     , 54-68. <a href="https://doi.org/10.1002/1878-0261.12600" title="DOI URL">https://doi.org/10.1002/1878-0261.12600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1878-0261.12600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1878-0261.12600%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DTR1801%2525E2%252580%252590ADC%25253A%252Ba%252Bhighly%252Bpotent%252BcMet%252Bantibody%2525E2%252580%252593drug%252Bconjugate%252Bwith%252Bhigh%252Bactivity%252Bin%252Bpatient%2525E2%252580%252590derived%252Bxenograft%252Bmodels%252Bof%252Bsolid%252Btumors%26aulast%3DGymnopoulos%26aufirst%3DMarco%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3D1%26spage%3D54%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jakob W.  Buecheler</span>, <span class="hlFld-ContribAuthor ">Matthias  Winzer</span>, <span class="hlFld-ContribAuthor ">Christian  Weber</span>, <span class="hlFld-ContribAuthor ">Henning  Gieseler</span>. </span><span class="cited-content_cbyCitation_article-title">Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>109 </em>
                                    (1)
                                     , 161-168. <a href="https://doi.org/10.1016/j.xphs.2019.08.006" title="DOI URL">https://doi.org/10.1016/j.xphs.2019.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2019.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DAlteration%252Bof%252BPhysicochemical%252BProperties%252Bfor%252BAntibody-Drug%252BConjugates%252Band%252BTheir%252BImpact%252Bon%252BStability%26aulast%3DBuecheler%26aufirst%3DJakob%2BW.%26date%3D2020%26volume%3D109%26issue%3D1%26spage%3D161%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingwen  Hu</span>, <span class="hlFld-ContribAuthor ">David M.  Stevens</span>, <span class="hlFld-ContribAuthor ">Sonny  Man</span>, <span class="hlFld-ContribAuthor ">Rachael M.  Crist</span>, <span class="hlFld-ContribAuthor ">Jeffrey D.  Clogston</span>. </span><span class="cited-content_cbyCitation_article-title">Total drug quantification in prodrugs using an automated elemental analyzer. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery and Translational Research</span><span> <strong>2019,</strong> <em>9 </em>
                                    (6)
                                     , 1057-1066. <a href="https://doi.org/10.1007/s13346-019-00649-8" title="DOI URL">https://doi.org/10.1007/s13346-019-00649-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13346-019-00649-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13346-019-00649-8%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%2520and%2520Translational%2520Research%26atitle%3DTotal%252Bdrug%252Bquantification%252Bin%252Bprodrugs%252Busing%252Ban%252Bautomated%252Belemental%252Banalyzer%26aulast%3DHu%26aufirst%3DYingwen%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D6%26spage%3D1057%26epage%3D1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanwen  Yang</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Michelle  Busch</span>, <span class="hlFld-ContribAuthor ">Charlene  Manning</span>, <span class="hlFld-ContribAuthor ">Kim  Alving</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (35)
                                     , 8115-8124. <a href="https://doi.org/10.1039/C9OB01639B" title="DOI URL">https://doi.org/10.1039/C9OB01639B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01639B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01639B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConvergent%252Bsynthesis%252Bof%252Bhydrophilic%252Bmonomethyl%252Bdolastatin%252B10%252Bbased%252Bdrug%252Blinkers%252Bfor%252Bantibody%2525E2%252580%252593drug%252Bconjugation%26aulast%3DYang%26aufirst%3DKanwen%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D35%26spage%3D8115%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madhuri  Jayathirtha</span>, <span class="hlFld-ContribAuthor ">Costel C.  Darie</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Antibody-Drug Conjugates by Mass Spectrometry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 251-263. <a href="https://doi.org/10.1007/978-3-030-15950-4_14" title="DOI URL">https://doi.org/10.1007/978-3-030-15950-4_14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-15950-4_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-15950-4_14%26sid%3Dliteratum%253Aachs%26atitle%3DInvestigation%252Bof%252BAntibody-Drug%252BConjugates%252Bby%252BMass%252BSpectrometry%26aulast%3DJayathirtha%26aufirst%3DMadhuri%26date%3D2019%26date%3D2019%26spage%3D251%26epage%3D263%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAdvancements%252Bof%252BMass%252BSpectrometry%252Bin%252BBiomedical%252BResearch%26aulast%3DWoods%26aufirst%3DAlisa%2BG.%26date%3D2019%26volume%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Charlene M.  Manning</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">Michelle M.  Busch</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (8)
                                     , 790-794. <a href="https://doi.org/10.1002/cmdc.201700722" title="DOI URL">https://doi.org/10.1002/cmdc.201700722</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700722%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252Bin%2525E2%252580%252585vitro%252BEvaluation%252Bof%252BMultivalent%252BDrug%252BLinkers%252Bfor%252BHigh-Drug-Load%252BAntibody-Drug%252BConjugates%26aulast%3DChen%26aufirst%3DBo%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D8%26spage%3D790%26epage%3D794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jakob W  Buecheler</span>, <span class="hlFld-ContribAuthor ">Matthias  Winzer</span>, <span class="hlFld-ContribAuthor ">Christian  Weber</span>, <span class="hlFld-ContribAuthor ">Henning  Gieseler</span>. </span><span class="cited-content_cbyCitation_article-title">High-throughput oxidation screen of antibody–drug conjugates by analytical protein A chromatography following IdeS digest. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy and Pharmacology</span><span> <strong>2018,</strong> <em>70 </em>
                                    (5)
                                     , 625-635. <a href="https://doi.org/10.1111/jphp.12873" title="DOI URL">https://doi.org/10.1111/jphp.12873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jphp.12873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjphp.12873%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520and%2520Pharmacology%26atitle%3DHigh-throughput%252Boxidation%252Bscreen%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Bby%252Banalytical%252Bprotein%252BA%252Bchromatography%252Bfollowing%252BIdeS%252Bdigest%26aulast%3DBuecheler%26aufirst%3DJakob%2BW%26date%3D2018%26date%3D2018%26volume%3D70%26issue%3D5%26spage%3D625%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rabin  Neupane</span>, <span class="hlFld-ContribAuthor ">Malin  Källsten</span>, <span class="hlFld-ContribAuthor ">Fredrik  Lehmann</span>, <span class="hlFld-ContribAuthor ">Jonas  Bergquist</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of mobile phase composition on the analysis of aggregates of antibody drug conjugates (ADCs) using size exclusion chromatography. </span><span class="cited-content_cbyCitation_journal-name">Analytical Methods</span><span> <strong>2018,</strong> <em>10 </em>
                                    (9)
                                     , 938-941. <a href="https://doi.org/10.1039/C7AY02696J" title="DOI URL">https://doi.org/10.1039/C7AY02696J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7AY02696J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7AY02696J%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Methods%26atitle%3DEffect%252Bof%252Bmobile%252Bphase%252Bcomposition%252Bon%252Bthe%252Banalysis%252Bof%252Baggregates%252Bof%252Bantibody%252Bdrug%252Bconjugates%252B%252528ADCs%252529%252Busing%252Bsize%252Bexclusion%252Bchromatography%26aulast%3DNeupane%26aufirst%3DRabin%26date%3D2018%26date%3D2018%26volume%3D10%26issue%3D9%26spage%3D938%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rabin  Neupane</span>, <span class="hlFld-ContribAuthor ">Jonas  Bergquist</span>. </span><span class="cited-content_cbyCitation_article-title">Analytical techniques for the characterization of Antibody Drug Conjugates: Challenges and prospects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Mass Spectrometry</span><span> <strong>2017,</strong> <em>23 </em>
                                    (6)
                                     , 417-426. <a href="https://doi.org/10.1177/1469066717733919" title="DOI URL">https://doi.org/10.1177/1469066717733919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1469066717733919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1469066717733919%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Mass%2520Spectrometry%26atitle%3DAnalytical%252Btechniques%252Bfor%252Bthe%252Bcharacterization%252Bof%252BAntibody%252BDrug%252BConjugates%25253A%252BChallenges%252Band%252Bprospects%26aulast%3DNeupane%26aufirst%3DRabin%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D6%26spage%3D417%26epage%3D426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feihu  Wang</span>, <span class="hlFld-ContribAuthor ">Michael  Porter</span>, <span class="hlFld-ContribAuthor ">Alexandros  Konstantopoulos</span>, <span class="hlFld-ContribAuthor ">Pengcheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Honggang  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2017,</strong> <em>267 </em>, 100-118. <a href="https://doi.org/10.1016/j.jconrel.2017.09.026" title="DOI URL">https://doi.org/10.1016/j.jconrel.2017.09.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2017.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2017.09.026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DPreclinical%252Bdevelopment%252Bof%252Bdrug%252Bdelivery%252Bsystems%252Bfor%252Bpaclitaxel-based%252Bcancer%252Bchemotherapy%26aulast%3DWang%26aufirst%3DFeihu%26date%3D2017%26volume%3D267%26spage%3D100%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Zongtao  Lin</span>, <span class="hlFld-ContribAuthor ">Kinsie  Arnst</span>, <span class="hlFld-ContribAuthor ">Duane  Miller</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (8)
                                     , 1281. <a href="https://doi.org/10.3390/molecules22081281" title="DOI URL">https://doi.org/10.3390/molecules22081281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22081281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22081281%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DTubulin%252BInhibitor-Based%252BAntibody-Drug%252BConjugates%252Bfor%252BCancer%252BTherapy%26aulast%3DChen%26aufirst%3DHao%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D8%26spage%3D1281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjun  Xue</span>, <span class="hlFld-ContribAuthor ">Priya  Sriraman</span>, <span class="hlFld-ContribAuthor ">Matthew V.  Myers</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Chen</span>, <span class="hlFld-ContribAuthor ">Brian  Melo</span>, <span class="hlFld-ContribAuthor ">Martha  Vallejo</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Maxwell</span>, <span class="hlFld-ContribAuthor ">Sekhar  Surapaneni</span>. </span><span class="cited-content_cbyCitation_article-title">Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 183-201. <a href="https://doi.org/10.1002/9781119371779.ch14" title="DOI URL">https://doi.org/10.1002/9781119371779.ch14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119371779.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119371779.ch14%26sid%3Dliteratum%253Aachs%26atitle%3DMass%252BSpectrometry-Based%252BMethodologies%252Bfor%252BPharmacokinetic%252BCharacterization%252Bof%252BAntibody%252BDrug%252BConjugate%252BCandidates%252BDuring%252BDrug%252BDevelopment%26aulast%3DXue%26aufirst%3DYongjun%26date%3D2017%26date%3D2017%26spage%3D183%26epage%3D201%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DProtein%252BAnalysis%252Busing%252BMass%252BSpectrometry%26aulast%3DLee%26aufirst%3DMike%2BS.%26date%3D2017%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Han  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhi-Gang  Qian</span>, <span class="hlFld-ContribAuthor ">Jian-Jiang  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Bioproduction of Antibody–Drug Conjugate Payload Precursors by Engineered Cell Factories. </span><span class="cited-content_cbyCitation_journal-name">Trends in Biotechnology</span><span> <strong>2017,</strong> <em>35 </em>
                                    (5)
                                     , 466-478. <a href="https://doi.org/10.1016/j.tibtech.2017.03.001" title="DOI URL">https://doi.org/10.1016/j.tibtech.2017.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tibtech.2017.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tibtech.2017.03.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Biotechnology%26atitle%3DBioproduction%252Bof%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BPayload%252BPrecursors%252Bby%252BEngineered%252BCell%252BFactories%26aulast%3DWang%26aufirst%3DJie%26date%3D2017%26volume%3D35%26issue%3D5%26spage%3D466%26epage%3D478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Rohrer</span>. </span><span class="cited-content_cbyCitation_article-title">MANUFACTURING CONCEPTS FOR ANTIBODY-DRUG CONJUGATES. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 595-614. <a href="https://doi.org/10.1002/9781119126942.ch27" title="DOI URL">https://doi.org/10.1002/9781119126942.ch27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119126942.ch27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119126942.ch27%26sid%3Dliteratum%253Aachs%26atitle%3DMANUFACTURING%252BCONCEPTS%252BFOR%252BANTIBODY-DRUG%252BCONJUGATES%26aulast%3DRohrer%26aufirst%3DThomas%26date%3D2017%26date%3D2017%26spage%3D595%26epage%3D614%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DProcess%252BScale%252BPurification%252Bof%252BAntibodies%26aulast%3DGottschalk%26aufirst%3DUwe%26date%3D2017%26date%3D2017%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Prodrug Strategy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 77-104. <a href="https://doi.org/10.1201/9781315370118-5" title="DOI URL">https://doi.org/10.1201/9781315370118-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1201/9781315370118-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1201%2F9781315370118-5%26sid%3Dliteratum%253Aachs%26atitle%3DProdrug%252BStrategy%26date%3D2016%26date%3D2016%26spage%3D77%26epage%3D104%26pub%3DCRC%2520Press%26atitle%3DBio-Targets%252Band%252BDrug%252BDelivery%252BApproaches%26aulast%3DMaiti%26aufirst%3DSabyasachi%26date%3D2016%26date%3D2016%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liuxi  Chen</span>, <span class="hlFld-ContribAuthor ">Lan  Wang</span>, <span class="hlFld-ContribAuthor ">Henry  Shion</span>, <span class="hlFld-ContribAuthor ">Chuanfei  Yu</span>, <span class="hlFld-ContribAuthor ">Ying Qing  Yu</span>, <span class="hlFld-ContribAuthor ">Lei  Zhu</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Weibin  Chen</span>, <span class="hlFld-ContribAuthor ">Kai  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2016,</strong> <em>8 </em>
                                    (7)
                                     , 1210-1223. <a href="https://doi.org/10.1080/19420862.2016.1204502" title="DOI URL">https://doi.org/10.1080/19420862.2016.1204502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19420862.2016.1204502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19420862.2016.1204502%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DIn-depth%252Bstructural%252Bcharacterization%252Bof%252BKadcyla%2525C2%2525AE%252B%252528ado-trastuzumab%252Bemtansine%252529%252Band%252Bits%252Bbiosimilar%252Bcandidate%26aulast%3DChen%26aufirst%3DLiuxi%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D7%26spage%3D1210%26epage%3D1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Balázs  Bobály</span>, <span class="hlFld-ContribAuthor ">Enikő  Sipkó</span>, <span class="hlFld-ContribAuthor ">Jenő  Fekete</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges in liquid chromatographic characterization of proteins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography B</span><span> <strong>2016,</strong> <em>1032 </em>, 3-22. <a href="https://doi.org/10.1016/j.jchromb.2016.04.037" title="DOI URL">https://doi.org/10.1016/j.jchromb.2016.04.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchromb.2016.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchromb.2016.04.037%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520B%26atitle%3DChallenges%252Bin%252Bliquid%252Bchromatographic%252Bcharacterization%252Bof%252Bproteins%26aulast%3DBob%25C3%25A1ly%26aufirst%3DBal%25C3%25A1zs%26date%3D2016%26volume%3D1032%26spage%3D3%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Cinzia  Stella</span>, <span class="hlFld-ContribAuthor ">Colin D.  Medley</span>, <span class="hlFld-ContribAuthor ">Jason A.  Gruenhagen</span>, <span class="hlFld-ContribAuthor ">Kelly  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography B</span><span> <strong>2016,</strong> <em>1032 </em>, 39-50. <a href="https://doi.org/10.1016/j.jchromb.2016.07.023" title="DOI URL">https://doi.org/10.1016/j.jchromb.2016.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchromb.2016.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchromb.2016.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520B%26atitle%3DAntibody-drug%252Bconjugate%252Bcharacterization%252Bby%252Bchromatographic%252Band%252Belectrophoretic%252Btechniques%26aulast%3DChen%26aufirst%3DTao%26date%3D2016%26volume%3D1032%26spage%3D39%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Li</span>, <span class="hlFld-ContribAuthor ">Fengshan  Wang</span>, <span class="hlFld-ContribAuthor ">Deqing  Sun</span>, <span class="hlFld-ContribAuthor ">Rongmei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2016,</strong> <em>24 </em>
                                    (7)
                                     , 590-602. <a href="https://doi.org/10.3109/1061186X.2016.1154561" title="DOI URL">https://doi.org/10.3109/1061186X.2016.1154561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/1061186X.2016.1154561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F1061186X.2016.1154561%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DA%252Breview%252Bof%252Bthe%252Bligands%252Band%252Brelated%252Btargeting%252Bstrategies%252Bfor%252Bactive%252Btargeting%252Bof%252Bpaclitaxel%252Bto%252Btumours%26aulast%3DLi%26aufirst%3DJuan%26date%3D2016%26date%3D2016%26volume%3D24%26issue%3D7%26spage%3D590%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steve  Knutson</span>, <span class="hlFld-ContribAuthor ">Erum  Raja</span>, <span class="hlFld-ContribAuthor ">Ryan  Bomgarden</span>, <span class="hlFld-ContribAuthor ">Marie  Nlend</span>, <span class="hlFld-ContribAuthor ">Aoshuang  Chen</span>, <span class="hlFld-ContribAuthor ">Ramaswamy  Kalyanasundaram</span>, <span class="hlFld-ContribAuthor ">Surbhi  Desai</span>, . </span><span class="cited-content_cbyCitation_article-title">Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2016,</strong> <em>11 </em>
                                    (6)
                                     , e0157762. <a href="https://doi.org/10.1371/journal.pone.0157762" title="DOI URL">https://doi.org/10.1371/journal.pone.0157762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0157762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0157762%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DDevelopment%252Band%252BEvaluation%252Bof%252Ba%252BFluorescent%252BAntibody-Drug%252BConjugate%252Bfor%252BMolecular%252BImaging%252Band%252BTargeted%252BTherapy%252Bof%252BPancreatic%252BCancer%26aulast%3DKnutson%26aufirst%3DSteve%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D6%26spage%3De0157762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Guillaume  Terral</span>, <span class="hlFld-ContribAuthor ">François  Debaene</span>, <span class="hlFld-ContribAuthor ">Elsa  Wagner-Rousset</span>, <span class="hlFld-ContribAuthor ">Julien  Marcoux</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Janin-Bussat</span>, <span class="hlFld-ContribAuthor ">Olivier  Colas</span>, <span class="hlFld-ContribAuthor ">Alain Van  Dorsselaer</span>, <span class="hlFld-ContribAuthor ">Sarah  Cianférani</span>. </span><span class="cited-content_cbyCitation_article-title">Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Proteomics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (2)
                                     , 157-183. <a href="https://doi.org/10.1586/14789450.2016.1132167" title="DOI URL">https://doi.org/10.1586/14789450.2016.1132167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/14789450.2016.1132167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2F14789450.2016.1132167%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Proteomics%26atitle%3DCutting-edge%252Bmass%252Bspectrometry%252Bmethods%252Bfor%252Bthe%252Bmulti-level%252Bstructural%252Bcharacterization%252Bof%252Bantibody-drug%252Bconjugates%26aulast%3DBeck%26aufirst%3DAlain%26date%3D2016%26date%3D2016%26volume%3D13%26issue%3D2%26spage%3D157%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Houzong  Yao</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Aiping  Lu</span>, <span class="hlFld-ContribAuthor ">Ge  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2016,</strong> <em>17 </em>
                                    (2)
                                     , 194. <a href="https://doi.org/10.3390/ijms17020194" title="DOI URL">https://doi.org/10.3390/ijms17020194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms17020194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms17020194%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMethods%252Bto%252BDesign%252Band%252BSynthesize%252BAntibody-Drug%252BConjugates%252B%252528ADCs%252529%26aulast%3DYao%26aufirst%3DHouzong%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D2%26spage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory S.  Hamilton</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids. </span><span class="cited-content_cbyCitation_journal-name">Biologicals</span><span> <strong>2015,</strong> <em>43 </em>
                                    (5)
                                     , 318-332. <a href="https://doi.org/10.1016/j.biologicals.2015.05.006" title="DOI URL">https://doi.org/10.1016/j.biologicals.2015.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biologicals.2015.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biologicals.2015.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBiologicals%26atitle%3DAntibody-drug%252Bconjugates%252Bfor%252Bcancer%252Btherapy%25253A%252BThe%252Btechnological%252Band%252Bregulatory%252Bchallenges%252Bof%252Bdeveloping%252Bdrug-biologic%252Bhybrids%26aulast%3DHamilton%26aufirst%3DGregory%2BS.%26date%3D2015%26volume%3D43%26issue%3D5%26spage%3D318%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica R.  McCombs</span>, <span class="hlFld-ContribAuthor ">Shawn C.  Owen</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2015,</strong> <em>17 </em>
                                    (2)
                                     , 339-351. <a href="https://doi.org/10.1208/s12248-014-9710-8" title="DOI URL">https://doi.org/10.1208/s12248-014-9710-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-014-9710-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-014-9710-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DAntibody%252BDrug%252BConjugates%25253A%252BDesign%252Band%252BSelection%252Bof%252BLinker%25252C%252BPayload%252Band%252BConjugation%252BChemistry%26aulast%3DMcCombs%26aufirst%3DJessica%2BR.%26date%3D2015%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D339%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Xie</span>, <span class="hlFld-ContribAuthor ">Zhijun  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Bioanalytical Assay for Characterization of Antibody-Drug Conjugates (ADCs). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 97-115. <a href="https://doi.org/10.1007/978-3-319-13081-1_6" title="DOI URL">https://doi.org/10.1007/978-3-319-13081-1_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-13081-1_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-13081-1_6%26sid%3Dliteratum%253Aachs%26atitle%3DBioanalytical%252BAssay%252Bfor%252BCharacterization%252Bof%252BAntibody-Drug%252BConjugates%252B%252528ADCs%252529%26aulast%3DXie%26aufirst%3DChen%26date%3D2015%26date%3D2015%26spage%3D97%26epage%3D115%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DWang%26aufirst%3DJeffrey%26date%3D2015%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Szabolcs  Fekete</span>, <span class="hlFld-ContribAuthor ">Alain  Beck</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Veuthey</span>, <span class="hlFld-ContribAuthor ">Davy  Guillarme</span>. </span><span class="cited-content_cbyCitation_article-title">Theory and practice of size exclusion chromatography for the analysis of protein aggregates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2014,</strong> <em>101 </em>, 161-173. <a href="https://doi.org/10.1016/j.jpba.2014.04.011" title="DOI URL">https://doi.org/10.1016/j.jpba.2014.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2014.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2014.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DTheory%252Band%252Bpractice%252Bof%252Bsize%252Bexclusion%252Bchromatography%252Bfor%252Bthe%252Banalysis%252Bof%252Bprotein%252Baggregates%26aulast%3DFekete%26aufirst%3DSzabolcs%26date%3D2014%26volume%3D101%26spage%3D161%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyungjun  Kim</span>, <span class="hlFld-ContribAuthor ">Yonghyun  Lee</span>, <span class="hlFld-ContribAuthor ">In-Hyun  Lee</span>, <span class="hlFld-ContribAuthor ">Sunghyun  Kim</span>, <span class="hlFld-ContribAuthor ">Daejin  Kim</span>, <span class="hlFld-ContribAuthor ">Phei Er  Saw</span>, <span class="hlFld-ContribAuthor ">Jinju  Lee</span>, <span class="hlFld-ContribAuthor ">Minsuk  Choi</span>, <span class="hlFld-ContribAuthor ">Yong-Chul  Kim</span>, <span class="hlFld-ContribAuthor ">Sangyong  Jon</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2014,</strong> <em>178 </em>, 118-124. <a href="https://doi.org/10.1016/j.jconrel.2014.01.015" title="DOI URL">https://doi.org/10.1016/j.jconrel.2014.01.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2014.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2014.01.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DSynthesis%252Band%252Btherapeutic%252Bevaluation%252Bof%252Ban%252Baptide%2525E2%252580%252593docetaxel%252Bconjugate%252Btargeting%252Btumor-associated%252Bfibronectin%26aulast%3DKim%26aufirst%3DHyungjun%26date%3D2014%26volume%3D178%26spage%3D118%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marya  Ahmed</span>, <span class="hlFld-ContribAuthor ">Ravin  Narain</span>. </span><span class="cited-content_cbyCitation_article-title">Physico-Chemical and Biochemical Properties of Bioconjugates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 431-443. <a href="https://doi.org/10.1002/9781118775882.ch18" title="DOI URL">https://doi.org/10.1002/9781118775882.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118775882.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118775882.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DPhysico-Chemical%252Band%252BBiochemical%252BProperties%252Bof%252BBioconjugates%26aulast%3DAhmed%26aufirst%3DMarya%26date%3D2014%26date%3D2014%26spage%3D431%26epage%3D443%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DChemistry%252Bof%252BBioconjugates%26aulast%3DNarain%26aufirst%3DRavin%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Vamvakaki</span>. </span><span class="cited-content_cbyCitation_article-title">Organic Nanoparticle Bioconjugate: Micelles, Cross-Linked Micelles, and Nanogels. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 203-238. <a href="https://doi.org/10.1002/9781118775882.ch7" title="DOI URL">https://doi.org/10.1002/9781118775882.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118775882.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118775882.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DOrganic%252BNanoparticle%252BBioconjugate%25253A%252BMicelles%25252C%252BCross-Linked%252BMicelles%25252C%252Band%252BNanogels%26aulast%3DVamvakaki%26aufirst%3DMaria%26date%3D2014%26date%3D2014%26spage%3D203%26epage%3D238%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DChemistry%252Bof%252BBioconjugates%26aulast%3DNarain%26aufirst%3DRavin%26date%3D2014%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sumit  Goswami</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Tsutomu  Arakawa</span>, <span class="hlFld-ContribAuthor ">Satoshi  Ohtake</span>. </span><span class="cited-content_cbyCitation_article-title">Developments and Challenges for mAb-Based Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2013,</strong> <em>2 </em>
                                    (4)
                                     , 452-500. <a href="https://doi.org/10.3390/antib2030452" title="DOI URL">https://doi.org/10.3390/antib2030452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib2030452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib2030452%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DDevelopments%252Band%252BChallenges%252Bfor%252BmAb-Based%252BTherapeutics%26aulast%3DGoswami%26aufirst%3DSumit%26date%3D2013%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D452%26epage%3D500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Li</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Li-zhe  Xue</span>, <span class="hlFld-ContribAuthor ">Pei-yong  Li</span>, <span class="hlFld-ContribAuthor ">De-yue  Yan</span>, <span class="hlFld-ContribAuthor ">Xin-yuan  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">188Re-labeled hyperbranched polysulfonamine as a robust tool for targeted cancer diagnosis and radioimmunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Polymer Science</span><span> <strong>2013,</strong> <em>31 </em>
                                    (3)
                                     , 530-540. <a href="https://doi.org/10.1007/s10118-013-1242-7" title="DOI URL">https://doi.org/10.1007/s10118-013-1242-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10118-013-1242-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10118-013-1242-7%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Polymer%2520Science%26atitle%3D188Re-labeled%252Bhyperbranched%252Bpolysulfonamine%252Bas%252Ba%252Brobust%252Btool%252Bfor%252Btargeted%252Bcancer%252Bdiagnosis%252Band%252Bradioimmunotherapy%26aulast%3DLi%26aufirst%3DNan%26date%3D2013%26date%3D2013%26volume%3D31%26issue%3D3%26spage%3D530%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiping  Zhang</span>, <span class="hlFld-ContribAuthor ">Lin  Mei</span>, <span class="hlFld-ContribAuthor ">Si-Shen  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Paclitaxel drug delivery systems. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Delivery</span><span> <strong>2013,</strong> <em>10 </em>
                                    (3)
                                     , 325-340. <a href="https://doi.org/10.1517/17425247.2013.752354" title="DOI URL">https://doi.org/10.1517/17425247.2013.752354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17425247.2013.752354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17425247.2013.752354%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Delivery%26atitle%3DPaclitaxel%252Bdrug%252Bdelivery%252Bsystems%26aulast%3DZhang%26aufirst%3DZhiping%26date%3D2013%26date%3D2013%26volume%3D10%26issue%3D3%26spage%3D325%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine R.  Kozak</span>, <span class="hlFld-ContribAuthor ">Helga  Raab</span>. </span><span class="cited-content_cbyCitation_article-title">Assay Methodologies and Challenges. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 41-56. <a href="https://doi.org/10.1007/978-1-4614-5456-4_3" title="DOI URL">https://doi.org/10.1007/978-1-4614-5456-4_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4614-5456-4_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4614-5456-4_3%26sid%3Dliteratum%253Aachs%26atitle%3DAssay%252BMethodologies%252Band%252BChallenges%26aulast%3DKozak%26aufirst%3DKatherine%2BR.%26date%3D2013%26date%3D2012%26spage%3D41%26epage%3D56%26pub%3DSpringer%2520New%2520York%26atitle%3DAntibody-Drug%252BConjugates%252Band%252BImmunotoxins%26aulast%3DPhillips%26aufirst%3DGail%2BLewis%26date%3D2013%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louisette  Basa</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 285-293. <a href="https://doi.org/10.1007/978-1-62703-541-5_18" title="DOI URL">https://doi.org/10.1007/978-1-62703-541-5_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-62703-541-5_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-62703-541-5_18%26sid%3Dliteratum%253Aachs%26atitle%3DDrug-to-Antibody%252BRatio%252B%252528DAR%252529%252Band%252BDrug%252BLoad%252BDistribution%252Bby%252BLC-ESI-MS%26aulast%3DBasa%26aufirst%3DLouisette%26date%3D2013%26date%3D2013%26spage%3D285%26epage%3D293%26pub%3DHumana%2520Press%26atitle%3DAntibody-Drug%252BConjugates%26aulast%3DDucry%26aufirst%3DLaurent%26date%3D2013%26volume%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalie J.  Thompson</span>, <span class="hlFld-ContribAuthor ">Sara  Rosati</span>, <span class="hlFld-ContribAuthor ">Rebecca J.  Rose</span>, <span class="hlFld-ContribAuthor ">Albert J. R.  Heck</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of mass spectrometry on the study of intact antibodies: from post-translational modifications to structural analysis. </span><span class="cited-content_cbyCitation_journal-name">Chem. Commun.</span><span> <strong>2013,</strong> <em>49 </em>
                                    (6)
                                     , 538-548. <a href="https://doi.org/10.1039/C2CC36755F" title="DOI URL">https://doi.org/10.1039/C2CC36755F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C2CC36755F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC2CC36755F%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Commun.%26atitle%3DThe%252Bimpact%252Bof%252Bmass%252Bspectrometry%252Bon%252Bthe%252Bstudy%252Bof%252Bintact%252Bantibodies%25253A%252Bfrom%252Bpost-translational%252Bmodifications%252Bto%252Bstructural%252Banalysis%26aulast%3DThompson%26aufirst%3DNatalie%2BJ.%26date%3D2013%26date%3D2013%26volume%3D49%26issue%3D6%26spage%3D538%26epage%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonor Munoz  Alcivar</span>, <span class="hlFld-ContribAuthor ">Yashwant  Pathak</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody-Mediated Drug Delivery Systems for Breast Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 35-55. <a href="https://doi.org/10.1002/9781118229019.ch3" title="DOI URL">https://doi.org/10.1002/9781118229019.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118229019.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118229019.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DAntibody-Mediated%252BDrug%252BDelivery%252BSystems%252Bfor%252BBreast%252BCancer%252BTherapeutics%26aulast%3DAlcivar%26aufirst%3DLeonor%2BMunoz%26date%3D2012%26date%3D2012%26spage%3D35%26epage%3D55%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAntibody-Mediated%252BDrug%252BDelivery%252BSystems%26aulast%3DPathak%26aufirst%3DYashwant%26date%3D2012%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laurent  Ducry</span>. </span><span class="cited-content_cbyCitation_article-title">Considerations of Linker Technologies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 355-374. <a href="https://doi.org/10.1002/9783527634057.ch12" title="DOI URL">https://doi.org/10.1002/9783527634057.ch12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527634057.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527634057.ch12%26sid%3Dliteratum%253Aachs%26atitle%3DConsiderations%252Bof%252BLinker%252BTechnologies%26aulast%3DDucry%26aufirst%3DLaurent%26date%3D2011%26date%3D2011%26spage%3D355%26epage%3D374%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BDelivery%252Bin%252BOncology%26aulast%3DKratz%26aufirst%3DFelix%26date%3D2011%26volume%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunzi  Li</span>, <span class="hlFld-ContribAuthor ">Bethany Powell  Gray</span>, <span class="hlFld-ContribAuthor ">Michael J.  McGuire</span>, <span class="hlFld-ContribAuthor ">Kathlynn C.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of a peptide–paclitaxel conjugate which targets the integrin αvβ6. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (18)
                                     , 5480-5489. <a href="https://doi.org/10.1016/j.bmc.2011.07.046" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.07.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.07.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.07.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bpeptide%2525E2%252580%252593paclitaxel%252Bconjugate%252Bwhich%252Btargets%252Bthe%252Bintegrin%252B%2525CE%2525B1v%2525CE%2525B26%26aulast%3DLi%26aufirst%3DShunzi%26date%3D2011%26volume%3D19%26issue%3D18%26spage%3D5480%26epage%3D5489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aldo  Laganà</span>, <span class="hlFld-ContribAuthor ">Iole  Venditti</span>, <span class="hlFld-ContribAuthor ">Ilaria  Fratoddi</span>, <span class="hlFld-ContribAuthor ">Anna Laura  Capriotti</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Caruso</span>, <span class="hlFld-ContribAuthor ">Chiara  Battocchio</span>, <span class="hlFld-ContribAuthor ">Giovanni  Polzonetti</span>, <span class="hlFld-ContribAuthor ">Filippo  Acconcia</span>, <span class="hlFld-ContribAuthor ">Maria  Marino</span>, <span class="hlFld-ContribAuthor ">Maria Vittoria  Russo</span>. </span><span class="cited-content_cbyCitation_article-title">Nanostructured functional co-polymers bioconjugate integrin inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Colloid and Interface Science</span><span> <strong>2011,</strong> <em>361 </em>
                                    (2)
                                     , 465-471. <a href="https://doi.org/10.1016/j.jcis.2011.05.041" title="DOI URL">https://doi.org/10.1016/j.jcis.2011.05.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jcis.2011.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jcis.2011.05.041%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Colloid%2520and%2520Interface%2520Science%26atitle%3DNanostructured%252Bfunctional%252Bco-polymers%252Bbioconjugate%252Bintegrin%252Binhibitors%26aulast%3DLagan%25C3%25A0%26aufirst%3DAldo%26date%3D2011%26volume%3D361%26issue%3D2%26spage%3D465%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rubi  Mahato</span>, <span class="hlFld-ContribAuthor ">Wanyi  Tai</span>, <span class="hlFld-ContribAuthor ">Kun  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Prodrugs for improving tumor targetability and efficiency. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2011,</strong> <em>63 </em>
                                    (8)
                                     , 659-670. <a href="https://doi.org/10.1016/j.addr.2011.02.002" title="DOI URL">https://doi.org/10.1016/j.addr.2011.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2011.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DProdrugs%252Bfor%252Bimproving%252Btumor%252Btargetability%252Band%252Befficiency%26aulast%3DMahato%26aufirst%3DRubi%26date%3D2011%26volume%3D63%26issue%3D8%26spage%3D659%26epage%3D670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aditya  Wakankar</span>, <span class="hlFld-ContribAuthor ">Yan  Chen</span>, <span class="hlFld-ContribAuthor ">Yatin  Gokarn</span>, <span class="hlFld-ContribAuthor ">Fredric S.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Analytical methods for physicochemical characterization of antibody drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">mAbs</span><span> <strong>2011,</strong> <em>3 </em>
                                    (2)
                                     , 161-172. <a href="https://doi.org/10.4161/mabs.3.2.14960" title="DOI URL">https://doi.org/10.4161/mabs.3.2.14960</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4161/mabs.3.2.14960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4161%2Fmabs.3.2.14960%26sid%3Dliteratum%253Aachs%26jtitle%3DmAbs%26atitle%3DAnalytical%252Bmethods%252Bfor%252Bphysicochemical%252Bcharacterization%252Bof%252Bantibody%252Bdrug%252Bconjugates%26aulast%3DWakankar%26aufirst%3DAditya%26date%3D2011%26date%3D2014%26volume%3D3%26issue%3D2%26spage%3D161%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franco  Dosio</span>, <span class="hlFld-ContribAuthor ">Barbara  Stella</span>, <span class="hlFld-ContribAuthor ">Silvia  Arpicco</span>, <span class="hlFld-ContribAuthor ">Luigi  Cattel</span>. </span><span class="cited-content_cbyCitation_article-title">Macromolecules as taxane delivery systems. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Delivery</span><span> <strong>2011,</strong> <em>8 </em>
                                    (1)
                                     , 33-55. <a href="https://doi.org/10.1517/17425247.2011.541437" title="DOI URL">https://doi.org/10.1517/17425247.2011.541437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17425247.2011.541437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17425247.2011.541437%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Delivery%26atitle%3DMacromolecules%252Bas%252Btaxane%252Bdelivery%252Bsystems%26aulast%3DDosio%26aufirst%3DFranco%26date%3D2011%26date%3D2010%26volume%3D8%26issue%3D1%26spage%3D33%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas C  Nicolaides</span>, <span class="hlFld-ContribAuthor ">Philip M  Sass</span>, <span class="hlFld-ContribAuthor ">Luigi  Grasso</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in targeted therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2010,</strong> <em>5 </em>
                                    (11)
                                     , 1123-1140. <a href="https://doi.org/10.1517/17460441.2010.521496" title="DOI URL">https://doi.org/10.1517/17460441.2010.521496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2010.521496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2010.521496%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAdvances%252Bin%252Btargeted%252Btherapeutic%252Bagents%26aulast%3DNicolaides%26aufirst%3DNicholas%2BC%26date%3D2010%26date%3D2010%26volume%3D5%26issue%3D11%26spage%3D1123%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of paclitaxel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Water-Soluble PTX−dPEG Conjugates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) DCM/MT, RT; (ii) NHS, DCC, DCM, <b>3</b>; (iii) TIPS/TFA; (iv) PTX-<b>L</b>-NHS, DIEA, DCM; (v) NHS, DCC, DCM.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of the single-MW dPEG branched (<b>2</b>) and linear (<b>3</b>) linkers used in the synthesis of the soluble PTX, <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) 50 mM PBS, pH 8.1.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Size-exclusion chromatograms (SE-HPLC) and MALDI-TOF mass spectra of C225 (A) and conjugates <b>11a</b>−<b>11d</b> (B−E) illustrating the degrees of purity and MWs for these compounds, respectively. SEC retention times decrease while the MALDI peaks broaden as the MW increases. The smaller left peaks in the mass spectra are the doubly charged half-MW peaks. All MALDI analyses were made with external calibration against bovine serum albumin at 66430.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. FACS analyses of the unconjugated C225 (B) and PTX conjugates <b>11a</b>−<b>11d</b> (C−F, respectively) against MDA-MB-468 human breast carcinoma cells. All conjugates showed a significant shift in the light intensity compared to a no-mAb run (A), indicating the preserved immunoreactivity of the antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/medium/jm-2009-00899g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cell proliferation inhibition in MDA-MB-468 human breast carcinoma cell line treated with either free PTX or each of the <b>11e</b>−<b>11h</b> conjugates at 10 nM drug equivalent concentration and with a 24 h exposure time. Surviving cell numbers were normalized against the untreated controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-2/jm900899g/production/images/large/jm-2009-00899g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm900899g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kohler, G. M., C.</span><span> </span><span class="NLM_article-title">Continuous cultures of fused cells secreting antibody of predefined specificity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">497</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1038%2F256495a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=1172191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1975&pages=495-497&author=G.+M.%2C+C.+Kohler&title=Continuous+cultures+of+fused+cells+secreting+antibody+of+predefined+specificity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous cultures of fused cells secreting antibody of predefined specificity</span></div><div class="casAuthors">Kohler G; Milstein C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5517</span>),
    <span class="NLM_cas:pages">495-7</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLHx9X4gieguxsqfvU0ziafW6udTcc2eYq005YQZbBLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FhtVOhtQ%253D%253D&md5=b5003f0bd9ce2870718bc392c40b89eb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F256495a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F256495a0%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DG.%2BM.%252C%2BC.%26atitle%3DContinuous%2520cultures%2520of%2520fused%2520cells%2520secreting%2520antibody%2520of%2520predefined%2520specificity%26jtitle%3DNature%26date%3D1975%26volume%3D256%26spage%3D495%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Goodwin, D. A.</span><span> </span><span class="NLM_article-title">Stategies for antibody targeting</span> <span class="citation_source-journal">Antib. Immunoconjugate Radiopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK38Xks1GmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=427-434&author=D.+A.+Goodwin&title=Stategies+for+antibody+targeting"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for antibody targeting</span></div><div class="casAuthors">Goodwin, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Antibody, Immunoconjugates, and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-34</span>CODEN:
                <span class="NLM_cas:coden">AIRAEB</span>;
        ISSN:<span class="NLM_cas:issn">0892-7049</span>.
    </div><div class="casAbstract">A review with 51 refs.  Hybridoma technol. has made large amts. of monoclonal antibody available in the form of highly homogeneous specific reagents for clin. use.  Pretargeted radioimmunodetection (PRAID), is a method of tumor imaging in which the antibody and the radiolabel are administered sep.  Nonradioactive antibody is given 1st (pretargeted), and allowed adequate time to reach max. tumor concn.  Depending on the antibody, this may take several days.  At the time of max. tumor concn. of nonradioactive antibody, the blood is quickly cleared of excess circulating nonradioactive antibody using a special i.v. "chase".  The radiolabel then is given and imaging done in 1-3 h.  The use of short-lived tracers (hours) to image antibodies that localize slowly (days) in vivo is an important advance made possible by this new technol.  An improvement in this system is the development of bispecific antibodies that could bind both in chelate and a tumor antigen.  Either hybrid antibodies or antibody conjugates could be used for this application.  It is clear that research into methods of controlling antibody background has produced many promising leads.  Methods of background redn. will be as important to the eventual successful clin. application of antibodies, as are improvements in antibody affinity, specificity and decreased antigenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9-QvQT4onIbVg90H21EOLACvtfcHk0lgrYA72Kmnb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xks1GmtLk%253D&md5=9b80120ab210e67eb57cd847703230ae</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DD.%2BA.%26atitle%3DStategies%2520for%2520antibody%2520targeting%26jtitle%3DAntib.%2520Immunoconjugate%2520Radiopharm.%26date%3D1991%26volume%3D4%26spage%3D427%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mamot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallab, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirpotin, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11631</span><span class="NLM_x">–</span> <span class="NLM_lpage">11638</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11631-11638&author=C.+Mamotauthor=D.+C.+Drummondauthor=C.+O.+Nobleauthor=V.+Kallabauthor=Z.+Guoauthor=K.+Hongauthor=D.+B.+Kirpotinauthor=J.+W.+Park&title=Epidermal+growth+factor+receptor-targeted+immunoliposomes+significantly+enhance+the+efficacy+of+multiple+anticancer+drugs+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DNoble%26aufirst%3DC.%2BO.%26aulast%3DKallab%26aufirst%3DV.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor-targeted%2520immunoliposomes%2520significantly%2520enhance%2520the%2520efficacy%2520of%2520multiple%2520anticancer%2520drugs%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11631%26epage%3D11638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Richman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denardo, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Donnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuscano, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukis, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meares, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamborn, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNardo, G. L.</span><span> </span><span class="NLM_article-title">High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5920</span><span class="NLM_x">–</span> <span class="NLM_lpage">5927</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1158%2F1078-0432.CCR-05-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16115934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5920-5927&author=C.+M.+Richmanauthor=S.+J.+Denardoauthor=R.+T.+O%27Donnellauthor=A.+Yuanauthor=S.+Shenauthor=D.+S.+Goldsteinauthor=J.+M.+Tuscanoauthor=T.+Wunauthor=H.+K.+Chewauthor=P.+N.+Laraauthor=D.+L.+Kukisauthor=A.+Natarajanauthor=C.+F.+Mearesauthor=K.+R.+Lambornauthor=G.+L.+DeNardo&title=High-dose+radioimmunotherapy+combined+with+fixed%2C+low-dose+paclitaxel+in+metastatic+prostate+and+breast+cancer+by+using+a+MUC-1+monoclonal+antibody%2C+m170%2C+linked+to+indium-111%2Fyttrium-90+via+a+cathepsin+cleavable+linker+with+cyclosporine+to+prevent+human+anti-mouse+antibody"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody</span></div><div class="casAuthors">Richman, Carol M.; DeNardo, Sally J.; O'Donnell, Robert T.; Yuan, Aina; Shen, Sui; Goldstein, Desiree S.; Tuscano, Joseph M.; Wun, Ted; Chew, Helen K.; Lara, Primo N.; Kukis, David L.; Natarajan, Arutselvan; Meares, Claude F.; Lamborn, Kathleen R.; DeNardo, Gerald L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5920-5927</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to solid tumors will likely require a combined modality approach.  In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer.  Exptl. Design: Patients were imaged with indium-111 (111In)-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-peptide-m170.  One week later, yttrium-90 (90Y)-m170 was infused (12 mCi/m2 for prostate cancer and 22 mCi/m2 for breast cancer).  Initial cohorts received radioimmunotherapy alone.  Subsequent cohorts received radioimmunotherapy followed 48 h later by paclitaxel (75 mg/m2).  Cyclosporine was given to prevent development of human anti-mouse antibody.  Results: Bone and soft tissue metastases were targeted by 111In-m170 in 15 of the 16 patients imaged.  Three prostate cancer patients treated with radioimmunotherapy alone had no grade 3 or 4 toxicity.  With radioimmunotherapy and paclitaxel, two of three prostate cancer patients developed transient grade 4 neutropenia.  Four breast cancer patients treated with radioimmunotherapy alone had grade 3 or 4 myelosuppression.  With radioimmunotherapy and paclitaxel, both breast cancer patients developed grade 4 neutropenia.  Three breast cancer patients required infusion of previously harvested peripheral blood stem cells because of neutropenic fever or bleeding.  One patient in this trial developed human anti-mouse antibody in contrast to 12 of 17 patients in a prior trial using m170-radioimmunotherapy without cyclosporine.  Conclusions: 111In/90Y-m170 targets prostate and breast cancer and can be combined with paclitaxel with toxicity limited to marrow suppression at the dose levels above.  The max. tolerated dose of radioimmunotherapy and fixed-dose paclitaxel with peripheral blood stem cell support has not been reached.  Cyclosporine is effective in preventing human anti-mouse antibody, suggesting the feasibility of multidose, "fractionated" therapy that could enhance clin. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpab64hSW9k67Vg90H21EOLACvtfcHk0liJQveEQqo4HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1Cju7k%253D&md5=7be8a557a016b53ab4b5e7afd7ddbd34</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0211%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DC.%2BM.%26aulast%3DDenardo%26aufirst%3DS.%2BJ.%26aulast%3DO%2527Donnell%26aufirst%3DR.%2BT.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DGoldstein%26aufirst%3DD.%2BS.%26aulast%3DTuscano%26aufirst%3DJ.%2BM.%26aulast%3DWun%26aufirst%3DT.%26aulast%3DChew%26aufirst%3DH.%2BK.%26aulast%3DLara%26aufirst%3DP.%2BN.%26aulast%3DKukis%26aufirst%3DD.%2BL.%26aulast%3DNatarajan%26aufirst%3DA.%26aulast%3DMeares%26aufirst%3DC.%2BF.%26aulast%3DLamborn%26aufirst%3DK.%2BR.%26aulast%3DDeNardo%26aufirst%3DG.%2BL.%26atitle%3DHigh-dose%2520radioimmunotherapy%2520combined%2520with%2520fixed%252C%2520low-dose%2520paclitaxel%2520in%2520metastatic%2520prostate%2520and%2520breast%2520cancer%2520by%2520using%2520a%2520MUC-1%2520monoclonal%2520antibody%252C%2520m170%252C%2520linked%2520to%2520indium-111%252Fyttrium-90%2520via%2520a%2520cathepsin%2520cleavable%2520linker%2520with%2520cyclosporine%2520to%2520prevent%2520human%2520anti-mouse%2520antibody%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5920%26epage%3D5927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Arap, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasqualini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruoslahti, E.</span><span> </span><span class="NLM_article-title">Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1126%2Fscience.279.5349.377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9430587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1cXmtl2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=377-380&author=W.+Arapauthor=R.+Pasqualiniauthor=E.+Ruoslahti&title=Cancer+treatment+by+targeted+drug+delivery+to+tumor+vasculature+in+a+mouse+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model</span></div><div class="casAuthors">Arap, Wadih; Pasqualini, Renata; Ruoslllahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5349</span>),
    <span class="NLM_cas:pages">377-380</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels.  When coupled to the anticancer drug doxorubicin, two of these peptides - one contg. an αv integrin-binding Arg-Gly-Asp motif and the other an Asn-Gly-Arg motif - enhanced the efficacy of the drug against human breast cancer xenografts in nude mice and also reduced its toxicity.  These results indicate that it may be possible to develop targeted chemotherapy strategies that are based on selective expression of receptors in tumor vasculature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV-EmRwSP4s7Vg90H21EOLACvtfcHk0liJQveEQqo4HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtl2juw%253D%253D&md5=3e0b95b3309a5cdc1353bf7e6de36ff8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5349.377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5349.377%26sid%3Dliteratum%253Aachs%26aulast%3DArap%26aufirst%3DW.%26aulast%3DPasqualini%26aufirst%3DR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCancer%2520treatment%2520by%2520targeted%2520drug%2520delivery%2520to%2520tumor%2520vasculature%2520in%2520a%2520mouse%2520model%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D377%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Novel agents on the horizon for cancer therapy</span> <span class="citation_source-journal">CA: Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=111-137&author=W.+W.+Maauthor=A.+A.+Adjei&title=Novel+agents+on+the+horizon+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNovel%2520agents%2520on%2520the%2520horizon%2520for%2520cancer%2520therapy%26jtitle%3DCA%253A%2520Cancer%2520J.%2520Clin.%26date%3D2009%26volume%3D59%26spage%3D111%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span> </span><span class="NLM_article-title">Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4919</span><span class="NLM_x">–</span> <span class="NLM_lpage">4924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990355x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4919-4924&author=A.+Safavyauthor=K.+P.+Raischauthor=M.+B.+Khazaeliauthor=D.+J.+Buchsbaumauthor=J.+A.+Bonner&title=Paclitaxel+derivatives+for+targeted+therapy+of+cancer%3A+toward+the+development+of+smart+taxanes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm990355x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990355x%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26atitle%3DPaclitaxel%2520derivatives%2520for%2520targeted%2520therapy%2520of%2520cancer%253A%2520toward%2520the%2520development%2520of%2520smart%2520taxanes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4919%26epage%3D4924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmon, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onetto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slichenmyer, W.</span><span> </span><span class="NLM_article-title">Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=10080588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXht1Wmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=478-484&author=A.+W.+Tolcherauthor=S.+Sugarmanauthor=K.+A.+Gelmonauthor=R.+Cohenauthor=M.+Salehauthor=C.+Isaacsauthor=L.+Youngauthor=D.+Healeyauthor=N.+Onettoauthor=W.+Slichenmyer&title=Randomized+phase+II+study+of+BR96-doxorubicin+conjugate+in+patients+with+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer</span></div><div class="casAuthors">Tolcher, Anthony W.; Sugarman, Steven; Gelmon, Karen A.; Cohen, Roger; Saleh, Mansoor; Isaacs, Claudine; Young, Leslie; Healey, Diane; Onetto, Nicole; Slichenmyer, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">478-484</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BMS-182248-1 (BR96-doxorubicin immunoconjugate) is a chimeric human/mouse monoclonal antibody linked to approx. eight doxorubicin mols.  The antibody is directed against the Lewis-Y antigen, which is expressed on 75% of all breast cancers but is limited in expression on normal tissues.  Preclin. xenograft models demonstrated significant antitumor activity, including cures.  A randomized phase II design was chosen to est. the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin.  Patients with measurable metastatic breast cancer and immunohistochem. evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 h or doxorubicin 60 mg/m2 every 3 wk.  Patients were stratified on the basis of prior doxorubicin exposure, visceral disease, and institution.  Cross-over to the apposite treatment arm was allowed with progressive or persistently stable disease.  Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable.  There was one partial response (7%) in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses (44%) in nine assessable patients receiving doxorubicin.  No patient experienced a clin. significant hypersensitivity reaction.  The toxicities were significantly different between the two treatment groups, with the BR96-doxorubicin conjugate group having limited hematol. toxicity, whereas gastrointestinal toxicities, including marked serum amylase and lipase elevations, nausea, and vomiting with gastritis, were prominent.  The BR96-doxorubicin immunoconjugate has limited clin. antitumor activity in metastatic breast cancer.  The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZFxjI_yzFwbVg90H21EOLACvtfcHk0lhVleQDQVJKHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXht1Wmur8%253D&md5=2596451b74b51e8e807c0cad537869d2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DGelmon%26aufirst%3DK.%2BA.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DSaleh%26aufirst%3DM.%26aulast%3DIsaacs%26aufirst%3DC.%26aulast%3DYoung%26aufirst%3DL.%26aulast%3DHealey%26aufirst%3DD.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DSlichenmyer%26aufirst%3DW.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520BR96-doxorubicin%2520conjugate%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D478%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Guided molecular missiles for tumor-targeting chemotherapy—case studies using the second-generation taxoids as warheads</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar700093f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=108-119&author=I.+Ojima&title=Guided+molecular+missiles+for+tumor-targeting+chemotherapy%E2%80%94case+studies+using+the+second-generation+taxoids+as+warheads"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Far700093f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700093f%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DGuided%2520molecular%2520missiles%2520for%2520tumor-targeting%2520chemotherapy%25E2%2580%2594case%2520studies%2520using%2520the%2520second-generation%2520taxoids%2520as%2520warheads%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D108%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Singh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinko, P. J.</span><span> </span><span class="NLM_article-title">Recent trends in targeted anticancer prodrug and conjugate design</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1802</span><span class="NLM_x">–</span> <span class="NLM_lpage">1826</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.2174%2F092986708785132997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=18691040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1802-1826&author=Y.+Singhauthor=M.+Palomboauthor=P.+J.+Sinko&title=Recent+trends+in+targeted+anticancer+prodrug+and+conjugate+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Recent trends in targeted anticancer prodrug and conjugate design</span></div><div class="casAuthors">Singh, Yashveer; Palombo, Matthew; Sinko, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1802-1826</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Anticancer drugs are often nonselective antiproliferative agents (cytotoxins) that preferentially kill dividing cells by attacking their DNA at some level.  The lack of selectivity results in significant toxicity to non-cancerous proliferating cells.  These toxicities along with drug resistance exhibited by the solid tumors are major therapy limiting factors that result into poor prognosis for patients.  Prodrug and conjugate design involves the synthesis of inactive drug derivs. that are converted to an active form inside the body and preferably at the site of action.  Classical prodrug and conjugate design have focused on the development of prodrugs that can overcome physicochem. (e.g., soly., chem. instability) or biopharmaceutical problems (e.g., bioavailability, toxicity) assocd. with common anticancer drugs.  The recent targeted prodrug and conjugate design, hinge on the selective delivery of anticancer agents to tumor tissues thereby avoiding their cytotoxic effects on non-cancerous cells.  Targeting strategies have attempted to take advantage of low extracellular pH, elevated enzymes in tumor tissues, the hypoxic environment inside the tumor core, and tumor-specific antigenes expressed on tumor cell surfaces.  The present review highlights recent trends in prodrug and conjugate rationale and design for cancer treatment.  The various approaches that are currently being explored are critically analyzed and a comparative account of the advantages and disadvantages assocd. with each approach is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraaVRH_vxxs7Vg90H21EOLACvtfcHk0lhVleQDQVJKHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbo%253D&md5=dcb67c51e04c97d8a838188e2b29b000</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F092986708785132997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785132997%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DPalombo%26aufirst%3DM.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DRecent%2520trends%2520in%2520targeted%2520anticancer%2520prodrug%2520and%2520conjugate%2520design%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1802%26epage%3D1826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Akamatsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreitman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junghans, R. P.</span><span> </span><span class="NLM_article-title">A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9829749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1cXns1Ogu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=2825-2832&author=Y.+Akamatsuauthor=J.+C.+Murphyauthor=K.+F.+Nolanauthor=P.+Thomasauthor=R.+J.+Kreitmanauthor=S.+O.+Leungauthor=R.+P.+Junghans&title=A+single-chain+immunotoxin+against+carcinoembryonic+antigen+that+suppresses+growth+of+colorectal+carcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells</span></div><div class="casAuthors">Akamatsu, Y.; Murphy, J. C.; Nolan, K. F.; Thomas, P.; Kreitman, R. J.; Leung, S-O.; Junghans, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2825-2832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The authors have engineered an anti-carcinoembryonic antigen (CEA) single-chain immunotoxin derived from humanized anti-CEA antibody (hMN14) and a truncated Pseudomonas exotoxin (PE), PE40.  The purified anti-CEA immunotoxin (hMN14(Fv)-PE40) was first measured for binding affinity against a CEA-pos. colorectal carcinoma cell line and compared with its parental IgG and the monovalent Fab fragment.  The Ka of sFv-PE40, Fab, and IgG were 5×107, 6×107, and 3×108 M-1, resp.  There was no affinity loss by conversion of Fab to the single-chain Fv, but these monovalent forms were 5-6-fold reduced in affinity compared with the parental IgG.  In cytotoxicity assays, the hMN14(Fv)-PE40 showed specific growth suppression of CEA-expressing colon cancer cell lines MIP-CEA (high CEA) and LS174T (moderate CEA) with IC50s of 12 ng/mL (0.2 nM) and 69 ng/mL (1.1 nM).  These IC50s correlated inversely with the surface expression of CEA, such that 50% killing was equiv. for each cell type when expressed in toxin mols. bound/cell (3000-5000).  The presence of sol. CEA up to 1000 ng/mL did not affect the cytotoxicity against CEA-expressing cells, with 50% suppression only at 4000 ng/mL that correlated with the binding Kd of the single-chain Fv.  The stability of the hMN14(Fv)-PE40 mol. at 37° was confirmed by bioassay and by lack of aggregation.  The authors' hMN14(Fv)-PE40 may be clin. useful for tumors with high CEA expression without affecting normal tissues with low or absent CEA, even in patients with high sol. antigen levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh9Ql_BJv4LVg90H21EOLACvtfcHk0liue7GyjdkW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXns1Ogu78%253D&md5=64ef9865b5db5b4be8eff0562dd13ea6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAkamatsu%26aufirst%3DY.%26aulast%3DMurphy%26aufirst%3DJ.%2BC.%26aulast%3DNolan%26aufirst%3DK.%2BF.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DKreitman%26aufirst%3DR.%2BJ.%26aulast%3DLeung%26aufirst%3DS.%2BO.%26aulast%3DJunghans%26aufirst%3DR.%2BP.%26atitle%3DA%2520single-chain%2520immunotoxin%2520against%2520carcinoembryonic%2520antigen%2520that%2520suppresses%2520growth%2520of%2520colorectal%2520carcinoma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26spage%3D2825%26epage%3D2832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kreitman, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastan, I.</span><span> </span><span class="NLM_article-title">Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2F%28SICI%291097-0215%2819990331%2981%3A1%3C148%3A%3AAID-IJC24%3E3.0.CO%3B2-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=10077166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVKrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1999&pages=148-155&author=R.+J.+Kreitmanauthor=Q.+C.+Wangauthor=D.+J.+FitzGeraldauthor=I.+Pastan&title=Complete+regression+of+human+B-cell+lymphoma+xenografts+in+mice+treated+with+recombinant+anti-CD22+immunotoxin+RFB4%28dsFv%29-PE38+at+doses+tolerated+by+cynomolgus+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys</span></div><div class="casAuthors">Kreitman, Robert J.; Wang, Qing-Cheng; FitzGerald, David J. P.; Pastan, Ira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-155</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">RFB4(dsFv)-PE38 is a recombinant immunotoxin in which the variable light domain (VL) is disulfide bonded via cysteine residues to the variable heavy domain (VH), which in turn is fused to PE38, a mutant form of Pseudomonas exotoxin A.  RFB4 binds to CD22, which is a differentiation antigen expressed on the majority of B-cell leukemias and lymphomas.  To examine the potential efficacy of RFB4(dsFv)-PE38 when administered at a dose schedule appropriate for phase I testing, mice bearing CA46 human CD22+ Burkitt's lymphoma xenografts were treated on alternate days i.v. for 3 doses (QOD ×3).  Complete regressions were obsd. in 80% and 100% of mice treated with 200 and 275 μg/kg QOD ×3, resp.  The higher dose was 27% of the LD50 and 34% of the LD10 in mice.  Because RFB4(dsFv)-PE38 is stable at 37°, it could also be given by continuous infusion using pumps placed in the peritoneal cavity; complete regressions also resulted from this mode of administration.  To study toxicol., a pilot toxicol. study of RFB4(dsFv)-PE38 was undertaken in cynomolgus monkeys, which like humans but unlike mice have CD22, which binds RFB4.  Doses of 100 and 500 μg/kg i.v. QOD ×3 were well tolerated, indicating that a dose that cured tumors in mice was tolerated by primates.  Based on these preclin. results, RFB4(dsFv)-PE38 is being developed for the treatment of patients with CD22-pos. leukemias and lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKJFEyUhlGbVg90H21EOLACvtfcHk0liue7GyjdkW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVKrs70%253D&md5=06f42e084559abd2da1a47d498119302</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819990331%2981%3A1%3C148%3A%3AAID-IJC24%3E3.0.CO%3B2-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819990331%252981%253A1%253C148%253A%253AAID-IJC24%253E3.0.CO%253B2-L%26sid%3Dliteratum%253Aachs%26aulast%3DKreitman%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%2BC.%26aulast%3DFitzGerald%26aufirst%3DD.%2BJ.%26aulast%3DPastan%26aufirst%3DI.%26atitle%3DComplete%2520regression%2520of%2520human%2520B-cell%2520lymphoma%2520xenografts%2520in%2520mice%2520treated%2520with%2520recombinant%2520anti-CD22%2520immunotoxin%2520RFB4%2528dsFv%2529-PE38%2520at%2520doses%2520tolerated%2520by%2520cynomolgus%2520monkeys%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D81%26spage%3D148%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bazooband, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span> </span><span class="NLM_article-title">De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc0100861" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1elt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=317-326&author=A.+Safavyauthor=D.+C.+Smithauthor=A.+Bazoobandauthor=D.+J.+Buchsbaum&title=De+novo+synthesis+of+a+new+diethylenetriaminepentaacetic+acid+%28DTPA%29+bifunctional+chelating+agent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Synthesis of a New Diethylenetriaminepentaacetic Acid (DTPA) Bifunctional Chelating Agent</span></div><div class="casAuthors">Safavy, Ahmad; Smith, Dale C., Jr.; Bazooband, Alireza; Buchsbaum, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diethylene triamine pentaacetic acid (DTPA) has been in extensive use as a metal chelator in the development of radiopharmaceuticals and contrast agents.  The former application uses DTPA mostly as a bifunctional chelating agent (BCA) conjugated to tumor-targeting vehicles (TTVs) such as monoclonal antibodies (MAbs) and receptor-directed peptides.  A new bifunctional DTPA deriv. was synthesized by a fully org. scheme.  This compd., N4,Nα,Nα,Nε,Nε-[pentakis(carboxymethyl)]-N4-(carboxymethyl)-2,6-diamino-4-azahexanoic hydrazide was prepd. by a convergent synthesis strategy using Nα-benzyloxycarbonyl-2,3-diaminopropionic acid as the starting compd.  This com. available material was used to build a functionalized triamine which served as the mol. core template for assembling the target mol.  To evaluate the conjugation and radiolabeling capabilities of this new mol., it was covalently attached to the anti-TAG-72 MAb, ΔCH2HuCC49, and the conjugate was radiolabeled in near-quant. yields with yttrium-90 (90Y) and lutetium-177 (177Lu).  Biodistribution of the 177Lu-labeled DTPA-ΔCH2HuCC49 in tumor-bearing nude mice demonstrated preservation of the immunoreactivity of the MAb as indicated by high tumor uptake.  In addn. to the introduction of a new bifunctional DTPA, this work reports on a novel synthetic approach for prepn. of this useful metal chelator and introduces a new conjugation protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUCv_CrUQglLVg90H21EOLACvtfcHk0liue7GyjdkW9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1elt7s%253D&md5=76c4c4a03e891027edeb9db81d5966a3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbc0100861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0100861%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DBazooband%26aufirst%3DA.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26atitle%3DDe%2520novo%2520synthesis%2520of%2520a%2520new%2520diethylenetriaminepentaacetic%2520acid%2520%2528DTPA%2529%2520bifunctional%2520chelating%2520agent%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sharkey, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. M.</span><span> </span><span class="NLM_article-title">Targeted therapy of cancer: new prospects for antibodies and immunoconjugates</span> <span class="citation_source-journal">CA: Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2006&pages=226-243&author=R.+M.+Sharkeyauthor=D.+M.+Goldenberg&title=Targeted+therapy+of+cancer%3A+new+prospects+for+antibodies+and+immunoconjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DTargeted%2520therapy%2520of%2520cancer%253A%2520new%2520prospects%2520for%2520antibodies%2520and%2520immunoconjugates%26jtitle%3DCA%253A%2520Cancer%2520J.%2520Clin.%26date%3D2006%26volume%3D56%26spage%3D226%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Recent advances in the new generation taxane anticancer agents</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16787308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=125-139&author=R.+Geneyauthor=J.+Chenauthor=I.+Ojima&title=Recent+advances+in+the+new+generation+taxane+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the new generation taxane anticancer agents</span></div><div class="casAuthors">Geney, R.; Chen, J.; Ojima, I.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-139</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent advances in the design and preclin. evaluations of promising new generation taxane anticancer agents were reviewed in this article.  Paclitaxel and docetaxel are two of the most important anticancer drugs today.  However, recent reports have shown that treatment with these drugs often encounters undesirable side effects as well as drug resistance.  Therefore, it is important to develop new taxane anticancer agents with fewer side effects, superior pharmacol. properties, and improved activity against drug-resistant human cancers.  Structure-activity relationship (SAR) studies led to the discovery of a series of highly active second-generation taxanes.  One of them, "Ortataxel" (SB-T-101131, IDN5109, BAY59-8862), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines, as well as human tumor xenografts in mice.  It is orally active and is currently in phase II clin. trials.  Photoaffinity labeling of microtubules and P-glycoprotein using photoreactive radiolabeled taxoids has disclosed the drug-binding domain of tubulin as well as Pgp.  Together with information on microtubule-bound fluorine-labeled taxoids obtained by solid-state NMR studies, the bioactive conformation of paclitaxel and taxoids appears to emerge.  Novel taxane-monoclonal antibody (mAb) immunoconjugates, have shown highly promising results for the tumor-specific delivery and release of an extremely cytotoxic, second-generation taxane.  Also, another novel series of second generation taxanes conjugated with n-3 polyunsatd. fatty acids, e.g. decosahexaenoic acid (DHA), has exhibited impressive antitumor activity with min. general toxicity against the highly drug-resistant DLD-1 human colon cancer xenografts in SCID mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZJJWUM_nE7Vg90H21EOLACvtfcHk0ljpM38jaXlVOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSqtbg%253D&md5=69be8a1b7f9742652898a5de8bbef505</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DRecent%2520advances%2520in%2520the%2520new%2520generation%2520taxane%2520anticancer%2520agents%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D125%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirikae, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirikae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Respicio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slayden, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojima, I.</span><span> </span><span class="NLM_article-title">Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050920y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=463-466&author=Q.+Huangauthor=F.+Kirikaeauthor=T.+Kirikaeauthor=A.+Pepeauthor=A.+Aminauthor=L.+Respicioauthor=R.+A.+Slaydenauthor=P.+J.+Tongeauthor=I.+Ojima&title=Targeting+FtsZ+for+antituberculosis+drug+discovery%3A+noncytotoxic+taxanes+as+novel+antituberculosis+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting FtsZ for Antituberculosis Drug Discovery: Noncytotoxic Taxanes as Novel Antituberculosis Agents</span></div><div class="casAuthors">Huang, Qing; Kirikae, Fumiko; Kirikae, Teruo; Pepe, Antonella; Amin, Amol; Respicio, Laurel; Slayden, Richard A.; Tonge, Peter J.; Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">463-466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening of 120 taxanes identified a no. of compds. that exhibited significant antituberculosis activity.  Rational optimization of selected compds. led to the discovery that the C-seco-taxane-multidrug-resistance (MDR) reversal agents (C-seco-TRAs) are noncytotoxic at the upper limit of soly. and detection (>80 μM), while maintaining MIC99 values of 1.25-2.5 μM against drug-resistant and drug-sensitive strains of Mycobacterium tuberculosis (MTB).  Treatment of MTB cells with TRA 3aa and 10a at the MIC caused filamentation and prolongation of the cells, a phenotypic response to FtsZ inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFdPVd5P1UtbVg90H21EOLACvtfcHk0ljpM38jaXlVOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7O&md5=40a2673981184262ba3d1dc2d6e0019f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm050920y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050920y%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKirikae%26aufirst%3DF.%26aulast%3DKirikae%26aufirst%3DT.%26aulast%3DPepe%26aufirst%3DA.%26aulast%3DAmin%26aufirst%3DA.%26aulast%3DRespicio%26aufirst%3DL.%26aulast%3DSlayden%26aufirst%3DR.%2BA.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DTargeting%2520FtsZ%2520for%2520antituberculosis%2520drug%2520discovery%253A%2520noncytotoxic%2520taxanes%2520as%2520novel%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Holmes, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theriault, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raber, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">1797</span><span class="NLM_x">–</span> <span class="NLM_lpage">1805</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1093%2Fjnci%2F83.24.1797-a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=1683908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK38%252FnvFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1991&pages=1797-1805&author=F.+A.+Holmesauthor=R.+S.+Waltersauthor=R.+L.+Theriaultauthor=A.+D.+Formanauthor=L.+K.+Newtonauthor=M.+N.+Raberauthor=A.+U.+Buzdarauthor=D.+K.+Fryeauthor=G.+N.+Hortobagyi&title=Phase+II+trial+of+taxol%2C+an+active+drug+in+the+treatment+of+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer</span></div><div class="casAuthors">Holmes F A; Walters R S; Theriault R L; Forman A D; Newton L K; Raber M N; Buzdar A U; Frye D K; Hortobagyi G N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1797-805</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation of many phase I clinical trials.  Consequently, investigators and the National Cancer Institute recommended that phase I and II studies of this agent use 24-hour infusions and antiallergic medications.  Using a premedication regimen effective in preventing hypersensitivity reactions, we have performed a phase II trial of taxol in patients with metastatic breast cancer.  Taxol was administered to 25 patients at a dose of 250 mg/m2 by 24-hour infusion every 21 days.  These patients had received only one prior chemotherapy regimen, either adjuvant to surgery or for metastatic disease; all but two had received doxorubicin.  In 60% of the patients, the dominant site of disease was the viscera.  All patients were assessable.  In April 1991, at a median time on study of 9 months (range, 5-13+ months), the objective response rate was 56% (12% complete and 44% partial; 95% confidence interval, 35%-76%).  Disease progressed in only 8% of the patients.  The median number of courses of therapy was 11.  Granulocytopenia was the dose-limiting toxic effect, but neutropenia with fever occurred in only 5% of 232 courses.  A chronic glove-and-stocking neuropathy developed in most patients, but no allergic reactions occurred.  We conclude that taxol is an active agent in the treatment of metastatic breast cancer and that it warrants continued study.  Currently, we are conducting a phase I trial of taxol plus doxorubicin.  Future trials should address the optimal effective dose, the optimal sequencing of combinations, mechanisms of drug resistance in tumors, and dose-limiting toxic effects (particularly cardiac toxic effects of taxol given as a single agent or in drug combinations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPnJK3qzA2H0loaUqgkFHkfW6udTcc2eYxC5uRXiGp-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252FnvFaqtw%253D%253D&md5=0ad79290315081933dabf72ce788ba8e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F83.24.1797-a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F83.24.1797-a%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DF.%2BA.%26aulast%3DWalters%26aufirst%3DR.%2BS.%26aulast%3DTheriault%26aufirst%3DR.%2BL.%26aulast%3DForman%26aufirst%3DA.%2BD.%26aulast%3DNewton%26aufirst%3DL.%2BK.%26aulast%3DRaber%26aufirst%3DM.%2BN.%26aulast%3DBuzdar%26aufirst%3DA.%2BU.%26aulast%3DFrye%26aufirst%3DD.%2BK.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DPhase%2520II%2520trial%2520of%2520taxol%252C%2520an%2520active%2520drug%2520in%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1991%26volume%3D83%26spage%3D1797%26epage%3D1805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Robert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asmar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilegbodu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loesch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raju, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobleigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albain, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCullough, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2786</span><span class="NLM_x">–</span> <span class="NLM_lpage">2792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1200%2FJCO.2005.04.1764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16782917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28XntV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2786-2792&author=N.+Robertauthor=B.+Leyland-Jonesauthor=L.+Asmarauthor=R.+Beltauthor=D.+Ilegboduauthor=D.+Loeschauthor=R.+Rajuauthor=E.+Valentineauthor=R.+Sayreauthor=M.+Cobleighauthor=K.+Albainauthor=C.+McCulloughauthor=L.+Fuchsauthor=D.+Slamon&title=Randomized+phase+III+study+of+trastuzumab%2C+paclitaxel%2C+and+carboplatin+compared+with+trastuzumab+and+paclitaxel+in+women+with+HER-2-overexpressing+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer</span></div><div class="casAuthors">Robert, Nicholas; Leyland-Jones, Brian; Asmar, Lina; Belt, Robert; Ilegbodu, Des; Loesch, David; Raju, Robert; Valentine, Elizabeth; Sayre, Robert; Cobleigh, Melody; Albain, Kathy; McCullough, Cecelia; Fuchs, Lea; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2786-2792</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2-overexpressing metastatic breast cancer (MBC).  Patients and Methods: HER-2 overexpression was defined as immunohistochem. staining scores of 2+ or 3+.  Between Nov. 1998 and May 2002, 196 women with HER-2-overexpressing MBC were randomly assigned to six cycles of either trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 every 3 wk (TP), or trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 and carboplatin area under the time-concn. curve = 6 every 3 wk (TPC) followed by weekly trastuzumab alone.  Results: Baseline characteristics of the 196 patients were well balanced between study arms.  Objective: response rate (ORR) was 52% (95% CI, 42% to 62%) for TPC vs. 36% (95% CI, 26% to 46%) for TP (P = .04).  Median progression-free survival (PFS) was 10.7 mo for TPC and 7.1 mo for TP (hazard ratio [HR], 0.66; 95% CI, 0.59 to 0.73; P = .03).  Improved clin. outcomes with TPC were most evident in HER-2 3+ patients, with an ORR of 57% (95% CI, 45% to 70%) v 36% (95% CI, 25% to 48%; P = .03) and median PFS of 13.8 v 7.6 mo (P = .005) for TPC and TP, resp. (HR, 0.55; 95% CI, 0.46 to 0.64).  Both regimens were well tolerated, and febrile neutropenia and neurotoxicity occurred infrequently; grade 4 neutropenia occurred more frequently with TPC (P < .01).  Conclusion: The addn. of carboplatin to paclitaxel and trastuzumab improved ORR and PFS in women with HER-2-overexpressing MBC.  This well-tolerated regimen represents a new therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXh2vAA2AjbVg90H21EOLACvtfcHk0lhpLAtb7aUCow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntV2hu7g%253D&md5=67b8f4e8e0d04bd141197cb71499b8e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.1764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.1764%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DN.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DAsmar%26aufirst%3DL.%26aulast%3DBelt%26aufirst%3DR.%26aulast%3DIlegbodu%26aufirst%3DD.%26aulast%3DLoesch%26aufirst%3DD.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DValentine%26aufirst%3DE.%26aulast%3DSayre%26aufirst%3DR.%26aulast%3DCobleigh%26aufirst%3DM.%26aulast%3DAlbain%26aufirst%3DK.%26aulast%3DMcCullough%26aufirst%3DC.%26aulast%3DFuchs%26aufirst%3DL.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DRandomized%2520phase%2520III%2520study%2520of%2520trastuzumab%252C%2520paclitaxel%252C%2520and%2520carboplatin%2520compared%2520with%2520trastuzumab%2520and%2520paclitaxel%2520in%2520women%2520with%2520HER-2-overexpressing%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2786%26epage%3D2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Reichman, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakes, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surbone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span> </span><span class="NLM_article-title">Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1943</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7691998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2c%252FhsFaitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=1943-1951&author=B.+S.+Reichmanauthor=A.+D.+Seidmanauthor=J.+P.+Crownauthor=R.+Heelanauthor=T.+B.+Hakesauthor=D.+E.+Lebwohlauthor=T.+A.+Gilewskiauthor=A.+Surboneauthor=V.+Currieauthor=C.+A.+Hudis&title=Paclitaxel+and+recombinant+human+granulocyte+colony-stimulating+factor+as+initial+chemotherapy+for+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer</span></div><div class="casAuthors">Reichman B S; Seidman A D; Crown J P; Heelan R; Hakes T B; Lebwohl D E; Gilewski T A; Surbone A; Currie V; Hudis C A; et al</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1943-51</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  A phase II study of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) as initial chemotherapy for metastatic breast cancer was conducted.  Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was used to ameliorate myelosuppression, the anticipated dose-limiting toxicity.  PATIENTS AND METHODS:  Twenty-eight patients with bidimensionally measurable breast cancer who had not received prior chemotherapy for metastatic disease were treated.  Taxol was administered at 250 mg/m2 as a continuous 24-hour intravenous (i.v.) infusion every 21 days. rhG-CSF was administered at 5 micrograms/kg/d subcutaneously on days 3 through 10.  RESULTS:  Objective responses were observed in 16 of 26 assessable patients (62%; 95% confidence interval, 41% to 80%).  There were three (12%) complete responses (CRs) and 13 (50%) partial responses (PRs).  Ten of 16 patients (63%) who had received prior adjuvant chemotherapy responded, which included one CR and four PRs among eight patients who had received prior doxorubicin-containing therapy.  Responses were observed in all sites of metastatic disease.  The median time to first objective response was 5 weeks (range, 1 to 14).  Administration of rhG-CSF was associated with a short duration of neutropenia (median, 2 days with absolute neutrophil count < 500 cells/microL).  Eight of 26 patients (31%) who received more than one course received subsequent therapy without dose reduction.  One hundred seventy-eight cycles of treatment were administered, with a median of six cycles per patient (range, one to 19).  Eight courses (4.5%) were associated with admissions for neutropenic fever.  Twenty-two patients (79%) did not require admission for neutropenic fever.  Treatment was well tolerated.  Adverse effects included generalized alopecia in all patients.  Myalgias, arthralgias, and peripheral neuropathy were mild.  No hypersensitivity reactions and no cardiac toxicity were observed.  CONCLUSION:  Taxol is highly active as initial chemotherapy for metastatic breast cancer.  Administration of rhG-CSF reduced the incidence, depth, and duration of neutropenia, compared with published prior experience.  Further studies of Taxol in breast cancer, including combinations with other active agents, are clearly warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlCSSJJnBNcZggzHGM8X5CfW6udTcc2ea5zkCoSovBv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FhsFaitg%253D%253D&md5=4d98a5b727efd94964f8d936d3d39792</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReichman%26aufirst%3DB.%2BS.%26aulast%3DSeidman%26aufirst%3DA.%2BD.%26aulast%3DCrown%26aufirst%3DJ.%2BP.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DHakes%26aufirst%3DT.%2BB.%26aulast%3DLebwohl%26aufirst%3DD.%2BE.%26aulast%3DGilewski%26aufirst%3DT.%2BA.%26aulast%3DSurbone%26aufirst%3DA.%26aulast%3DCurrie%26aufirst%3DV.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26atitle%3DPaclitaxel%2520and%2520recombinant%2520human%2520granulocyte%2520colony-stimulating%2520factor%2520as%2520initial%2520chemotherapy%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1993%26volume%3D11%26spage%3D1943%26epage%3D1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Seidman, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichman, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakes, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilewski, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsythe, P.</span><span> </span><span class="NLM_article-title">Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7537798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2M3ls12gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1995&pages=1152-1159&author=A.+D.+Seidmanauthor=B.+S.+Reichmanauthor=J.+P.+Crownauthor=T.+J.+Yaoauthor=V.+Currieauthor=T.+B.+Hakesauthor=C.+A.+Hudisauthor=T.+A.+Gilewskiauthor=J.+Baselgaauthor=P.+Forsythe&title=Paclitaxel+as+second+and+subsequent+therapy+for+metastatic+breast+cancer%3A+activity+independent+of+prior+anthracycline+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response</span></div><div class="casAuthors">Seidman A D; Reichman B S; Crown J P; Yao T J; Currie V; Hakes T B; Hudis C A; Gilewski T A; Baselga J; Forsythe P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1152-9</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  Two phase II clinical trials were performed to determine efficacy and tolerability of paclitaxel (Taxol; Bristol-Myers Squibb Co, Wallingford, CT) and granulocyte colony-stimulating factor ([G-CSF] Neupogen; Amgen, Inc, Thousand Oaks, CA) as second or subsequent therapy for metastatic breast cancer.  PATIENTS AND METHODS:  Paclitaxel plus G-CSF was administered as a second stage IV regimen to 25 patients with metastatic breast cancer at a dose of 250 mg/m2 intravenously over 24 hours.  Fifty-two patients received paclitoxel plus G-CSF at 200 mg/m2 as a third or subsequent regimen (no restriction on number of prior regimens or on prior high-dose chemotherapy).  All patients had received prior anthracycline treatment, and ultimately had progressive bidimensionally measurable disease.  RESULTS:  Twenty-five of 76 patients (32.8%) had a major objective response (95% confidence interval [CI], 14% to 37%).  The median duration of response was 7 months (range, 1 to 20+).  Responses were as likely in patients with disease demonstrated to be unresponsive to anthracycline, ie, de novo resistance (11 of 37, or 30%) as in those with disease that once exhibited anthracycline sensitivity, ie, acquired resistance, (10 of 31, or 32%).  G-CSF administration was associated with febrile neutropenic episodes in 36 of 402 cycles (9%) in 16 of 76 patients (21%).  CONCLUSION:  Paclitaxel's clinically significant activity against metastatic breast cancer extends to patients with many prior chemotherapy regimens.  The lack of impact of prior doxorubicin therapy on the likelihood of subsequent response to paclitaxel suggests an important role for this agent in the treatment of refractory metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT91Me59PbBsJ0d-O_J5C0AfW6udTcc2ea5zkCoSovBv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3ls12gtA%253D%253D&md5=acefa73c8d652b510aa8e5506a964aa5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSeidman%26aufirst%3DA.%2BD.%26aulast%3DReichman%26aufirst%3DB.%2BS.%26aulast%3DCrown%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DT.%2BJ.%26aulast%3DCurrie%26aufirst%3DV.%26aulast%3DHakes%26aufirst%3DT.%2BB.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DGilewski%26aufirst%3DT.%2BA.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DForsythe%26aufirst%3DP.%26atitle%3DPaclitaxel%2520as%2520second%2520and%2520subsequent%2520therapy%2520for%2520metastatic%2520breast%2520cancer%253A%2520activity%2520independent%2520of%2520prior%2520anthracycline%2520response%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1995%26volume%3D13%26spage%3D1152%26epage%3D1159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Chang, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boros, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asbury, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubins, J.</span><span> </span><span class="NLM_article-title">Dose-escalation study of weekly 1 h paclitaxel administration in patients with refractory cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">S17-69</span><span class="NLM_x">–</span> <span class="NLM_lpage">S17-71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1997&pages=S17-69-S17-71&author=A.+Y.+Changauthor=L.+Borosauthor=R.+Asburyauthor=L.+Huiauthor=J.+Rubins&title=Dose-escalation+study+of+weekly+1+h+paclitaxel+administration+in+patients+with+refractory+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%2BY.%26aulast%3DBoros%26aufirst%3DL.%26aulast%3DAsbury%26aufirst%3DR.%26aulast%3DHui%26aufirst%3DL.%26aulast%3DRubins%26aufirst%3DJ.%26atitle%3DDose-escalation%2520study%2520of%2520weekly%25201%2520h%2520paclitaxel%2520administration%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D1997%26volume%3D24%26spage%3DS17-69%26epage%3DS17-71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Dorr, R. T.</span><span> </span><span class="NLM_article-title">Pharmacology and toxicology of Cremophor EL diluent</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">S11</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1994&pages=S11-S14&author=R.+T.+Dorr&title=Pharmacology+and+toxicology+of+Cremophor+EL+diluent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DR.%2BT.%26atitle%3DPharmacology%2520and%2520toxicology%2520of%2520Cremophor%2520EL%2520diluent%26jtitle%3DAnn.%2520Pharmacother.%26date%3D1994%26volume%3D28%26spage%3DS11%26epage%3DS14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayhew, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolcsak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavanaugh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janoff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernacki, R. J.</span><span> </span><span class="NLM_article-title">Activity of paclitaxel liposome formulations against human ovarian tumor xenografts</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2F%28SICI%291097-0215%2819970328%2971%3A1%3C103%3A%3AAID-IJC17%3E3.0.CO%3B2-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9096672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Kisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=103-107&author=A.+Sharmaauthor=E.+Mayhewauthor=L.+Bolcsakauthor=C.+Cavanaughauthor=P.+Harmonauthor=A.+Janoffauthor=R.+J.+Bernacki&title=Activity+of+paclitaxel+liposome+formulations+against+human+ovarian+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of paclitaxel liposome formulations against human ovarian tumor xenografts</span></div><div class="casAuthors">Sharma, Amarnath; Mayhew, Eric; Bolcsak, Lois; Cavanaugh, C.; Harmon, P.; Janoff, Andrew; Bernacki, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss</span>)
        </div><div class="casAbstract">Although the current clin. formulation of paclitaxel (Taxol) is an important new anti-cancer agent, it has significant side effects, some of which are related to its formulation in Cremophor/ethanol.  Paclitaxel is difficult to formulate for i.v. administration because of its poor aq. soly.  Here, the authors report the therapeutic effects of 2 liposome formulations of paclitaxel against human ovarian A121 tumor growing as an s.c. xenograft in athymic nude mice.  The liposome formulations used were ETL and TTL, which have 1 or 3 lipid components, resp.  TTL was used as a reconstituted lyophilizate or as a stable aq. suspension.  ETL was used as a reconstituted lyophilizate only.  Both paclitaxel-liposome formulations were much better tolerated than Taxol after i.v. or i.p. administration.  The acute reactions seen after Taxol administration did not occur when paclitaxel-liposome formulations were administered.  All ETL and TTL prepns. significantly delayed A121 tumor growth similarly to Taxol at equiv. doses and schedules.  Based on pharmacokinetic data, it is possible that paclitaxel rapidly dissocs. from ETL or TTL after i.v. administration and distributes in a manner similarly to Taxol.  ETL and TTL formulations may be useful clin. not only for eliminating toxic effects of the Cremophor/ethanol vehicle but also for allowing alterations in route and schedule of drug administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLcDMGT9gNgrVg90H21EOLACvtfcHk0lg8PeRJOkuXLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Kisrw%253D&md5=b59185fa89dffd0868a6364b56756b93</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819970328%2971%3A1%3C103%3A%3AAID-IJC17%3E3.0.CO%3B2-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819970328%252971%253A1%253C103%253A%253AAID-IJC17%253E3.0.CO%253B2-J%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMayhew%26aufirst%3DE.%26aulast%3DBolcsak%26aufirst%3DL.%26aulast%3DCavanaugh%26aufirst%3DC.%26aulast%3DHarmon%26aufirst%3DP.%26aulast%3DJanoff%26aufirst%3DA.%26aulast%3DBernacki%26aufirst%3DR.%2BJ.%26atitle%3DActivity%2520of%2520paclitaxel%2520liposome%2520formulations%2520against%2520human%2520ovarian%2520tumor%2520xenografts%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1997%26volume%3D71%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Payne, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhingra, K.</span><span> </span><span class="NLM_article-title">Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia</span> <span class="citation_source-journal">South. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1097%2F00007611-199605000-00022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=8638189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK283htFSntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1996&pages=542-545&author=J.+Y.+Payneauthor=F.+Holmesauthor=P.+R.+Cohenauthor=R.+Gagelauthor=A.+Buzdarauthor=K.+Dhingra&title=Paclitaxel%3A+severe+mucocutaneous+toxicity+in+a+patient+with+hyperbilirubinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia</span></div><div class="casAuthors">Payne J Y; Holmes F; Cohen P R; Gagel R; Buzdar A; Dhingra K</div><div class="citationInfo"><span class="NLM_cas:title">Southern medical journal</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">542-5</span>
        ISSN:<span class="NLM_cas:issn">0038-4348</span>.
    </div><div class="casAbstract">Paclitaxel is a novel anticancer drug that is being increasingly used to treat cancer of the breast and other organs.  We describe a patient with metastatic breast cancer and liver dysfunction who had severe mucocutaneous toxicity after administration of a standard dose of paclitaxel.  Another interesting finding in this patient was that the administration of paclitaxel led to a prompt resolution of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia, which had previously proven to be refractory to multiple conventional antihypercalcemic agents as well as anthracycline-containing chemotherapy combination.  The need for definitive guidelines for paclitaxel administration in the setting of hepatic dysfunction and the potentially unique sensitivity of PTHrP--producing cells to paclitaxel are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTM3w-66-99mDslzEEsg76ufW6udTcc2eZathta9jd2U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283htFSntg%253D%253D&md5=0a1a937b4d78a6ec9c7baafc75e4aedf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00007611-199605000-00022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007611-199605000-00022%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DJ.%2BY.%26aulast%3DHolmes%26aufirst%3DF.%26aulast%3DCohen%26aufirst%3DP.%2BR.%26aulast%3DGagel%26aufirst%3DR.%26aulast%3DBuzdar%26aufirst%3DA.%26aulast%3DDhingra%26aufirst%3DK.%26atitle%3DPaclitaxel%253A%2520severe%2520mucocutaneous%2520toxicity%2520in%2520a%2520patient%2520with%2520hyperbilirubinemia%26jtitle%3DSouth.%2520Med.%2520J.%26date%3D1996%26volume%3D89%26spage%3D542%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R. C.</span><span> </span><span class="NLM_article-title">Paclitaxel (taxol)</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1056%2FNEJM199504133321507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=7885406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1995&pages=1004-1014&author=E.+K.+Rowinskyauthor=R.+C.+Donehower&title=Paclitaxel+%28taxol%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel (taxol)</span></div><div class="casAuthors">Rowinsky E K; Donehower R C</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1004-14</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDsoUwRBKuB62q3xNe7a7QfW6udTcc2eZathta9jd2U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ptFKisg%253D%253D&md5=918362934f39ee3362db9d2bed1c71cb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJM199504133321507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199504133321507%26sid%3Dliteratum%253Aachs%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26atitle%3DPaclitaxel%2520%2528taxol%2529%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D332%26spage%3D1004%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matusiak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatnagar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helson, L.</span><span> </span><span class="NLM_article-title">Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide “scorpion” molecule</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc050224c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=565-570&author=A.+Safavyauthor=K.+P.+Raischauthor=D.+Matusiakauthor=S.+Bhatnagarauthor=L.+Helson&title=Single-drug+multiligand+conjugates%3A+synthesis+and+preliminary+cytotoxicity+evaluation+of+a+paclitaxel-dipeptide+%E2%80%9Cscorpion%E2%80%9D+molecule"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Drug Multiligand Conjugates: Synthesis and Preliminary Cytotoxicity Evaluation of a Paclitaxel-Dipeptide "Scorpion" Molecule</span></div><div class="casAuthors">Safavy, Ahmad; Raisch, Kevin P.; Matusiak, Damien; Bhatnagar, Saloni; Helson, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the targeting properties of receptor-directed drug-peptide conjugates, a multiligand approach was proposed and a model "scorpion" conjugate consisting of two peptide "claws" and a paclitaxel (PTX) "tail", was synthesized.  The cell surface receptor-directed peptide used in this single-drug multiligand (SDML) model was a segment of the amphibian peptide bombesin (BBN) which had the Y6Q7W8A9V10G11H12L13M14-NH2 sequence, designated here as BBN[6-14].  Due to the lipophilic nature of both PTX and BBN[6-14], "scorpion" conjugate had a low water soly.  To enhance the soly., PEG derivs. of this conjugate were prepd. with the polymer inserted either in the claws or in the tail regions.  In a preliminary random screening, "scorpion" conjugate showed superior cytotoxic activity in several GRPR-pos. human cancer cell lines as compared to free PTX and two single-drug single-ligand (SDSL) conjugates.  In a receptor blocking expt., addn. of excess unconjugated BBN[6-14] ligand reduced the cytotoxicity of "scorpion" conjugate , indicating the receptor-mediated mechanism of drug delivery.  The PEG-derived conjugates showed activities which were intermediate between SDSL and the SDML congeners.  Also, an increase in the no. of the PEG segments lowered cytotoxicity, possibly due to steric hindrance against ligand-receptor binding.  Taken together, these results demonstrate the potential of the multiligand approach in the design of receptor-targeting conjugates for tumor-specific drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcE2tKB3qP6LVg90H21EOLACvtfcHk0lhRb8i_I_70iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFKiu7k%253D&md5=6831d78ca852d106412788c1bc7d6404</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbc050224c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc050224c%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DMatusiak%26aufirst%3DD.%26aulast%3DBhatnagar%26aufirst%3DS.%26aulast%3DHelson%26aufirst%3DL.%26atitle%3DSingle-drug%2520multiligand%2520conjugates%253A%2520synthesis%2520and%2520preliminary%2520cytotoxicity%2520evaluation%2520of%2520a%2520paclitaxel-dipeptide%2520%25E2%2580%259Cscorpion%25E2%2580%259D%2520molecule%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D565%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waksal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arani, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc020033z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=302-310&author=A.+Safavyauthor=J.+A.+Bonnerauthor=H.+Waksalauthor=D.+J.+Buchsbaumauthor=G.+Y.+Gillespieauthor=M.+B.+Khazaeliauthor=R.+B.+Araniauthor=D.+T.+Chenauthor=M.+Carpenterauthor=K.+P.+Raisch&title=Synthesis+and+biological+evaluation+of+paclitaxel-C225+conjugate+as+a+model+for+targeted+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Paclitaxel-C225 Conjugate as a Model for Targeted Drug Delivery</span></div><div class="casAuthors">Safavy, Ahmad; Bonner, James A.; Waksal, Harlan W.; Buchsbaum, Donald J.; Gillespie, G. Yancey; Khazaeli, M. B.; Arani, Ramin; Chen, Dung-Tsa; Carpenter, Mark; Raisch, Kevin P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-310</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumor-targeted drug delivery is an attractive strategy in cancer treatment.  We have previously reported a paclitaxel model conjugate using a bombesin receptor-recognizing peptide in which the drug cytotoxicity against H1299 human nonsmall cell lung cancer was enhanced compared to unconjugated taxol.  In an effort to expand the development of tumor-recognizing taxanes, paclitaxel (PTX, taxol) was conjugated to the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MAb) Erbitux (C225) to serve as a model MAb-mediated drug delivery compd.  Thus, paclitaxel was derivatized at its 2'-hydroxy function by introduction of a succinate linker, and the carboxyl group of the latter was covalently attached to C225 through amide bond formation.  The final product conjugate (PTXC225) was analyzed mass spectrometrically for assessment of the drug-to-antibody ratios.  Cytotoxicity screening of the drug-antibody conjugate against A431, UM-SCC-1, and UM-SCC-6 cells indicated an enhancement in cytotoxic effect of paclitaxel as compared to those of the free drug, the intact antibody, and a phys. mixt. of the 2 (the controls).  In A431 cells, the conjugate showed 25% of apoptosis induction as compared to little or no apoptosis caused by the controls.  Biodistribution anal. of the PTXC225 in tumor-implanted nude mice and a tyrosine-kinase assay showed that conjugation of the drug did not interfere with the immunoreactivity of the antibody.  The 24-h tumor uptake of C225 and PTXC225 were 11.7 and 7.1% of the injected dose/g of tissue (percent ID/g), resp., which were not significantly different.  Also, in A431-implanted nude mice, the conjugate and C225 showed tumor growth inhibition effects of 57.2 and 41.2%, resp., against a saline-treated control, which were not significantly different from each other.  This lack of difference in the in vivo antitumor activity of the MAb-delivered drug and free PTX may be due to either a relatively low dose of the antibody-delivered drug (346 μg/kg), or an untimely release of it, or both.  The tumor growth inhibition pattern of the conjugate, however, was identical to that of C225, indicating that the attachment of PTX did not affect the antigen-binding and growth inhibitory features of the MAb.  These preliminary results demonstrate the potential of tumor-targeted delivery of taxol as a promising strategy in cancer treatment and warrant further work to develop more suitable drug-MAb linkers as well as improved dosage and treatment protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXG8dWRogOALVg90H21EOLACvtfcHk0lhRb8i_I_70iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsQ%253D%253D&md5=a7f8436350e960ac5dc9a073d2a08953</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fbc020033z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc020033z%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DWaksal%26aufirst%3DH.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26aulast%3DGillespie%26aufirst%3DG.%2BY.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DArani%26aufirst%3DR.%2BB.%26aulast%3DChen%26aufirst%3DD.%2BT.%26aulast%3DCarpenter%26aufirst%3DM.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520paclitaxel-C225%2520conjugate%2520as%2520a%2520model%2520for%2520targeted%2520drug%2520delivery%26jtitle%3DBioconjugate%2520Chem.%26date%3D2003%26volume%3D14%26spage%3D302%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Safavy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georg, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Velde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raisch, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safavy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpenter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khazaeli, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchsbaum, D. J.</span><span> </span><span class="NLM_article-title">Site-specifically traced drug release and biodistribution of a paclitaxel−antibody conjugate toward optimization of the linker structure</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049868v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Wnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1264-1274&author=A.+Safavyauthor=G.+I.+Georgauthor=D.+Vander+Veldeauthor=K.+P.+Raischauthor=K.+Safavyauthor=M.+Carpenterauthor=W.+Wangauthor=J.+A.+Bonnerauthor=M.+B.+Khazaeliauthor=D.+J.+Buchsbaum&title=Site-specifically+traced+drug+release+and+biodistribution+of+a+paclitaxel%E2%88%92antibody+conjugate+toward+optimization+of+the+linker+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure</span></div><div class="casAuthors">Safavy, Ahmad; Georg, Gunda I.; Vander Velde, David; Raisch, Kevin P.; Safavy, Kamellia; Carpenter, Mark; Wang, Wenquan; Bonner, James A.; Khazaeli, M. B.; Buchsbaum, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1274</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumor-directed drug delivery is a promising strategy in cancer treatment, and in this field, monoclonal antibodies constitute an important class of targeting vehicles.  A crit. issue in the design of targeting conjugates is the timing of the release of the cytotoxic payload, with the ideal situation being the release at the max. tumor uptake of the targeting mol.  A site-specific radiolabeling technique was used to elucidate the biodistribution and in vivo drug release pattern of an antibody conjugate of paclitaxel in which the drug and the antibody moieties were connected by a succinate (SX) linker.  In this new method, a metabolite of PTX, 3'-(4-hydroxyphenyl)paclitaxel (3'-OH-PTXSX) was used as a tyrosine mimic for the synthesis of the drug site-labeled conjugate.  This was achieved by iodogen 125I-labeling of 3'-OH-PTXSX and subsequent conjugation to C225.  The antibody site-labeled conjugate (ASL, PTXSX-[125I]-C225) was prepd. by direct radioiodination of PTXSXC225.  Biodistribution of these compds. was studied in Balb/c nude mice bearing DU-145 human prostate carcinoma xenografts.  While the 4 and 24 h tumor uptake (in percent injected dose per g of tissue, %ID/g) for [125I]-3'-OH-PTXSXC225 were 3.3 ± 1.5 and 1.7 ± 0.6%ID/g, the PTXSX-[125I]-C225 showed tumor uptake values of 3.8 ± 4.2 and 14.8 ± 4.2%ID/g at these time points.  This difference in the tumor uptake over time indicated an early cleavage of the drug with respect to the antibody tumor localization.  This was further confirmed by an in vitro drug release kinetics study leading to a half-life of about 2 h for PTXSXC225 under physiol. conditions.  To increase the stability of the PTX-MAb bond, a new conjugate (PTXGLC225) with glutaric acid (GL) as the linker was synthesized.  Under the same conditions, the PTXGLC225 showed a 16-fold increase in the half-life (t1/2) of the drug release.  The effect of the increased t1/2 of this compd. on the antitumor activity of the conjugate was tested in a DU-145 human prostate tumor-implanted mouse model.  In comparison to a previous similar expt. with PTXSXC225, better antitumor activity was obsd. for the PTXGLC225 conjugate as compared to controls.  These results demonstrated the first time use of radioiodinated 3'-OH-PTX for in vivo tracing of a paclitaxel conjugate and application of the resulting information to the design of a therapeutically more useful PTX-MAb linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJgUYAfOcd_LVg90H21EOLACvtfcHk0lhRb8i_I_70iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Wnsrs%253D&md5=81008be7a100d819caef0269c36adeb4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbc049868v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049868v%26sid%3Dliteratum%253Aachs%26aulast%3DSafavy%26aufirst%3DA.%26aulast%3DGeorg%26aufirst%3DG.%2BI.%26aulast%3DVander%2BVelde%26aufirst%3DD.%26aulast%3DRaisch%26aufirst%3DK.%2BP.%26aulast%3DSafavy%26aufirst%3DK.%26aulast%3DCarpenter%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DKhazaeli%26aufirst%3DM.%2BB.%26aulast%3DBuchsbaum%26aufirst%3DD.%2BJ.%26atitle%3DSite-specifically%2520traced%2520drug%2520release%2520and%2520biodistribution%2520of%2520a%2520paclitaxel%25E2%2588%2592antibody%2520conjugate%2520toward%2520optimization%2520of%2520the%2520linker%2520structure%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D1264%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Naramura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillies, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisfeld, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, B. M.</span><span> </span><span class="NLM_article-title">Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma</span> <span class="citation_source-journal">Cancer Immunol. Immunother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1007%2FBF01518458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=8402738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK2cXhs1Wis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=343-349&author=M.+Naramuraauthor=S.+D.+Gilliesauthor=J.+Mendelsohnauthor=R.+A.+Reisfeldauthor=B.+M.+Mueller&title=Therapeutic+potential+of+chimeric+and+murine+anti-%28epidermal+growth+factor+receptor%29+antibodies+in+a+metastasis+model+for+human+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma</span></div><div class="casAuthors">Naramura, Mayumi; Gillies, Stephen D.; Mendelsohn, John; Reisfeld, Ralph A.; Mueller, Barbara M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">343-9</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    </div><div class="casAbstract">On many tumors, high nos. of epidermal growth factor (EGF) receptors provide a target for antibody-mediated tumor therapy.  The authors evaluate here the therapeutic potential of a mouse/human chimeric anti-(EGF receptor) antibody and compare it to the parental murine antibody in a xenograft model for metastatic melanoma.  The authors' model is based on the human cell line M24met, which overexpresses the EGF receptor and metastasizes spontaneously in SCID mice.  Both the chimeric anti-(EGF receptor) antibody (ch225) and the mouse monoclonal antibody (m225) exhibited saturable, high-affinity binding to M24met cells and were equiv. in their ability to target M24met tumors in mice.  Neither anti-(EGF receptor) antibodies nor EGF modulated the growth of M24met cells in vitro.  Further anal. revealed that the EGF receptor on these cells is not phosphorylated upon EGF binding, indicating an anomalous receptor on these cells.  In antibody-dependent cellular cytotoxicity expts., ch225 and m225 were potent mediators of M24met cytolysis by effector cells.  Antibody-mediated cytotoxicity revealed a marked species preference, with ch225 activating human peripheral blood mononuclear cells and m225 activating mouse splenocytes and to a lesser degree mouse macrophages.  Neither antibody mediated cytolysis in the presence of human complement.  In SCID mice, m225 suppressed spontaneous metastasis considerably while ch225 had only a modest effect.  Thus, in the M24met melanoma tumor model, anti-(EGF receptor) antibodies suppress spontaneous metastasis solely by activating immune effector cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxMnBHqdxx7Vg90H21EOLACvtfcHk0lgEuEnhDfia1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhs1Wis70%253D&md5=a26106f7ccdf2c4cf6a8363a6db8ca82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2FBF01518458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01518458%26sid%3Dliteratum%253Aachs%26aulast%3DNaramura%26aufirst%3DM.%26aulast%3DGillies%26aufirst%3DS.%2BD.%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DReisfeld%26aufirst%3DR.%2BA.%26aulast%3DMueller%26aufirst%3DB.%2BM.%26atitle%3DTherapeutic%2520potential%2520of%2520chimeric%2520and%2520murine%2520anti-%2528epidermal%2520growth%2520factor%2520receptor%2529%2520antibodies%2520in%2520a%2520metastasis%2520model%2520for%2520human%2520melanoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D1993%26volume%3D37%26spage%3D343%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Goldstein, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prewett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuklys, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockwell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, J.</span><span> </span><span class="NLM_article-title">Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">–</span> <span class="NLM_lpage">1318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=9815926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK28XjvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=1311-1318&author=N.+I.+Goldsteinauthor=M.+Prewettauthor=K.+Zuklysauthor=P.+Rockwellauthor=J.+Mendelsohn&title=Biological+efficacy+of+a+chimeric+antibody+to+the+epidermal+growth+factor+receptor+in+a+human+tumor+xenograft+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model</span></div><div class="casAuthors">Goldstein, Neil I.; Prewett, Marie; Zuklys, Kazys; Rockwell, Patricia; Mendelsohn, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1311-18</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There seems to be an assocn. between up-regulation of the epidermal growth factor receptor (EGFR) and poor clin. prognosis for a no. of human cancers.  The 225 antibody is a highly specific murine monoclonal antibody that binds specifically to the human EGFR with an affinity equal to its ligand, competes with the ligand for binding, and blocks activation of the receptor tyrosine kinase.  In addn., 225 has been shown to inhibit the growth of human tumor xenografts in athymic nude mice.  The 225 antibody has recently been chimerized with human IgG1 in its const. region to increase its clin. utility by decreasing the potential for generation of human anti-mouse antibodies in recipients.  This report compares the biol. effects of 225 and its chimeric counterpart (designated C225) against established A431 tumor xenografts in nude mice.  C225 was more effective than 225 in inhibiting tumor growth in this model.  In addn., many of the animals treated with C225 were tumor free at the end of each treatment protocol.  The dissocn. const. of C225 was about 5-fold lower than 225.  This suggested that the increased capacity of C225 to compete with ligand for binding to the EGFR was responsible for its enhanced in vivo antitumor effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeedZsCNr2urVg90H21EOLACvtfcHk0lgEuEnhDfia1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvF2gsA%253D%253D&md5=d2e6bb5aadb3999f91c785db383521d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DN.%2BI.%26aulast%3DPrewett%26aufirst%3DM.%26aulast%3DZuklys%26aufirst%3DK.%26aulast%3DRockwell%26aufirst%3DP.%26aulast%3DMendelsohn%26aufirst%3DJ.%26atitle%3DBiological%2520efficacy%2520of%2520a%2520chimeric%2520antibody%2520to%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520a%2520human%2520tumor%2520xenograft%2520model%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1995%26volume%3D1%26spage%3D1311%26epage%3D1318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Karashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slaton, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettaway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinney, C. P.</span><span> </span><span class="NLM_article-title">Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1253</span><span class="NLM_x">–</span> <span class="NLM_lpage">1264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=12006546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVWjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1253-1264&author=T.+Karashimaauthor=P.+Sweeneyauthor=J.+W.+Slatonauthor=S.+J.+Kimauthor=D.+Kedarauthor=J.+I.+Izawaauthor=Z.+Fanauthor=C.+Pettawayauthor=D.+J.+Hicklinauthor=T.+Shuinauthor=C.+P.+Dinney&title=Inhibition+of+angiogenesis+by+the+antiepidermal+growth+factor+receptor+antibody+ImClone+C225+in+androgen-independent+prostate+cancer+growing+orthotopically+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone c225 in androgen-independent prostate cancer growing orthotopically in nude mice</span></div><div class="casAuthors">Karashima, Takashi; Sweeney, Paul; Slaton, Joel W.; Kim, Sun J.; Kedar, Daniel; Izawa, Jonathan I.; Fan, Zhen; Pettaway, Curtis; Hicklin, Daniel J.; Shuin, Taro; Dinney, Colin P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1253-1264</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In human androgen-independent prostate cancer (PCa), epidermal growth factor receptor (EGFR) regulates angiogenesis, tumor growth, and progression.  In this study, we evaluated whether the blockade of EGFR by the anti-EGFR antibody ImClone C225 (IMC-C225) inhibited tumor growth and metastasis by inhibiting angiogenesis, and whether paclitaxel enhanced the results of therapy in androgen-independent PCa.  PC-3M-LN4 PCa cells were implanted orthotopically in athymic nude mice and treated with i.p. IMC-C225 (1 mg twice a week) and/or paclitaxel (200 μg once a week).  In vitro treatment of PC-3M-LN4 with IMC-C225 inhibited EGFR autophosphorylation without any significant antiproliferative effect.  In contrast, in vivo therapy with IMC-C225 alone (P < 0.05) or in combination with paclitaxel (P < 0.005) significantly inhibited PCa growth and metastasis.  Serum levels of interleukin (IL) 8 were lower after therapy, and IL-8 mRNA expression was down-regulated within the tumors after therapy.  The down-regulation of IL-8 correlated with reduced microvessel d.  IMC-C225 reduced tumor cell proliferation, enhanced p27kip1 expression, and induced tumor and endothelial cell apoptosis.  These studies indicate that IMC-C225 has significant antitumor effect in this murine model, mediated in part by inhibition of cellular proliferation and angiogenesis, and by enhancement of apoptosis.  The simultaneous administration of paclitaxel enhanced this effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14K44uXs-lbVg90H21EOLACvtfcHk0lgEuEnhDfia1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVWjs78%253D&md5=c4f4a7ef4a34df1602c867d29cfea4ee</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarashima%26aufirst%3DT.%26aulast%3DSweeney%26aufirst%3DP.%26aulast%3DSlaton%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DKedar%26aufirst%3DD.%26aulast%3DIzawa%26aufirst%3DJ.%2BI.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DPettaway%26aufirst%3DC.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DDinney%26aufirst%3DC.%2BP.%26atitle%3DInhibition%2520of%2520angiogenesis%2520by%2520the%2520antiepidermal%2520growth%2520factor%2520receptor%2520antibody%2520ImClone%2520C225%2520in%2520androgen-independent%2520prostate%2520cancer%2520growing%2520orthotopically%2520in%2520nude%2520mice%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1253%26epage%3D1264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Reusch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davol, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, L. G.</span><span> </span><span class="NLM_article-title">Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1158%2F1078-0432.CCR-05-1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=16397041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=183-190&author=U.+Reuschauthor=M.+Sundaramauthor=P.+A.+Davolauthor=S.+D.+Olsonauthor=J.+B.+Davisauthor=K.+Demelauthor=J.+Nissimauthor=R.+Rathoreauthor=P.+Y.+Liuauthor=L.+G.+Lum&title=Anti-CD3+x+anti-epidermal+growth+factor+receptor+%28EGFR%29+bispecific+antibody+redirects+T-cell+cytolytic+activity+to+EGFR-positive+cancers+in+vitro+and+in+an+animal+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model</span></div><div class="casAuthors">Reusch, Ursula; Sundaram, Magesh; Davol, Pamela A.; Olson, Sarah D.; Davis, James B.; Demel, Kurt; Nissim, Julie; Rathore, Ritesh; Liu, Paul Y.; Lum, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Targeting epidermal growth factor receptor (EGFR) overexpressed by many epithelial-derived cancer cells with anti-EGFR monoclonal antibodies (mAb) inhibits their growth.  A limited no. of clin. responses in patients treated with the anti-EGFR mAb, (cetuximab), may reflect variability in EGFR type or signaling in neoplastic cells.  This study combines EGFR-targeting with the non-MHC-restricted cytotoxicity of anti-CD3 activated T cells (ATC) to enhance receptor-directed cytotoxicity.  Exptl. Design: ATC from normal and patient donors were expanded ex vivo.  Specific cytolytic activity of ATC armed with anti-CD3 x anti-EGFR (EGFRBi) against EGFR-expressing cancer cells derived from lung, pancreas, colon, prostate, brain, skin, or EGFR-neg. breast cancer cells was evaluated in 51Cr release assays.  In vivo studies comparing tumor growth delay induced by EGFRBi-armed ATCs or cetuximab were done in severe combined immunodeficient/Beige mice (SCID-Beige) bearing COLO 356/FG pancreatic and LS174T colorectal tumors.  Results: At effector/target ratios from 3.125 to 50, both EGFRBi-armed normal and patient ATC were significantly more cytotoxic, by 23% to 79%, against EGFR-pos. cells over ATC, cetuximab, anti-CD3 alone, or ATC armed with irrelevant BiAb directed at CD20.  EGFRBi-armed ATC also secreted significantly higher levels of some TH1/TH2 cytokines compared with ATC alone.  In mice, i.v. infusions of EGFRBi-armed ATC (0.001 mg equiv./infusion) were equally effective as cetuximab (1 mg/infusion) alone for significantly delaying growth of established COLO 356/FG but not LS174T tumors compared with mice that received ATC alone or vehicle (P < 0.001).  Conclusions: Combining EGFR antibody targeting with T cell-mediated cytotoxicity may overcome some limitations assocd. with EGFR-targeting when using cetuximab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi9hOZnWz2zbVg90H21EOLACvtfcHk0li26ofiAdtJfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gltw%253D%253D&md5=e61989eca1e15a817609cf95db16cfeb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1855%26sid%3Dliteratum%253Aachs%26aulast%3DReusch%26aufirst%3DU.%26aulast%3DSundaram%26aufirst%3DM.%26aulast%3DDavol%26aufirst%3DP.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BD.%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DDemel%26aufirst%3DK.%26aulast%3DNissim%26aufirst%3DJ.%26aulast%3DRathore%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%2BY.%26aulast%3DLum%26aufirst%3DL.%2BG.%26atitle%3DAnti-CD3%2520x%2520anti-epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bispecific%2520antibody%2520redirects%2520T-cell%2520cytolytic%2520activity%2520to%2520EGFR-positive%2520cancers%2520in%2520vitro%2520and%2520in%2520an%2520animal%2520model%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D183%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Thompson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. N.</span><span> </span><span class="NLM_article-title">The EGF receptor: structure, regulation and potential role in malignancy</span> <span class="citation_source-journal">Cancer Surv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=2824044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A280%3ADyaL1c%252Flt1Krug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1985&pages=767-788&author=D.+M.+Thompsonauthor=G.+N.+Gill&title=The+EGF+receptor%3A+structure%2C+regulation+and+potential+role+in+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The EGF receptor: structure, regulation and potential role in malignancy</span></div><div class="casAuthors">Thompson D M; Gill G N</div><div class="citationInfo"><span class="NLM_cas:title">Cancer surveys</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">767-88</span>
        ISSN:<span class="NLM_cas:issn">0261-2429</span>.
    </div><div class="casAbstract">Retroviral onc genes are derived from cellular proto-oncogenes that may function in normal cellular growth control.  The epidermal growth factor (EGF) receptor is the proto-oncogene of erbB; both possess intrinsic protein tyrosine kinase activity, a property shared by several retroviral onc genes.  The EGF receptor is a transmembrane glycoprotein with an external EGF binding domain and a cytoplasmic region that is homologous with other tyrosine kinases. erbB lacks the EGF binding and carboxyl terminal regions, which are thought to be important in regulation.  The EGF receptor is regulated by several mechanisms: stimulation by ligand binding and self-phosphorylation, inhibition by heterologous phosphorylation and downregulation by ligand.  EGF binding stimulates several early events, including phosphatidylinositol (PI) turnover in A431 cells.  A PI kinase activity copurifies with the EGF receptor and some other tyrosine kinases, but this is a contaminant as it can be separated from the EGF receptor.  Although the role of proto-onc genes in human malignancy is incompletely defined, increased numbers of EGF receptors are present in several types of human tumours.  Overexpression of EGF receptors, as occurs in human epidermoid carcinoma A431 cells, can augment cell growth because of increased formation of active ligand:receptor complexes.  Gene amplification is the mechanism underlying overexpression of EGF receptors in A431 cells and in some glioblastoma multiforme tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl44d6i0TfOS86Js-BCLiifW6udTcc2ebk0DGskddN2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c%252Flt1Krug%253D%253D&md5=ad2ee6e58aded1a439c41e73b5785560</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DD.%2BM.%26aulast%3DGill%26aufirst%3DG.%2BN.%26atitle%3DThe%2520EGF%2520receptor%253A%2520structure%252C%2520regulation%2520and%2520potential%2520role%2520in%2520malignancy%26jtitle%3DCancer%2520Surv.%26date%3D1985%26volume%3D4%26spage%3D767%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">The epidermal growth factor receptor as a multi-functional allosteric protein</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3119</span><span class="NLM_x">–</span> <span class="NLM_lpage">3123</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00409a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1988&pages=3119-3123&author=J.+Schlessinger&title=The+epidermal+growth+factor+receptor+as+a+multi-functional+allosteric+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fbi00409a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00409a002%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520as%2520a%2520multi-functional%2520allosteric%2520protein%26jtitle%3DBiochemistry%26date%3D1988%26volume%3D27%26spage%3D3119%26epage%3D3123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Carpenter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span> </span><span class="NLM_article-title">Epidermal growth factor</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1146%2Fannurev.bi.48.070179.001205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=382984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaE1MXltVers78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1979&pages=193-216&author=G.+Carpenterauthor=S.+Cohen&title=Epidermal+growth+factor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor</span></div><div class="casAuthors">Carpenter, Graham; Cohen, Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-216</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    </div><div class="casAbstract">A review with 206 refs. on the physiol., chem., and phys. properties of the title compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNYFT7lWszw7Vg90H21EOLACvtfcHk0liIV0ZhkPCGBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltVers78%253D&md5=d883ab25e84f3d627980a46ce234a655</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.48.070179.001205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.48.070179.001205%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DG.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DEpidermal%2520growth%2520factor%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1979%26volume%3D48%26spage%3D193%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Pathak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matrisian, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magun, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, S. E.</span><span> </span><span class="NLM_article-title">Effect of epidermal growth factor on clonogenic growth of primary human tumor cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm900899g&amp;key=10.1002%2Fijc.2910300611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm900899g&amp;key=6298120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaL3sXkslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1982&pages=745-750&author=M.+A.+Pathakauthor=L.+M.+Matrisianauthor=B.+E.+Magunauthor=S.+E.+Salmon&title=Effect+of+epidermal+growth+factor+on+clonogenic+growth+of+primary+human+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of epidermal growth factor on clonogenic growth of primary human tumor cells</span></div><div class="casAuthors">Pathak, Meera A.; Matrisian, Lynn M.; Magun, Bruce E.; Salmon, Sydney E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">745-50</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">The effect of epidermal growth factor (EGF)  [62229-50-9] on the soft agar colony-forming ability of fresh human tumor cells was assessed in 40 specimens obtained from various types of carcinoma, including those of the breast, endometrium, ovary, and other sites.  Cells from 4 established human tumor cell lines (3 breast and 1 endometrial) were also studied.  The addn. of EGF at 50 ng/mL resulted in a 50% higher cloning efficiency in soft agar in 40% of the samples of fresh human tumors.  When cells from tumor cell lines were plated in semi-solid medium contg. EGF, the no. of colonies formed was at least twice as high as controls.  Specific receptors for EGF were detected by using radioiodinated EGF in early-passage cell cultures from some of the tumors tested for clonogenicity.  The no. of receptors ranged from 0.3 to 3.27 × 105/cell.  Cells from 2 melanoma specimens possessed <0.3 × 103 EGF receptors/cell.  No correlation was found between the no. of EGF receptors on a cell surface and the mitogenic effect of EGF on the same tumor cells grown in semisolid medium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zWIham5RPrVg90H21EOLACvtfcHk0liIV0ZhkPCGBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXkslKluw%253D%253D&md5=fc8540da514879ee616ce713ed52087a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910300611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910300611%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DM.%2BA.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26aulast%3DMagun%26aufirst%3DB.%2BE.%26aulast%3DSalmon%26aufirst%3DS.%2BE.%26atitle%3DEffect%2520of%2520epidermal%2520growth%2520factor%2520on%2520clonogenic%2520growth%2520of%2520primary%2520human%2520tumor%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1982%26volume%3D30%26spage%3D745%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Singletary, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brock, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajani, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, A. M.</span><span> </span><span class="NLM_article-title">Biological effect of epidermal growth factor on the in vitro growth of human tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1987&pages=403-406&author=S.+E.+Singletaryauthor=F.+L.+Bakerauthor=G.+Spitzerauthor=S.+L.+Tuckerauthor=B.+Tomasovicauthor=W.+A.+Brockauthor=J.+A.+Ajaniauthor=A.+M.+Kelly&title=Biological+effect+of+epidermal+growth+factor+on+the+in+vitro+growth+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingletary%26aufirst%3DS.%2BE.%26aulast%3DBaker%26aufirst%3DF.%2BL.%26aulast%3DSpitzer%26aufirst%3DG.%26aulast%3DTucker%26aufirst%3DS.%2BL.%26aulast%3DTomasovic%26aufirst%3DB.%26aulast%3DBrock%26aufirst%3DW.%2BA.%26aulast%3DAjani%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DA.%2BM.%26atitle%3DBiological%2520effect%2520of%2520epidermal%2520growth%2520factor%2520on%2520the%2520in%2520vitro%2520growth%2520of%2520human%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1987%26volume%3D47%26spage%3D403%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Real, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuevas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berciano, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Juan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Roman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafarga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Luna, J. L.</span><span> </span><span class="NLM_article-title">Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">8151</span><span class="NLM_x">–</span> <span class="NLM_lpage">8157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8151-8157&author=P.+J.+Realauthor=A.+Benitoauthor=J.+Cuevasauthor=M.+T.+Bercianoauthor=A.+de+Juanauthor=P.+Cofferauthor=J.+Gomez-Romanauthor=M.+Lafargaauthor=J.+M.+Lopez-Vegaauthor=J.+L.+Fernandez-Luna&title=Blockade+of+epidermal+growth+factor+receptors+chemosensitizes+breast+cancer+cells+through+up-regulation+of+Bnip3L"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReal%26aufirst%3DP.%2BJ.%26aulast%3DBenito%26aufirst%3DA.%26aulast%3DCuevas%26aufirst%3DJ.%26aulast%3DBerciano%26aufirst%3DM.%2BT.%26aulast%3Dde%2BJuan%26aufirst%3DA.%26aulast%3DCoffer%26aufirst%3DP.%26aulast%3DGomez-Roman%26aufirst%3DJ.%26aulast%3DLafarga%26aufirst%3DM.%26aulast%3DLopez-Vega%26aufirst%3DJ.%2BM.%26aulast%3DFernandez-Luna%26aufirst%3DJ.%2BL.%26atitle%3DBlockade%2520of%2520epidermal%2520growth%2520factor%2520receptors%2520chemosensitizes%2520breast%2520cancer%2520cells%2520through%2520up-regulation%2520of%2520Bnip3L%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8151%26epage%3D8157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Reilly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scollard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallis, K. A.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1031</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1023-1031&author=R.+M.+Reillyauthor=P.+Chenauthor=J.+Wangauthor=D.+Scollardauthor=R.+Cameronauthor=K.+A.+Vallis&title=Preclinical+pharmacokinetic%2C+biodistribution%2C+toxicology%2C+and+dosimetry+studies+of+111In-DTPA-human+epidermal+growth+factor%3A+an+auger+electron-emitting+radiotherapeutic+agent+for+epidermal+growth+factor+receptor-positive+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DScollard%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DR.%26aulast%3DVallis%26aufirst%3DK.%2BA.%26atitle%3DPreclinical%2520pharmacokinetic%252C%2520biodistribution%252C%2520toxicology%252C%2520and%2520dosimetry%2520studies%2520of%2520111In-DTPA-human%2520epidermal%2520growth%2520factor%253A%2520an%2520auger%2520electron-emitting%2520radiotherapeutic%2520agent%2520for%2520epidermal%2520growth%2520factor%2520receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D1023%26epage%3D1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Deutsch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugwitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suffness, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalkow, L.</span><span> </span><span class="NLM_article-title">Synthesis of congeners and prodrugs: water soluble prodrugs of taxol with potent antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00124a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=788-792&author=H.+Deutschauthor=J.+Glinskiauthor=M.+Hernandezauthor=R.+Haugwitzauthor=V.+Narayananauthor=M.+Suffnessauthor=L.+Zalkow&title=Synthesis+of+congeners+and+prodrugs%3A+water+soluble+prodrugs+of+taxol+with+potent+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm00124a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00124a011%26sid%3Dliteratum%253Aachs%26aulast%3DDeutsch%26aufirst%3DH.%26aulast%3DGlinski%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DHaugwitz%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DV.%26aulast%3DSuffness%26aufirst%3DM.%26aulast%3DZalkow%26aufirst%3DL.%26atitle%3DSynthesis%2520of%2520congeners%2520and%2520prodrugs%253A%2520water%2520soluble%2520prodrugs%2520of%2520taxol%2520with%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D788%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prestwich, G. D.</span><span> </span><span class="NLM_article-title">Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc9900338" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm900899g&amp;key=1%3ACAS%3A528%3ADyaK1MXksF2ltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=755-763&author=Y.+Luoauthor=G.+D.+Prestwich&title=Synthesis+and+selective+cytotoxicity+of+a+hyaluronic+acid-antitumor+bioconjugate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Selective Cytotoxicity of a Hyaluronic Acid-Antitumor Bioconjugate</span></div><div class="casAuthors">Luo, Yi; Prestwich, Glenn D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A cell-targeted prodrug was developed for the anti-cancer drug Taxol, using hyaluronic acid (HA) as the drug carrier.  HA-Taxol bioconjugates were synthesized by linking the Taxol 2'-OH via a succinate ester to adipic dihydrazide-modified HA (HA-ADH).  The coupling of Taxol-NHS ester and HA-ADH provided several HA bioconjugates with different levels of ADH modification and different Taxol loadings.  A fluorescent BODIPY-HA was also synthesized to illustrate cell targeting and uptake of chem. modified HA using confocal microscopy.  HA-Taxol conjugates showed selective toxicity toward the human cancer cell lines (breast, colon, and ovarian) that are known to overexpress HA receptors, while no toxicity was obsd. toward a mouse fibroblast cell line at the same concns. used with the cancer cells.  The drug carrier HA-ADH was completely nontoxic.  The selective cytotoxicity is consistent with the results from confocal microscopy, which demonstrated that BODIPY-HA only entered the cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ObajqdMOPbVg90H21EOLACvtfcHk0lhc96lEvZEj1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksF2ltLs%253D&md5=0d98607a32ee66e70381d4018457c831</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbc9900338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc9900338%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPrestwich%26aufirst%3DG.%2BD.%26atitle%3DSynthesis%2520and%2520selective%2520cytotoxicity%2520of%2520a%2520hyaluronic%2520acid-antitumor%2520bioconjugate%26jtitle%3DBioconjugate%2520Chem.%26date%3D1999%26volume%3D10%26spage%3D755%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i25"><a href="/doi/suppl/10.1021/jm900899g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_81732"></div></div></div></div></div><hr /></hr><p class="last">Comparative <sup>1</sup>H NMR for paclitaxel, polymers <b>2</b> and <b>3</b>, and product <b>9a</b>, mass spectra, and HPLC charts. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm900899g/suppl_file/jm900899g_si_001.pdf">jm900899g_si_001.pdf (3.79 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm900899g&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm900899g%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-2" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm900899g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1007KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac44b690ea294","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
